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Abstract 
Cellular events rely on protein-protein interactions that are often mediated by modular 
domains which recognize particular sequence motifs in binding partners. The NUMB 
protein is the first described cell fate determinant and multifaceted adaptor that is involved 
in a wide variety of cellular events. NUMB mainly mediates protein interactions via its 
modular PTB domain. Here we present a systematic investigation of the NUMB-PTB 
interactome by employing an integrative strategy combining both protein and peptide 
arrays. We profiled NUMB-PTB binding specificity and interacting proteins genome-wide. 
The receptor tyrosine kinases (RTKs) are found highly enriched in the interactome, raising 
the possibility that NUMB may act as a universal binding partner of RTKs. To further 
validate this hypothesis, we focused on the interaction between NUMB and Anaplastic 
Lymphoma Kinase (ALK), which promotes oncogenesis in a number of cancer types. 
Consistent with the prediction based on our proteomic study, NUMB-PTB directly binds 
to two motifs in ALK in vitro and in vivo. Intriguingly, functional analysis reveals that 
NUMB-ALK interaction regulates ALK activity antagonistically in an isoform dependent 
manner, by directing ALK to distinct post-endocytic trafficking destinations. Our study 
provides mechanistic insight into ALK regulation, explains the controversial behaviors of 
NUMB in tumorigenesis at the molecular level, and further reveals a biomarker of potential 
clinical value. 
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Chapter 1  
1 General introduction 
1.1 The multifaceted adaptor protein NUMB 
NUMB is the first characterized cell fate determinant, originally described in Drosophila 
in 1989, where it plays a role in controlling the fate of progeny derived from sensory organ 
precursors (Uemura et al., 1989). Later in 1994, NUMB was reported to regulate cell fate 
through asymmetrical distribution in daughter cells during sensory organ precursor 
division (Rhyu et al., 1994). NUMB is universally distributed at the membrane periphery 
during interphase, but preferentially accumulates at one spindle pole during mitotic 
division and thus is inherited by only one daughter cell which then develops a distinct cell 
fate. It subsequently became clear that NUMB directly binds to and counteracts the 
membrane receptor NOTCH (neurogenic locus notch homologue protein) in this cell 
lineage, since NOTCH gain-of-function mutations matched the phenotype of NUMB loss-
of-function mutations (Guo et al., 1996). The report of this novel yet significant NUMB 
function has henceforth captivated the attention of researchers. 
The NUMB gene is evolutionarily conserved from fly to human. Drosophila NUMB 
(dNUMB) and mammalian NUMB (mNUMB) proteins are also functionally conserved, 
since ectopic expression of mNUMB complemented the phenotype of dNUMB knockout 
in Drosophila (Salcini et al., 1997; Zhong et al., 1996; Zhong et al., 1997). In general, the 
NUMB protein exhibits a complex pattern of functions such as the control of asymmetric 
cell division and cell fate, endocytosis, cell adhesion, cell migration, ubiquitination and 
several signaling pathways (Gulino et al., 2010). The complexity of NUMB is likely due 
to multiple isoforms generated by alternative splicing, and their diverse expression and 
subcellular localization patterns. In humans, studies on NUMB mainly focus on its role in 
tumorigenesis and have shown the involvement of NUMB in a variety of cancer-related 
events and signaling pathways (Gulino et al., 2010; Pece et al., 2011). In particular, NUMB 
has been defined as a tumor suppressor by counteracting the function of NOTCH, one of 
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the major oncogenic receptors in many different tumor types (Espinoza and Miele, 2013; 
Leong and Gao, 2008), or by stabilizing p53 to attenuate the immortality of cancer cells 
(Colaluca et al., 2008).  
1.1.1 NUMB structure and isoforms 
In different species, the NUMB proteins share a similar structure as presented in Fig.1.1. 
Mammalian NUMB contains an N-terminal phosphotyrosine binding (PTB) domain, a 
proline rich region (PRR), as well as two Asp-Pro-Phe (DPFs) motifs and one Asn-Pro-
Phe (NPF) motif at the C-terminus (Bork and Margolis, 1995; Li et al., 1997; Li et al., 
1998; Zwahlen et al., 2000). The PTB domain and PRR are the major protein interaction 
sites in NUMB, and contribute to most NUMB functions that have been characterized to 
date. The PTB domain is crucial for the membrane association of NUMB, because it 
directly interacts with a number of membrane localized/associated proteins (Dho et al., 
1999; Dho et al., 2006; Gulino et al., 2010), such as the receptor tyrosine kinases ErbB2 
and ALK discussed in Chapter 2. These interactions assimilate NUMB into various 
signaling transduction pathways initiated from the cell membrane. The PRR, as well as the 
DPF and NPF motifs, directly interact with various endocytic adaptor proteins such as α-
adaptin and Eps15 (Salcini et al., 1997; Santolini et al., 2000). This interaction pattern 
implicates the potential role of NUMB in endocytosis regulation. Indeed, NUMB has been 
shown to regulate the endocytosis of various membrane localized receptors thus indirectly 
altering their downstream signaling transduction (Gulino et al., 2010).  
In both mice and humans, NUMB undergoes alternative splicing to produce at least 9 
isoforms based on the Uniprot database. Alternative splicing occurs in exon 3 in the PTB 
domain or exon 9 in the PRR to generate the four major isoforms: p72 (inclusion of both 
exons), p71 (inclusion of exon 9), p66 (inclusion of exon 3) and p65 (exclusion of both 
exons) (Dho et al., 1999; Verdi et al., 1999). Five shorter isoforms have also been reported, 
but their characteristics and functions are not well studied.  
Although the diverse biological effects of the four major isoforms have been reported in a 
number of studies, the functional mechanisms of these isoforms have not been well 
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elucidated. It is speculated that the diversity is mainly caused by differences in protein 
binding specificities among the long (L) and short (S) variants of PTB domain and PRR. 
 
Figure.1.1 Structure of mammalian NUMB isoforms 
Overview of NUMB protein isoforms in human. The human genome encodes two NUMB 
homologs, NUMB and NUMB-like (NUMBL). NUMB undergoes alternative splicing to generate 
at least 9 isoforms, including 4 major isoforms that have been characterized. The four isoforms 
(hNUMB1-p72 isoform; hNUMB2-p66 isoform; hNUMB3-p71 isoform; hNUMB4-p65 isoform) 
are differentiated by alternative splicing in the PTB domain (exon 3) and PRR (exon9). NUMBL 
only expresses one protein, which is similar to the hNUMB4-p65 isoform and contains the short 
forms of both PTB domain and PRR. 
A small 11 amino acid insert in the PTB domain distinguishes p72-NUMB/p66-NUMB 
(PTBL, or PTBi) from p71-NUMB/p65-NUMB (PTBS, or PTBo) (sequence: ERKFF 
KGFFG K). This variation in the PTB domain is believed to determine the subcellular 
localizations of NUMB isoforms. The PTBL isoforms, p72 and p66, tend to localize at the 
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cell membrane periphery, PTBS isoforms, p71 and p65, are predominantly cytosolic (Dho 
et al., 1999a). A binding partner of NUMB, the Ligand of NUMB-protein X (LNX), which 
is an E3 ubiquitin ligase, is reported to ubiquitinate PTBL isoforms but not PTBS isoforms 
(Dho et al., 1998; Nie et al., 2004; Nie et al., 2002). Other than these examples of functional 
diversity, few differences have been described between the PTBL and PTBS isoforms. As 
will be presented in Chapter 3, the PTBL and PTBS isoforms exhibit no differences in 
binding to NxxF and NxxY motifs or ALK receptor tyrosine kinase both in vitro and in 
vivo.  
A large 48 amino acid insert in the PRR distinguishes p72-NUMB/p71-NUMB (PRRL, or 
PRRi) from p66-NUMB/p65-NUMB (PRRS, or PRRo) (sequence: ANGTD SAFHV 
LAKPA HTALA PVAMP VRETN PWAHA PDAAN KEIAA TCS). In preliminary 
studies, the PRRL and PRRS variants exhibited distinct functional patterns in different 
models of development. In vitro, the PRRS isoforms promote cell differentiation and are 
mainly expressed in the early stages of neural crest stem cell development, while the PRRL 
isoforms promote cell proliferation and are expressed throughout the entire developmental 
process (Verdi et al., 1999). In vivo, an expression pattern switch was observed during 
mouse neuronal development. Expression of PRRL or PRRS isoforms was prominent before 
and after the cortical progenitor differentiation (Bani-Yaghoub et al., 2007). However, only 
the PRRL isoforms were detected consistently in adult mouse brain tissue (Dho et al., 1999). 
A similar effect was also observed in mouse pancreatic and rat retinal development, in 
which overexpression of PRRL isoforms coincides with an expanding progenitor 
population (Dooley et al., 2003; Yoshida et al., 2003). Although the NUMB gene only 
expresses one protein without alternative splicing in Drosophila, ectopic expression of 
human PRRL and PRRS isoforms results in proliferation and differentiation of neural stem 
cells respectively (Toriya et al., 2006).  
Nevertheless, the mechanism of this isoform-dependent functional diversity has not been 
well elucidated at the molecular level. It is speculated that this diversity correlates with 
distinct interactomes for PRRL and PRRS isoforms in specific genetic backgrounds. In 
Chapter 3, a model will be presented that will partially explain a functional difference 
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between NUMB PRRL and PRRS isoforms. The isoforms are found to direct a receptor 
tyrosine kinase to different destinations during endosomal sorting.  
1.1.2 NUMB in cancer as a tumor suppressor 
Despite the important function of NUMB in the neural system and brain development, 
current research in human NUMB is centered on studying its role in cancer biology. It is 
not surprising that this cell fate determinant is involved in tumorigenesis. Previously, a 
conceptual correlation between cancer and asymmetric cell division was established 
(Morrison and Kimble, 2006; Reya et al., 2001). Stem cells are defined by their ability to 
generate more stem cells, known as self-renewal, as well as differentiating cells, usually 
via asymmetric cell division. A number of cell fate determinants, including NUMB, are 
involved in the regulation of asymmetric cell division. Impairment of this process can result 
in an imbalance between self-renewal and differentiation, resulting in disordered cell 
division and proliferation, which are key characteristics of cancer cells. Along with the 
correlation between cancer and asymmetric division, NUMB has been defined as a tumor 
suppressor since it attenuates the activity of the NOTCH receptor, one of the most 
frequently deregulated receptors in solid tumors (Flores et al., 2014), and assists in the 
stabilization of p53 to increase apoptotic susceptibility of immortal cancer cells (Colaluca 
et al., 2008). 
1.1.2.1 NUMB regulates the NOTCH signaling pathway  
The NOTCH (neurogenic locus notch homologue protein) pathway is an evolutionarily 
conserved signaling pathway present in most multicellular organisms, which has received 
increased recognition as a major deregulated signaling pathway in many solid tumors 
(Espinoza and Miele, 2013; Leong and Gao, 2008). In tumorigenesis, the pivotal function 
of NOTCH is similar to that of the NUMB protein, which controls cell fate determination 
and cellular proliferation (Artavanis-Tsakonas et al., 1999; Chiba, 2006). At the tissue 
level, NOTCH is also involved in angiogenesis and epithelial-mesenchymal transition 
(EMT) (Leong and Karsan, 2006). 
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The human NOTCH family consists of four homologs (NOTCH1-4). NOTCH proteins are 
expressed as full-length unprocessed proteins composed of a large extra cellular domain, a 
single transmembrane domain, and an intracellular domain. During transportation from the 
secretory system to cell membrane, NOTCH proteins are cleaved to generate two subunits: 
one consisting of the majority of the extracellular domain, and the other consisting the 
remaining extracellular domain, the transmembrane domain and the intracellular domain 
(Blaumueller et al., 1997; Capobianco et al., 1997). The two subunits finally associate via 
a calcium-dependent, noncovalent interaction to form a mature heterodimeric 
transmembrane receptor. 
NOTCH proteins are activated by a transmembrane ligand family of DSL proteins (Delta 
and Serrate/Jagged in Drosophila and mammals, LAG-2 in Caenorhabditis elegans) with 
five members in mammals: Jagged 1/2 and Delta-like 1/3/4, whose extracellular regions 
serve as NOTCH ligands (Nam et al., 2003). Upon ligand binding, the NOTCH 
extracellular domain undergoes a conformational change, resulting in the exposure of a 
cleavage site.  ADAM (a disintegrin and metalloproteinase) family proteins Kuzbanian 
(ADAM10) and TACE (ADAM17) shed the extracellular domain at this site, followed by 
another intracellular cleavage mediated by γ-secretase to release the entire intracellular 
fragment of NOTCH (NICD, NOTCH intracellular domain) (Bray, 2006; Brou et al., 2000; 
Wilkin and Baron, 2005). The NICD functions as a transcription co-activator after 
translocation into the nucleus, where it interacts with CSL nuclear transcription factor 
(CBF1/RBPJ, recombining binding protein suppressor of hairless), or the family of 
MASTERMIND transcription activators (MAML1/2/3) to promote the expression of genes 
required for the execution of NOTCH pleiotropic functions (Brou, 2009; Davis and Turner, 
2001; Iso et al., 2003). In mammals, the primary targets of NOTCH are genes belonging to 
the basic helix-loop-helix (bHLH) DNA binding proteins (Iso et al., 2003), containing at 
least two families: the hairy/enhancer-of-slit (HES) family and the hairy-related 
transcription factor (HRT, also known as HEY) family. Because both the NOTCH 
receptors and the DSL ligands are transmembrane proteins, activation of the NOTCH 
pathway is intercellular and directional from signal sending (DSL expressing) cells to 
signal receiving (NOTCH expressing) cells.  
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In healthy tissue, the best-characterized function of NOTCH is the determination of cell 
fate (Artavanis-Tsakonas et al., 1999; Chiba, 2006; Lai, 2004). Similarly to NUMB, 
aberrant NOTCH signaling has been implicated in human cancer (Roy et al., 2007). 
NOTCH was first identified as an oncogene in T-cell acute lymphoblastic leukemia (T-
ALL) in the form of chromosomal translocation fusion protein containing the N-terminal 
region of the T-cell receptor beta (TCRβ) and C-terminal of NOTCH (Ellisen et al., 1991). 
Identical to many other translocation fusion proteins of membrane receptors, this leads to 
expression of a constitutively active form of NOTCH, which continuously stimulates 
downstream signaling (Greenwald, 1994). It was later discovered that deregulation of 
NOTCH signaling is potentially oncogenic in a multitude of solid tumors and several other 
types of leukemia as well (Espinoza and Miele, 2013; Pancewicz and Nicot, 2011). To date, 
this list has rapidly expanded and contains almost all major solid cancer types, including 
cervical, head and neck, endometrial, renal, lung, pancreatic, ovarian, prostate, esophageal, 
oral, hepatocellular and gastric carcinomas, osteosarcoma, mesothelioma, melanoma, 
gliomas, medulloblastomas and rhabdomyosarcoma (Espinoza and Miele, 2013).  
The mechanisms of NOTCH signaling over-activation vary, but deregulation by NUMB 
loss-of-function plays a pivotal role in this process. In fact, altered NOTCH signaling (by 
intact NOTCH gene) is diagnosed in approximately one third of non-small-cell lung cancer 
(NSCLC) cases, which are correlated with wild type p53 and NUMB deletion. In contrast, 
gain-of-function NOTCH mutations are only identified in a much smaller fraction (around 
10%) of NSCLC cases (Westhoff et al., 2009). The NUMB-NOTCH interplay is well-
recognized as a tumor suppressor, however the precise mechanism continues to be 
reappraised based on new evidence. To date, several models have been proposed based on 
isolated reports. NUMB promotes NOTCH endocytosis and lysosomal degradation to 
attenuate NOTCH protein level in cells (Barth and Köhler, 2014; McGill et al., 2009; 
Yamamoto et al., 2010). In addition, NUMB increases NOTCH ubiquitination and 
degradation (McGill and McGlade, 2003), but it remains uncertain whether this 
ubiquitination takes place during the endocytosis of NOTCH, a situation that is common 
in the regulation of many membrane receptors. Other evidence also supports that NUMB 
binding prevents nuclear transportation of the NICD domain following full activation and 
cleavage of NOTCH (Berdnik et al., 2002; Frise et al., 1996; Gho et al., 1996). The models 
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of NOTCH activation, signal transduction, NUMB regulation are illustrated in Fig.1.2, and 
recently reviewed by Flores et al  (Flores et al., 2014).  
 
Figure.1.2 NUMB-regulated NOTCH signal transduction 
Overview of NUMB mediated inhibition of NOTCH signaling pathways. Upon ligand binding, 
NOTCH undergoes two cleavages and generates an intracellular fragment NICD, which is 
subsequently imported into the nucleus and functions as transcription co-activator. NOTCH-
regulated genes are widely involved in a number of cellular events. NUMB directly binds to 
NOTCH at the membrane periphery, which promotes NOTCH internalization and lysosomal 
degradation.  
 
1.1.2.2 NUMB stabilizes p53 to decrease immortality of cancer cells 
Tumor protein p53, also known as TP53 or the “guardian of the genome”, is the first 
identified tumor suppressor gene, originally described in 1979, and is also the most 
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commonly mutated gene in all cancer types and most widely studied tumor suppressor in 
research. At the cellular level, p53 is the central controller of cell mortality and plays a 
pivotal role in growth arrest, senescence, and apoptosis in response to a broad array of 
cellular damage events (Levine, 1997). 
The human p53 gene encodes a 43.7-kDa (53-kDa on SDS PAGE) protein with several 
evolutionarily conserved domains including an N-terminal transcription-activation 
domain, a proline rich domain, a DNA-binding domain and a C-terminal Chomo-
oligomerization domain. Typically, p53 maintains a relatively inactive form and low 
protein level in cells. Upon stimulation of cellular stresses, for example, DNA damage, 
oxidative stress or osmotic shock, p53 quickly accumulates and switches to an active form 
through a conformational change, and in turn assembles into a tetramer with full 
transcription regulation activity.  Hundreds of genes are then upregulated by the p53 
tetramer, including the key DNA repairing protein PCNA (Proliferating cell nuclear 
antigen) and cell cycle regulator p21 (CIP1/WAF1, cyclin-dependent kinase inhibitor). 
The regulation, and activation of p53 mainly relies on rapid post-translational 
modifications. Previously, MDM2 (mouse double minute 2 homolog) has emerged as the 
principal cellular antagonist of p53 (Moll and Petrenko, 2003). MDM2 was first found to 
be associated with p53 (Momand et al., 1992), and subsequently identified as a E3-
ubiquitin ligase that mediates the p53 ubiquitination and lysosomal degradation (Haupt et 
al., 1997; Kubbutat et al., 1997). p53 and MDM2 form an auto-regulatory feedback loop. 
MDM2 is a direct transcription target gene of p53, thus active p53 stimulates MDM2 
expression. In turn, MDM2 blocks p53 activity by mono-ubiquitinating p53 for 
degradation in both nuclear and cytoplasmic proteasomes. Cells have also employed 
various mechanisms to disrupt the balance of this feedback loop in response to stresses. 
DNA damage can promote the phosphorylation of both p53 and MDM2, thereby 
preventing the interaction and stabilizing p53 (Lakin and Jackson, 1999). Conversely, 
receptor tyrosine kinase stimulated Akt (RAC-α serine/threonine-protein kinase) activation 
phosphorylates MDM2 to promote MDM2 nuclear import, which destabilizes p53 in the 
nucleus (Zhou et al., 2001).  
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Figure.1.3 Control of p53 activity by NUMB and MDM2 
Overview of the regulation of p53 signaling pathway. Typically, p53 maintains a relatively inactive 
form and low protein level in cells. Upon stimulation, p53 quickly accumulates and switches to an 
active form by assembling a tetramer that functions as an activator of transcription. p53-regulated 
genes are widely involved in cell death related events as shown in the figure. MDM2 is an E3 ligase 
that binds to p53 and promotes p53 degradation. NUMB-p53 binding prevents p53 from MDM2 
mediated ubiquitination thus attenuating the immortality of cells. 
NUMB has been found to associate with MDM2 (Juven-Gershon et al., 1998) but the 
function of this interaction was not elucidated until the tricomplex NUMB/MDM2/p53 was 
described a decade later (Colaluca et al., 2008). In this complex, NUMB binding prevents 
p53 from ubiquitination by MDM2, thus increasing p53 level in cells (Fig.1.3). In primary 
breast cancer cells lacking NUMB, p53 level decreases due to ubiqutination which in turn 
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promotes resistance to chemotherapeutics. In addition, the NUMB-p53 interaction was 
further found to be regulated by Set8 (N-lysine methyltransferase SETD8) (Dhami et al., 
2013). The dynamic methylation of NUMB Lysine-158 and Lysine-163 regulates the 
interaction between NUMB and p53. Overexpression of Set8 interrupts the NUMB-p53 
interaction and abolishes NUMB-induced apoptosis. These findings, combined with the 
parallel NUMB-NOTCH signaling, predict a potential of adjuvant therapy design for 
NUMB-defective cancer types that usually display poor prognosis.  
1.1.3 The controversial functions of NUMB in cancer 
To date, it is known that NUMB has multiple functions at both cellular and tissue levels 
due to the vast number of NUMB binding partners and the functional diversity among 
NUMB isoforms. In addition to the negative regulatory effects on NOTCH deregulation 
and p53 instability, NUMB is also known to directly bind at least three receptor tyrosine 
kinases (RTKs) (EGFR/EphB2 /TrkB) and attenuate the activation of RTK downstream 
signaling (Jiang et al., 2012; Nishimura et al., 2006; Zhou et al., 2011).  Even though direct 
evidence is lacking to make a solid conclusion, it is speculated that NUMB may act as a 
universal regulator for endocytosis of membrane localized proteins. In a similar mechanism 
for NOTCH, NUMB likely deregulates RTK activity by promoting endocytosis and 
subsequent degradation of these receptors.  
In contrast, NUMB also exhibits some oncogenic properties in an isoform dependent 
manner. As mentioned above, the four major NUMB isoforms are generated by alternative 
splicing in exon3 and exon9, and named based on their molecular weights: p72 
(PTBL/PRRL), p71 (PTBS/PRRL), p66 (PTBL/PRRS) and p65 (PTBS/PRRS). It has been 
well established that PRRL and PRRS isoforms have distinct functions in developmental 
models of several organs and tissues. PTBL and PTBS may also differ in function since p72 
and p66 tend to localize to the cell membrane periphery while p71 and p65 generally 
distribute in the cytoplasm.  Consistently, PRRL isoforms, but not PRRS isoforms, have 
been found prominent in a number of cancer types from a large-scale transcript analysis of 
clinical samples, including breast cancer, colon cancer and lung cancer (Misquitta-Ali et 
al., 2011). In some lung cancer cells it has also been shown that inclusion of exon 9 
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correlates with cell proliferation (Bechara et al., 2013; Westhoff et al., 2009). In addition, 
the RBM5/6 and RBM10 splicing factors, which are responsible for NUMB exon 9 
inclusion or exclusion, regulate cancer cell proliferation conversely (Bechara et al., 2013). 
Together, these observations clearly reveal that NUMB-PRRL isoforms are potentially 
oncogenic, and these isoforms contribute to the activation of at least one common signaling 
pathways of cell proliferation in both development and tumorigenesis. 
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1.2 Receptor tyrosine kinases in cancer  
1.2.1 Tyrosine phosphorylation  
Phosphorylation is the most common reversible post-translational-modification (PTM) of 
proteins. 518 protein kinases have been identified in the human genome, constituting about 
1.7% of all human genes. These kinases, as well as kinase substrates and phosphatases, are 
involved in many different cellular events, including metabolism, transcription, cell cycle 
progression, cytoskeletal rearrangement and cell movement, apoptosis and differentiation 
(Manning et al., 2002), and deregulation of kinase activity is a hallmark of a multitude of 
cancer types. To date in cancer treatment, most approved target therapeutics are either 
small molecule kinase inhibitor or receptor kinase inhibition antibodies. 
Serine/threonine kinase activities were first reported in 1954 (Burnett and Kennedy, 1954). 
Nearly 25 years later,  tyrosine phosphorylation was described (Eckhart et al., 1979; Sefton 
et al., 1980) even though in 1933 phosphotyrosine synthesis already revealed the 
theoretical possibility of tyrosine phosphorylation (Levene and Schormueller, 1933). The 
human genome harbors 90 protein tyrosine kinases (PTKs), while most other (~400) 
kinases are serine/threonine kinases (Manning et al., 2002). Compared to serine/threonine 
phosphorylation, tyrosine phosphorylation is relatively rare and contributes approximately 
5% of all amino acid phosphorylation (Ushiro and Cohen, 1980). Unlike most serine or 
threonine phosphorylation, tyrosine phosphorylation normally has a very short half-life in 
cells (seconds in many cases) due to the presence of extremely active phosphotyrosine 
phosphatases (PTPs) (Hunter, 2014). However, the dynamic nature greatly facilitates RTK 
role as signal transduction modulators, which rely on fast changes of status. From a 
structural perspective, tyrosine phosphorylation is also distinct from serine/threonine 
phosphorylation. The phosphate on a tyrosine residue is linked to the O4 position of the 
phenolic ring, which is much farther away from the peptide backbone, compared to the 
phosphate on the β-OH groups on serine and threonine residues. This provides a more 
recognizable site for specific binding, thereby allowing the evolution of highly-specific 
tyrosine kinases, p-Tyr-binding domains and phosphatases (Hunter, 2014). 
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In animals, a three-part molecular toolkit is employed to regulate tyrosine phosphorylation 
and p-Tyr-mediated signaling: PTKs, protein tyrosine phosphatases (PTPs) and p-Tyr-
recognition domains, respectively, as “writer”, “erasers” and “readers” of p-Tyr 
modifications. PTKs add p-Tyr modifications, PTPs remove the modifications, while p-
Tyr-recognition domains readout the modifications. Besides the 90 PTKs, the human 
genome encodes 107 PTPs or dual specificity phosphatases, and hundreds of p-Tyr-
recognition proteins including 121 members of the Src homology 2 (SH2) domain family 
(Liu et al., 2012; Liu et al., 2006; Liu et al., 2011). Based on all these modules, humans 
have developed a multi-layered regulation network that precisely tunes the tyrosine 
phosphorylation dynamics for over 10,000 sites throughout the genome (Liu et al., 2012; 
Tan et al., 2009). 
 
Figure.1.4 Three-part toolkit of tyrosine phosphorylation 
Three-part modeling system of p-Tyr signaling. The “writer” PTKs phosphorylate select tyrosine 
residues in the substrate proteins. The p-Tyr residues are recognized by the “reader” p-Tyr-
recognition domain containing proteins (SH2, for example). And the “eraser” PTPs remove the 
phosphate groups from the tyrosine residues in the substrate proteins.  
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1.2.2 Tyrosine phosphorylation mediated cell signaling 
Tyrosine kinases are generally divided into two major families based on their sub-cellular 
localizations: the transmembrane receptor tyrosine kinase (RTK) family with 58 members 
which fall into 20 subfamilies, and the cytoplasmic tyrosine kinase (or non-receptor 
tyrosine kinase) family with 32 members which falls into at least 9 subfamilies. All RTKs 
have a similar molecular architecture, containing an amino terminus ligand binding site in 
the extracellular region, a single transmembrane domain, an intracellular tyrosine kinase 
domain, and, in many RTKs, a carboxy terminus tail with multiple p-Tyr sites that are 
crucial for signal transduction. RTKs serve as an entry portal for a large number of 
extracellular growth factors, and undergo a similar process to activate and transfer the 
signal into the cytoplasm. In general, the growth factors (ligands) from the extracellular 
matrix first bind to the ligand binding site on the RTK extracellular region. This ligand-
binding mediates a dimerization between two RTK molecules which is the key event in 
RTK activation. This dimerization then brings two intracellular kinase domains into close 
proximity, which in turn phosphorylates the tyrosine residues in the activation loop. The 
activation loop is a short conserved peptide located in the catalytic core of the kinase. In 
all tyrosine kinases, the activation loop harbors 1~3 tyrosine residues that, in most cases, 
are the first tyrosine(s) to be phosphorylated during kinase activation. Structural studies 
have revealed that phosphorylation of the activation loop enables kinase substrate and ATP 
binding (Hubbard et al., 1994; Lemmon and Schlessinger, 2010). After activation of the 
kinase domain by intermolecular auto-phosphorylation, the active kinase domain further 
generates more p-Tyr sites in the intracellular region for recruiting cytoplasmic signaling 
proteins (p-Tyr-recognition proteins) to initiate the cytoplasmic signaling transduction 
(Ullrich and Schlessinger, 1990). It should be noted that the growth factors can facilitate 
the dimerization via at least three different mechanisms: (1) ligand-induced receptor-
mediated dimerization, which is elucidated from structural studies of the best known ErbB 
(epidermal growth factor receptor) RTK subfamily. Ligand binding results in a 
conformational change in ErbB extracellular regions, which in turn exposes the 
dimerization sites (Burgess et al., 2003); (2) Dimeric ligands, a number of RTKs, including 
PDGFR, KIT and their other homologs, lack a dimerization site in the extracellular region 
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and their dimerization is mediated by the direct interaction between two ligand molecules 
(Bae et al., 2009); (3) Ligand and accessory molecule-mediated dimerization, which relies 
on binding of both ligands and other effectors from the extracellular matrix (Schlessinger 
et al., 2000). Intriguingly, a small subset of RTKs can dimerize even in the absence of 
activation ligands, meaning a ligand-independent self-activation (Lemmon and 
Schlessinger, 2010).  
Cytoplasmic tyrosine kinases are normally activated via cross-activation with RTKs, in 
which the kinase domain of an activated RTK directly interacts with a cytoplasmic tyrosine 
kinase and phosphorylates its activation loop (Lemmon and Schlessinger, 2010). For 
instance, the cytoplasmic Src kinase specifically localizes at the cell membrane periphery 
where it can interact with at least two RTKs, ErbB1 (EGFR) and ErbB2. Once activated 
by the EGF (epidermal growth factor) ligand, ErbB1 and ErbB2 sequentially activate the 
Src kinase in the cytoplasm (Kim et al., 2005). 
Following ligand-stimulated RTK activations and sequential cross-activations of non-
receptor tyrosine kinases, active kinases will phosphorylate a number of downstream 
substrate proteins. Interestingly, profiling of the global tyrosine phosphorylation network 
following growth factor stimulation exhibited that, in many cases, the highly 
phosphorylated proteins are the RTKs and non-receptor tyrosine kinases. In addition to the 
activation loop, tyrosine phosphorylation is also frequently found at other sites in both the 
kinase and non-catalytic regions. For example, the four members of the ErbB RTK 
subfamily contain 72 p-Tyr sites (ErbB1/EGFR-22, ErbB2-13, ErbB3-14, ErbB4-23) in 
total, and the non-receptor tyrosine kinase Src contains at least 9 p-Tyr sites. As shown in 
Fig.1.5, a number of well-characterized biologically-functional p-Tyr sites have been 
illustrated in the intracellular region of EGFR receptor. Most of these p-Tyr sites are 
generated by intermolecular auto-phosphorylation, while at least two sites (p-Tyr-845/p-
Tyr-1101) are phosphorylated by Src tyrosine kinase. These p-Tyr sites can be broadly 
classified into two groups: signaling-related sites and self-regulatory-related sites, which 
act conversely in the regulation of RTK activity/signaling transduction. For the signaling-
related p-Tyr, different sites are recognized by different p-Tyr-recognition (SH2) and 
phosphotyrosine-binding domain (PTB) proteins, thereby initiating the assembly of 
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different signaling complexes in the cell membrane periphery to transduce growth factor 
stimulated signaling. Two major signaling pathways, the PI3K (phosphatidylinositol-4,5-
bisphosphate 3-kinase) signaling pathway and the MAPK (mitogen-activated protein 
kinase) signaling pathway which are also termed as survival pathway and proliferation 
pathway in cancer biology, are activated by phosphorylation of Y-1068/1086/1148 and Y-
1101 respectively. Although not well elucidated, some other p-Tyr sites in the EGFR 
intracellular region may also promote the activation of PI3K or MAPK signaling pathways, 
because in vitro SH2-p-Tyr binding assay revealed more p-Tyr sites in EGFR binding to 
PI3K/MAPK-related SH2 proteins such as Grb2. The other group of p-Tyr sites, which 
also play a role as docking sites for SH2 proteins, are mainly involved in negative self-
regulation of EGFR. p-Tyr-1045 and p-Tyr-1173 are two key self-regulatory sites distinct 
in their regulation mechanisms. p-Tyr-1045 is recognized by a SH2-containing E3 
ubiquitin ligase Cbl. Upon Cbl binding, the nearby lysine residues are ubiqutinated which 
serve as a sorting signal for targeting activated EGFR to coated pits for endocytosis and 
subsequent lysosomal degradation (Ettenberg et al., 1999; Grovdal et al., 2004; Visser Smit 
et al., 2009). p-Tyr-1173 binds to the SH2 domain-containing protein tyrosine phosphatase 
(SHP-1), which dephosphorylates the EGFR intracellular region to attenuate signaling 
(Keilhack et al., 1998). It is now well known that tyrosine phosphorylation can further 
introduce other types of post-translational-modification to RTKs via recruiting respective 
SH2 containing PTM modulators, which, in many cases, conversely regulate the activities 
of RTKs in a feedback regulatory loop (Hunter, 2007; Lemmon and Schlessinger, 2010).  
Because p-Tyr-SH2 binding only depends on a small peptide fragment around the 
phosphotyrosine residue, these SH2-containing proteins can potentially act universally. For 
instance, the Cbl recognizes a number of active RTKs, including but not limited to KIT, 
FLT1, FGFR1, FGFR2, PDGFRA, PGGFRB, EGFR, CSF1R, EPHA8 and KDR, as 
summarized in the Uniprot Database. Since RTKs stimulate signaling by employing the 
same set of SH2-containing proteins, RTKs are highly functionally-redundant especially 
in the activation of PI3K and MAPK signaling pathways, which contribute prominently to 
cancer cell immortality and fast proliferation. Therefore, targeting tyrosine kinase has 
become a promising strategy in treating specific cancer types in the clinic. As of February 
2016, 46 target therapeutics have been clinically approved by FDA for cancer treatment, 
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of which 28 are small molecule kinase inhibitors and 18 are humanized antibodies. It is 
easy to tell the significance of tyrosine kinase inhibitors (TKIs) simply by the statistics: 25 
of 28 small molecule inhibitors mimic the ATP structure to block the catalytic core of 
tyrosine kinases, while 6 of 18 antibodies are designed to interrupt ligand stimulated RTK 
dimerization. In clinical diagnosis, determination of PTK gene amplification or protein 
expression level has also become standard procedure for a number of cancer types. For 
instance, approximately 30% of breast cancers are diagnosed as having ErbB2 gene 
amplification (HER2 positive).  
 
Figure.1.5 Functions of select p-Tyr sites in the EGFR receptor 
Multiple p-Tyr sites are generated in the intracellular region of EGFR following ligand stimulated 
EGFR dimerization and activation. Most sites are produced by intermolecular auto-
phosphorylation between dimerized EGFR molecules. At least two sites, p-Tyr-845 and p-Tyr-
1101 are phosphorylated by Src tyrosine kinase that associates with EGFR at the cell membrane 
periphery. The p-Tyr sites serve as docking sites for different SH2-containing proteins, which plays 
different roles after binding to EGFR. Sites marked in grey are self-regulation sites: (1) p-Tyr-845 
stabilizes the kinase in an active status; (2) p-Tyr-974 promotes EGFR internalization; (3) p-Tyr-
1045 binds to an E3 ubiquitin ligase Cbl thus increasing EGFR ubiquitination and degradation; (4) 
p-Tyr-1173 binds to PTP that attenuates EGFR phosphorylation level. Sites marked in blue are 
signaling transduction sites. p-Tyr-1068/1086/1148 all stimulate the MAPK signal pathways while 
p-Tyr-1101 only stimulates the PI3K signaling pathway. 
19 
 
Despite the quickly-expanding understanding of RTK-mediated signal transduction, our 
knowledge of the spatiotemporal dynamics of how RTK signaling controls specific cellular 
events has lagged behind (Volinsky and Kholodenko, 2013). Two great challenges have 
been encountered along the way. One limitation is that a reliable high-throughput approach 
to quickly profile the kinase-substrate pairings in the kinome is lacking. Even though not 
as abundant as serine/threonine phosphorylation in the human proteome, over 10,000 p-
Tyr sites have been identified in human due to recent improvements in p-Tyr-enrichment 
and mass-spectrometry (MS) approaches, while most are non-PTK p-Tyr-sites. Many non-
PTK p-Tyr sites have been proven functional and implicated in a wide range of cellular 
events (Reynolds et al., 2014). The best-studied Src tyrosine kinase is the first described 
oncogene and PTK (Hunter and Sefton, 1980), which has only 67 substrates 
(PhosphoSitePlus Database) that have been verified in vitro and in vivo almost four decades 
after its discovery. Many p-Tyr sites in these substrates have been shown to be correlated 
with the transformation ability of Src kinase (Reynolds et al., 2014). The slowly emerging 
kinase-substrate pairings are largely due to the promiscuous nature of PTKs, which makes 
the conventional kinase-assay-based approaches not necessarily reliable. In addition, the 
functional redundancy and cross-activation of PTKs also limits the application of MS based 
in vivo approaches.  
Even if the kinase-substrate is systematically paired, we are also facing another challenge 
in deciphering the complex signaling network. A good example exhibiting the complexity 
of RTK signaling is from studies on PC12 cells. Treatment by two different growth factors, 
NGF (nerve growth factor) and EGF (epidermal growth factor), resulted in different 
biological effects in PC12 cells (Morooka and Nishida, 1998). NGF initiates the 
differentiation of PC12 cells while EGF only stimulates cell proliferation. However, this is 
not caused by the activation of different RTKs that NGF/EGF target (Tyk/ErbB, 
respectively), but because of the different durations of the active status of MAPK signaling 
pathway, which was confirmed in another study using a light-controlled MAPK activation 
system (Zhang et al., 2014).  This interesting observation has raised many questions yet to 
be answered, but clearly demonstrates the complex nature of the p-Tyr-mediated signaling 
network. If simply focusing on the network of ErbB subfamily, some progress has been 
made to draw a relatively comprehensive network of regulation map, as reviewed by 
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Yarden and Sliwkowski (Yarden and Sliwkowski, 2001). The overall signaling network is 
divided into three major layers: input, signal processing and output. (1) The input layer 
consists of four ErbB subfamily members and a number of extracellular growth factors 
(ligands). ErbB receptors can form either heterodimers or homodimers, and different 
growth factors favor different dimers. These diversified dimers among ErbB receptors 
consequently generate different combinations of p-Tyr sites (SH2 docking sites) in their 
intracellular regions, thereby recruiting different groups of SH2-containing signaling 
complexes. At this input layer, the relative abundance of growth factors and ErbB proteins 
differentiate the signal output. (2) In the signal-processing layer, as expected, the assembly 
of different SH2-containing signaling complexes in the membrane periphery will result in 
the activation of different signaling processing components. Similarly, the abundance of 
these SH2-containing proteins will determine the direction of signal transduction. In 
addition, several feedback loops exist between the input layer and the signal-processing 
layer, for example, Cbl E3 ligase binds to p-Tyr sites in ErbB and the subsequent 
ubiquitination promotes ErbB degradation, as introduced earlier. (3) The output layer is the 
least-understood and most complicated part in this network. Because most pTyr sites 
identified in Src kinase substrates contribute to Src transformation ability (Reynolds et al., 
2014), it can be speculated that a large number of uncharacterized tyrosine phosphorylated 
proteins may be implicated in a broad range of cellular events in tumorigenesis.  
1.2.3 Endocytosis regulates RTK signaling 
Endocytosis is a process in which cells take in extracellular materials by engulfing and 
fusing them with the cell membrane. Depending on the materials cells take up, endocytosis 
is further classified as pinocytosis (cell drinking) and phagocytosis (cell eating). A common 
destination of the internalized material is digestion/degradation in the lysosome, which is 
why endocytosis is termed as cell drinking and eating. On the other hand, cells also 
evacuate intracellular materials via an opposing process called exocytosis. Endocytosis and 
exocytosis are key cellular events and essential for material exchange between cells and 
the environment. Another well-known function of endocytosis is found in the immune 
system, in which some immune cells actively capture and internalize pathogens, foreign 
particles or debris from dying cells by phagocytosis. 
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Besides the material exchange, endocytosis is one of the major regulators of the activity 
and signaling of RTKs, as well as many other receptors on the cell membrane. These 
transmembrane proteins are internalized along with a portion of the cell membrane, 
inserted in the lipid bilayer of endosomal vesicles and subsequently degraded in the 
lysosome. At the cell surface, endocytosis is constitutively occurring for internalizing 
RTKs, which is crucial for RTK function in both an inactive status and a ligand-stimulated 
active status of cells.   
In the inactive cells, endocytosis is a process required for the renewal of RTKs on the cell 
membrane. Internalized RTKs have two distinct destinations following endocytosis, 
recycling back to the membrane from early endosomal vesicles or compartmentalizing in 
late endosomal vesicles. This process is also termed endosomal sorting and is regulated by 
a number of effectors that dynamically control the balance between recycling and 
degradation. The rate of RTK endocytosis is usually slower compared to that of RTK 
synthesis and delivery from Golgi apparatus to membrane. Thus, RTKs can retain a 
relatively high abundance on the cell membrane, which is thought to facilitate an 
expeditious response to extracellular growth signals (binding of ligands) (Goh and Sorkin, 
2013).  Altogether, endocytosis, protein synthesis and delivery and the preference of 
endosomal sorting decide the renewal rate of RTKs and assist in maintaining RTK stability 
on the cell membrane.  
Upon ligand stimulated activation, cells also employ endocytosis to regulate the signaling 
from RTKs. As introduced earlier, ligand binding quickly triggers auto-phosphorylation in 
the intracellular regions of RTKs to generate multiple p-Tyr sites, which then recruit SH2 
containing proteins that function in signaling transduction or RTK self-regulation (Fig.1.5). 
During this process, some endocytic proteins can be recruited to the RTKs, thus initiating 
a fast endocytosis. Conventionally, endocytosis is thought to negatively regulate RTK 
activity and signaling by decreasing RTK abundance on the cell membrane and promoting 
RTK degradation, even though a portion of internalized RTK is recycled back to the 
membrane. Studies on the endocytosis of EGFR have provided solid evidence to support 
this model. Upon activation, the EGF-EGFR complex is detectable in endosomal vesicles 
within 2~5 minutes following EGF stimulation (Beguinot et al., 1984; Haigler et al., 1979). 
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Simultaneously, the free (un-liganded) EGFR still undergoes endocytosis but at a rate at 
least 10-fold slower (Wiley et al., 1991). Following internalization, EGFR is degraded in 
the lysosome, thus overall EGFR activity and downstream MAPK and PI3K signaling are 
attenuated. 
This model has been challenged by some recent studies, which reveal that ligand-
stimulated RTK endocytosis may play a role as both a positive and negative regulator of 
RTKs.  RTKs are still able to signal in the endosomal system before degradation and the 
effect of endocytosis varies under different circumstances (Kermorgant and Parker, 2008; 
Kermorgant et al., 2004; McPherson et al., 2001; Miaczynska et al., 2004). It is 
unsurprising that membrane-localized EGFR is confirmed as the major contributor to the 
activation of MAPK and PI3K signaling. However, EGF bound EGFR is found to remain 
active in endosomal vesicles, while the EGFR intracellular region is still exposed to the 
cytoplasm and able to recruit SH2 containing proteins for assembly of signaling complexes 
(Brankatschk et al., 2012; Sousa et al., 2012). It is estimated that endosomal EGF-EGFR 
may contribute ~10% to the activation of MAPK and PI3K signaling in specific 
environments. In addition, it is reported that endocytosis of EGFR is required for the 
activation of a subset of signaling transducers, suggesting endosomal EGF-EGFR may 
primarily activate some side signaling pathways in the cytoplasm (Vieira et al., 1996). The 
most promising evidence comes from a study of MET (hepatocyte growth factor receptor) 
RTK, which clearly demonstrates the pivotal role of endocytosis in MET oncogenicity 
(Joffre et al., 2011). This study takes advantage of a MET mutant that exhibits 
accumulation on the endosome due to increased endocytosis/recycling activity and 
decreased levels of degradation. Blocking endocytosis has little effect on MET auto-
phosphorylation but significantly inhibits anchorage-independent growth, in vivo 
tumorigenesis and in vivo metastasis. In summary, RTK function results not only from 
ligand stimulated auto-phosphorylation but also from the altered subcellular localizations 
during endocytosis. Endocytosis may bring an extra spatiotemporal regulatory layer to the 
RTK signaling network. 
Endocytosis has also been defined as a potential therapeutic target for some specific cancer 
types. A study in EGFR-positive lung cancer reports that abnormal endocytosis is 
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associated with intrinsic resistance to the EGFR small molecule inhibitor gefitinib. The 
deregulation of Rab25, an endocytic protein, results in drug resistance by inducing 
continuous EGFR endocytosis, and the knock-down of Rab25 is able to re-sensitize these 
resistant cells to gefitinib (Jo et al., 2014). Drug resistance to target therapeutics is a major 
problem facing current cancer research, and is common in all RTK positive cancer types 
(Holohan et al., 2013). The drug resistance can be intrinsic, which is present before 
treatment, or acquired during treatment. For instance, although diagnosed as HER2 positive, 
around 70% of patients have little or no response to the ErbB2 inhibitor Herceptin (Baselga 
et al., 1996). In the remaining 30% of patients, many of them will develop acquired 
resistance quickly after receiving the treatment, usually within months, which is caused by 
therapy-induced adaptive responses or positive selection of an intrinsically-resistant 
subpopulation. The mechanism of resistance is highly complicated and yet not 
systematically evaluated in large scale studies. From a number of individual reports, there 
are two common causes: (1) mutations in the ATP binding site prevent binding of the small 
molecule kinase inhibitors (Coco et al., 2012; Kobayashi et al., 2005); (2) activation of 
alternative signaling pathways bypasses the drug inhibition (Lu et al., 2001). This study 
first reveals that abnormal endocytosis contributes to drug resistance in RTK positive 
cancer types. However, the mechanism is not clearly elucidated, and it is only speculated 
that continuous EGFR endocytosis induced by Rab25 overexpression stimulates gefitinib-
resistance related signaling.  
1.2.4 ALK-positive cancers and ALK target therapeutics 
The receptor tyrosine kinase Anaplastic lymphoma kinase (ALK), also known as CD246 
(cluster of differentiation 246), was first described during the identification of a 2;5 
chromosomal translocation in anaplastic large-cell non-Hodgkin’s lymphoma (ALCL) 
(Morris et al., 1994; Shiota et al., 1994). ALK belongs to a small RTK subfamily, 
consisting of only two members ALK and LTK (leukocyte receptor tyrosine kinase), as 
defined by their unique extracellular domains containing a glycine-rich region (Palmer et 
al., 2009). Based on their kinase domain similarities, ALK/LTK are closely related to the 
insulin receptor tyrosine kinase subfamily. Previously, a few potential ALK ligands were 
reported but none have been well characterized (Murray et al., 2015; Stoica et al., 2001; 
24 
 
Stoica et al., 2002). Compared to many other well-studied RTKs, ALK is not functionally 
significant in physiology, and only highly-expressed in the neural system during the early 
developmental stage (Morris et al., 1994). 
ALK did not draw attention from researchers until multiple reports in 2008 defined it as a 
biomarker and therapeutic target in neuroblastomas (Carén et al., 2008; Chen et al., 2008; 
George et al., 2008; Janoueix-Lerosey et al., 2008; Mossé et al., 2008), including four 
Nature reports. Since then, ALK has been shown to be involved in the initiation and 
progression of many different cancer types, including lymphomas, neuroblastoma, non-
small-cell lung cancer (NSCLC), colorectal cancer and melanomas (Hallberg and Palmer, 
2013). The activity of ALK can be deregulated by mutation, gene amplification, 
translocation fusion and as reported recently, alternative transcription initiation (Wiesner 
et al., 2015). It should be noted that the ALK locus is a hotspot of translocation, though the 
reason remains unclear. Over 30 ALK kinase domain containing fusion proteins with at 
least 22 fusion partners have been identified in different cancers (Fig.1.6). The frequencies 
of these translocations vary, except for the EML4 (echinoderm microtubule-associated 
protein-like 4) fusion which has been diagnosed in 4%~7% of NSCLC and shown to 
promote and maintain the malignant behavior of the cancer cells (Sasaki et al., 2010; Soda 
et al., 2007). The oncogenic fusion partners share characteristics, which generally promote 
the dimerization of the ALK kinase domain, a mechanism that mimics the ligand stimulated 
dimerization of RTKs in the cytoplasm. Similar to other RTK positive tumors, deregulated 
ALK promotes tumorigenesis by constitutively stimulating MAPK and PI3K signaling 
pathways. Because ALK normally maintains a low level and is likely not functionally 
essential in adults, ALK inhibition exhibited remarkably strong drug tolerance, meaning a 
higher dose is applicable  in clinic with less adverse effects (Crescenzo and Inghirami, 
2015).  
The first generation ALK small molecule inhibitor crizotinib (Xalkori®, Pfizer) was 
granted an accelerated approval by FDA in 2011 for the treatment of advanced NSCLC 
with EML4-ALK fusion, which set a record from discovery to therapy progressing in less 
than three years. In addition, the second generation inhibitor alectinib (Alecensa®, Roche) 
was also granted an accelerated approval in December, 2015. 
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Figure.1.6 Oncogenic forms of ALK 
Overview of the ALK de-regulated forms in tumorigenesis. Similar to that in other RTK positive 
cancer types, overexpression and constitutively active (kinase) mutations are common in ALK 
positive cancers. It’s intriguing that ALK forms over 30 different translocation fusion proteins with 
at least 22 fusion partners in a multitude of cancer types. Adapted from (Hallberg and Palmer, 
2013). 
Despite the oncogenic potential and therapeutic value of ALK, the mechanism of ALK 
regulation remains elusive.  Currently most efforts have been put toward the investigation 
of ALK deregulation in different cancer types or the mechanism of crizotinib resistance. In 
the following chapters, we will present a mechanistic insight into NUMB mediated ALK 
regulation as a potentially universal negative regulatory system for RTKs. 
26 
 
1.3 Scope of thesis project 
NUMB is a multifaceted protein that is involved in a broad range of cellular events. In 
cancer biology, NUMB has exhibited opposing biological effects, either as a tumor 
suppressor via attenuating oncogenic NOTCH signaling, assisting in p53 stabilization, or 
as a potential oncogene.  The oncogenic nature of NUMB is not mechanistically elucidated 
but supported by a number of clinical sample based studies. At the molecular level, the 
complex nature of NUMB function is speculated to be caused by the heterogeneity of 
NUMB interacting proteins in different genetic backgrounds. 
To uncover the mechanisms of NUMB functions, particularly in cancer biology, we 
designed a stepwise strategy to first decipher NUMB binding specificity and identify novel 
NUMB binding partners via an integrated high-throughput approach. It is intriguing that a 
number of RTKs bind NUMB both in vitro and in vivo, revealing that NUMB may act as 
a universal regulator of RTKs. These findings, once further validated, could potentially 
contribute to the personal diagnosis and therapy of RTK positive cancer types, for example 
the combination of RTK deregulation and NUMB depletion may indicate a more severe 
prognosis. Our following work mainly focuses on the ALK receptor, which is the 
therapeutic target in a number of cancers. To date two generations of ALK inhibitors have 
been clinically approved. We found that NUMB regulates ALK endocytosis, similar to its 
regulation of NOTCH receptor. Interestingly, following internalization, the two NUMB 
isoforms p72 and p66 direct ALK into distinct destinations in endosomal sorting. The p72 
isoform mainly recycles ALK back to the membrane to sustain the active status of ALK 
signaling while the p66 isoform attenuates ALK signaling by mediating ALK degradation 
in the lysosome. Consistently, the two isoforms exhibited opposing effects in anchorage-
dependent cancer cell growth. This NUMB-ALK interaction does not rely on ALK 
phosphorylation, and it is still uncertain whether this interaction responds to ALK 
activation thus forming a feedback regulatory loop.  The promotion of endocytosis has 
been coupled with RTK activation as reported in many preliminary studies, and the 
endocytosis is thought to be a significant strategy employed by the cells to self-balance 
RTK activity.  
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Overall, our findings provide a mechanistic insight into ALK regulation and the 
tumorigenic potential of the p72-NUMB isoform, and further reveal markers of potential 
clinical value. 
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Chapter 2  
2 Investigation of NUMB-PTB interactome  
2.1 Abstract 
Cellular events rely on protein-protein interactions that are often mediated by the modular 
domains which recognize particular sequence motifs within their binding partners.  The 
NUMB protein is the first described cell fate determinant that is conserved from fly to 
human. Further studies have since revealed the complex nature of NUMB functions that 
are involved in a wide range of cellular events. As a tumor suppressor, NUMB attenuates 
the activity of NOTCH which is one of the most deregulated receptors in cancer, and 
stabilizes p53 from ubiquitination and degradation. NUMB mainly mediates protein 
interactions via its modular PTB domain. Here we present a systematic investigation of the 
NUMB-PTB interactome by employing an integrative strategy combining both protein 
array and peptide array. NUMB-PTB binding specificity is thoroughly profiled and 
explained at a structural level. Interestingly, we find that RTKs are highly enriched in the 
NUMB interactome. The interactions with select RTKs are further verified in vivo, 
including ALK, ErbB2 and FGR. Our study not only provides a systematic overview of the 
NUMB-PTB interactome, but also reveals novel interactions between NUMB and RTKs 
that have potential clinical value for the diagnosis and treatment of RTK positive cancers. 
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2.2 Introduction 
Proteins involved in many important cellular events are often found to be interacting with 
each other. Protein-protein interactions (PPIs) play a pivotal role in biological processes 
and mediate signaling transduction that is often mis-regulated in many cancers (Arkin and 
Wells, 2004). Characterizing the interactome of a certain protein can be crucial to 
systematically understand its functions. NUMB is the first defined cell fate determinant, 
originally identified in Drosophila (Rhyu et al., 1994; Uemura et al., 1989). NUMB plays 
an important role in the development of both Drosophila and mammals, especially in the 
development of the neural system. NUMB-deficient mice die at an early embryonic stage 
and display severe neural defects (Zhong et al., 2000). At the molecular level, NUMB 
exhibits a complex array of functions and is involved in a multitude of biological processes 
including ubiquitination-mediated protein degradation, endocytosis, cell adhesion, cell 
polarity, cell migration and tumorigenesis (Gulino et al., 2010). This wide range of roles is 
likely due to the heterogeneity of NUMB-interacting proteins from different genetic 
backgrounds. 
Most NUMB functions are uncovered during identification of novel NUMB-binding 
proteins. For instance, NUMB was found to play a role in the ubiquitin network by directly 
interacting with several E3 ligases: Mdm2 (Juven-Gershon et al., 1998), Lnx (Nie et al., 
2002), Itch (Di Marcotullio et al., 2006) and Siah1 (Susini et al., 2001). NUMB has also 
been defined as an endocytic protein because it interacts with endocytic regulators EH, 
EPS15, EPS15R and AP-2 (Berdnik et al., 2002; Salcini et al., 1997) and localizes to the 
cell membrane peripheral region (Dho et al., 1999). During endocytosis, NUMB mediates 
the internalization of a number of membrane associated proteins, including NOTCH, 
Integrins, E-cadherin and TrkB, all of which were discovered through their interactions 
with NUMB (McGill et al., 2009a; Nishimura and Kaibuchi, 2007; Sato et al., 2011; Wang 
et al., 2009; Zhou et al., 2011). Similarly, the function of NUMB in cell polarity and 
migration was discovered alongside the identification of NUMB-Par complex 
(Par3/Par6/aPKC) interaction (Nishimura and Kaibuchi, 2007; Sato et al., 2011; Wang et 
al., 2009).  
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As an adaptor protein, NUMB contains a prototypical protein-protein interaction domain, 
the phosphotyrosine binding (PTB) domain, which is evolutionarily and functionally 
conserved. Based on the SMART database, there exists at least 5208 PTB domains within 
4530 proteins across different species. In particular, the human genome encodes 46 
proteins containing 51 PTB domains. PTB domain-containing proteins are often adaptor 
and scaffold proteins, which organize and regulate the signaling networks involved in a 
wide variety of biological processes (Uhlik et al., 2005). PTB domains can be classified 
into three groups: IRS-1/Dok-like, Shc-like, and Dab-like (Uhlik et al., 2005). The IRS-
1/Dok-like and Shc-like groups are phosphotyrosine-dependent; they specifically bind to 
p-Tyr sites similar to SH2 domain containing proteins. The Dab-like group also recognizes 
tyrosine residues, but the binding is phosphotyrosine independent. NUMB-PTB is one of 
many PTB domains that belong to the Dab-like group. Even though they are not directly 
involved in tyrosine phosphorylation mediated signaling transduction, Dab-like PTB 
containing proteins participate in the regulation of various cellular events such as 
endocytosis (Howell et al., 1999; Kinoshita et al., 2001), cell membrane protein processing 
(Guenette et al., 1999; Hill et al., 2003), asymmetric cell division (Chien et al., 1998) and 
integrin-mediated cell adhesion (Chang et al., 1997; Filardo et al., 1995).  
Considering the complexity of its functional pattern, it is not surprising that NUMB has 
been implicated in cancer as a tumor suppressor. The cancer-related role of NUMB mainly 
relies on the interplay between NUMB and either the NOTCH receptor, or MDM2/p53 
complex. NUMB directly binds to NOTCH (Guo et al., 1996) and p53 (Dhami et al., 2013) 
through its PTB domain but regulates NOTCH and p53 via different mechanisms. NUMB 
promotes the internalization and subsequent degradation of cell membrane-localized 
NOTCH, thus attenuating NOTCH-stimulated signaling of cell proliferation (McGill et al., 
2009b; McGill and McGlade, 2003). In contrast, NUMB stabilizes p53 activity by 
preventing MDM2-mediated ubiquitination and degradation of p53 (Colaluca et al., 2008). 
Both NUMB-NOTCH and NUMB-p53 interactions bear great potential for the 
development of novel anti-cancer targeted therapeutics, whose functions and applications 
can be elucidated through a systematic investigation of the NUMB interactome. 
Conventionally, a number of high-throughput methods have been developed for mapping 
the interactome, such as affinity-purification mass spectrometry (AP/MS), and the hybrid-  
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Figure.2.1 A strategy to identify NUMB-PTB binding specificity and interactome 
The Green text boxes represent operation, while the blue text boxes represent output. A 
commercially available ProtoArray was probed with purified NUMB PTB domain. In 
complementary experiments, the specificity profile of NUMB PTB, as determined by OPAL 
peptide array, was used to score the NxxF/Y motifs in the pool of proteins identified by ProtoArray 
using the computer program SMALI. NxxF/Y motifs scored above a cut off value were further 
validated in vitro and in vivo.  
reporting systems: yeast two hybrid (Y2H). Although AP/MS is one of the most powerful 
approaches for PPI studies, the technique does not distinguish between direct and indirect 
interactions or detect low-abundance proteins. Y2H is useful in vivo system, but is less 
time- and cost-efficient. Here we represent an alternative strategy for effectively mapping 
the interactome of the NUMB PTB domain (Fig.2.1). Briefly the direct NUMB-PTB 
43 
 
interactors were profiled by probing biotinylated NUMB-PTB on a commercially available 
protein array, which contains 8274 purified and normalized human proteins. 
Simultaneously, an oriented peptide array library (OPAL) (Rodriguez et al., 2004) was 
synthesized and probed with the NUMB-PTB. The data was processed using the SMALI 
(scoring matrix-assisted ligand identification) program (Li et al., 2008a) to generate a 
prediction of NUMB-PTB binding specificity and sites. The PTB-binding proteins and 
sites were further validated using protein-peptide binding assay, immunoprecipitation and 
pull down assay. Intriguingly, we identified several receptor tyrosine kinases (RTK) as 
PTB direct binding partners both in vitro and in vivo, which had never been reported before. 
In addition, when the PTB binding site predictions were applied across the whole human 
genome, a number of RTKs were high-scored and ranked at the top of the list. One such 
interaction occurs between NUMB and ALK, a receptor tyrosine kinase involved in 
tumorigenesis (presented in Chapter 3). NUMB mediates ALK internalization and 
regulates its post-endosomal trafficking antagonistically in an isoform-dependent manner. 
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2.3 Material and methods 
2.3.1 Cell culture  
HeLa cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS), 100 µg/ml penicillin, 100 µg/ml streptomycin and 2 
mg/ml L-glutamine. SKBR3 cells were grown in Roswell Park Memorial Institute (RPMI) 
1640 medium supplemented with 10% FBS, 100 µg/ml penicillin, 100 µg/ml streptomycin 
and 2 mg/ml L-glutamine. HEK293/ALK stable cells were grown in DMEM supplemented 
with 10% FBS, 100 µg/ml penicillin, 100 µg/ml streptomycin, 2 µg/ml puromycin and 2 
mg/ml L-glutamine. Cells were incubated at 37 °C in a humidified atmosphere containing 
5% carbon dioxide.  
2.3.2 GST-NUMB-PTB expression, purification and biotinylation 
The BL21 strain of Escherichia coli was transformed with pGEX6P3-dNUMB-PTB or 
pGEX6P3-mNUMB-PTBL/PRBS. Positive colonies were cultured in Lysogeny Broth (LB) 
medium to a density of OD600 0.6~0.8, then the protein expression was induced with 0.5 
mM IPTG for 16 hours at 18°C. The bacterial cells were harvested and pellets were re-
suspended in PBS buffer containing complete protease inhibitors (Roche). Triton X-100 
was added to a final concentration of 2%, lysozyme was added to a final concentration 1 
mg/ml and benzonase was added to a final concentration 20 units/ml. The suspension was 
sonicated six times (10 seconds each) on ice and then lysed for 30 min at room temperature. 
Lysates were centrifuged at 15,000 × g for 30 min at 4°C and the supernatant was collected. 
Purification of GST-tagged proteins was performed with glutathione resin (GE healthcare). 
The resin was washed with PBS buffer three times. The lysate supernatant was loaded to 
the resin followed by three column volume washes with PBS buffer, then eluted with 10 
mM glutathione in PBS buffer (no elution step for pulldown assay). To determine GST-
protein purity, a small amount of purified protein (or protein on resin) was boiled with 
SDS-loading dye and then analyzed by SDS-PAGE/Coomassie staining. The GST NUMB-
PTB domains used for the Protoarray hybridization were biotin-labeled using EZ-Link™ 
Sulfo-NHS-Biotinylation Kit (Thermo) in 1×PBS buffer. 
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2.3.3 ProtoArray hybridization 
The Protoarray Human microarray (Invitrogen) was equilibrated at room temperature for 
30 minutes prior to blocking. The array was arranged barcode-side up in each well of a 
chilled 4-chamber incubation tray. 5 ml blocking buffer (50 mM HEPES pH 7.5, 200 mM 
NaCl, 0.08% Triton X-100, 25% Glycerol, 20 mM Reduced glutathione, 1 mM DTT and 
1× Synthetic Block) was then added to the array and incubated for 1 hour at 4 °C with slow 
shaking. After blocking buffer was removed, biotinylated GST-dNUMB-PTB was diluted 
to final concentration of 5 µM in washing buffer (1×PBS, pH 7.4, 1×Synthetic Block, 0.1% 
Tween 20) to form the blotting solution. 120 µL of blotting solution was added on top of 
the array surface and then a LifterSlip cover glass was carefully attached to the array. The 
array was blotted for 90 minutes at 4 °C without shaking. The cover glass was then 
removed and the array was washed with washing buffer 5 times for 5 minutes each at 4 °C 
with slow shaking. The array was visualized by incubation with 5 ml Alexa Fluor 647-
conjugated streptavidin for 90 minutes at 4 °C with gentle shaking. Then the array was 
washed again following the same procedures as above. Finally, the array was dipped into 
distilled water once to remove salt residues and scanned using Tecan fluorescence 
microarray scanner. Data were analyzed using ArrayPro software. 
2.3.4 Transient transfection 
Plasmid DNA was first diluted in serum-free Minimum Essential Media (MEM) to a final 
concentration of 0.01 µg/µl. For each 10-cm dish, 40µl X-tremeGENE HP DNA 
transfection reagent (Roche) was mixed with 1ml plasmid DNA in MEM. The mixture was 
added to the culture dish (10ml) after 15 min incubation at room temperature. After 
transfection, cells were incubated for 48~72 hours to allow for ectopic gene expression. 
2.3.5 Immunoprecipitation, pull down and western blotting 
Cultured cells were lysed in ice-cold mammalian cell lysis buffer (1% Triton X-100, 50 
mM Tris-pH 7.2, 150 mM NaCl, 2 mM MgCl2, 0.1 mM EDTA, 0.1 mM EGTA, 0.5 mM 
DTT, 10 mM NaF) containing complete protease inhibitors (Roche). Cell debris was 
removed by centrifugation, and 500 µg of supernatant protein was incubated for four hours 
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in the presence of 1 µg antibody and 30 µl of 50% slurry protein G-Sepharose beads 
(Roche), or 1 µg immobilized GST fusion protein (beads). The beads were subsequently 
washed three times with lysis buffer and boiled with SDS-loading dye. The precipitates 
were resolved by SDS-PAGE. Proteins were then transferred to polyvinylidene fluoride 
PVDF membrane using semi-dry transferring method, and detected by immunoblotting 
with appropriate antibodies and visualized by enhanced chemi-luminescence (ECL). 
2.3.6 Free peptide and peptide array synthesis 
Both free and membrane-bound peptides were synthesized using an automatic Intavis AG 
workstation from amino acid monomers protected with Fmoc (9-fluorenylmethyl-
oxycarbonyl). Rink-resin (Rink-NH2) was used to couple the first amino acid in free 
peptide synthesis, whereas the amine-derivate cellulose membrane (cellulose-NH2) was 
made to couple the first amino acid in on-membrane peptide synthesis. In each synthesis 
cycle, the carboxyl group of Fmoc-protected amino acid (Fmoc-R-COOH) was first linked 
to the amine group of the previous amino acid (or Rink-NH2) through an amide bond. All 
unoccupied amine groups were then blocked (acetylated) by acetic anhydride to prevent 
incorrect amide bonds forming in subsequent cycles. Next, the Fmoc group was removed 
by piperidine (de-protecting) to release the free amine group primed for linking the 
carboxyl group of next amino acid residue. Fluorescein-NHS was linked to the amine group 
of the last amino acid in free peptide synthesis. After synthesis, the on-membrane peptides 
were treated with a mixture containing 47.5% TFA (trifluoroacetic acid), 1.5% TIPS (tri-
isopropylsilane) and 51% water, to remove all other protecting groups on amino acid side 
chains. The free peptides were treated with a mixture containing 95% TFA, 3% TIPS and 
2% water to de-protect side chains while cleaving the peptide from Rink-resin. 
2.3.7 Far western assay for peptide membrane blotting 
The peptide membrane was blocked with 5% skim milk in TBST buffer (0.1 M Tris-HCl, 
pH 7.4, 150 mM NaCl, and 0.1% Tween 20) for 1 hour at room temperature, with slow 
shaking. GST-fusion proteins were added directly into the blocking buffer to reach a final 
concentration of 1µg/ml and incubated with the peptide array membrane for 1 hour at room 
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temperature, with slow shaking. The membrane was then washed with TBST buffer three 
times for 5 minutes each with shaking. Next, anti-GST-HRP antibody was added at 1:3000 
(v/v) into 5% milk in TBST buffer. The membrane was incubated for 1 hour at room 
temperature with slow shaking followed by the same washing procedures as above. Finally, 
the bound GST-protein was visualized using ECL.  
2.3.8 Determination of dissociation constant 
The dissociation constant between protein and peptide was determined using a fluorescence 
polarization (FP) assay. Proteins and fluorescein labelled peptides were prepared following 
the procedures introduced above. To reduce variation, two independent tests were prepared 
simultaneously. 384-well flat bottom plates (Corning-3537) were used for the assay and a 
PerkinElmer Envision 2103 plate reader was used for evaluating FP. The peptides 
(approximate 2 µM each, mass) were dissolved in 100 µl DMSO and 3µl was diluted 100 
fold in water. The concentrations of the proteins were determined and adjusted to 50 µM. 
2-fold serial dilutions were set up to result in 16 different protein concentrations ranging 
from 0 to 50 µM. 30 µl of each protein sample was mixed with 5 µl peptide in the 384-well 
plate and the FP was measured. Non-linear fit was approximated by assuming peptide 
concentration was much lower than Kd value in the following equation: 
∆FP = FPobs - FP0 = FPmax x [domain] / (KD + [domain]) 
The full equation without the approximation can be found in this study (Kaushansky et al., 
2010). 
2.3.9 Consensus binding motif and SMALI matrix 
The OPAL membrane was scanned and the intensity was quantified on a Bio-Rad imaging 
system. To generate consensus motifs based on specific binding signals, the average 
background signal of the membrane was subtracted from the dataset. Since a conspicuous 
column of Lys or Arg was detected in the corresponding OPAL screen, these strong Lys 
or Arg signals are position-independent. To minimize position-independent effect, the 
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value for each Lys or Arg spot was readjusted by subtracting the average of the Lys or Arg 
in the column. See more details for SMALI scoring in (Li et al., 2008b). 
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2.4 Results 
2.4.1 Screening NUMB PTB domain binding proteins using protein array 
Similar amounts of protein are presented in each spot on the ProtoArray, creating equalized 
conditions for NUMB-PTB binding regardless of protein expression in different genetic 
backgrounds. The ProtoArray consists of 48 (12×4) grids, and each grid contains 400 
(20×20) spots (Suppl.S1). The ProtoArray was incubated with 5 µM of biotinylated GST-
NUMB-PTB domain followed by labelling with Alexa Fluor 647 streptavidin, and then the 
signal of hybridization was measured using a fluorescent micro-slide reader as shown in 
Fig.2.2A. Only a small portion of spots yielded a detectable signal, indicating the positive 
binders. The intact datasets for all grids were quantified and analyzed by ArrayProxy 
software.  
The Z-scores were calculated for the signal intensity of each individual spot. To further 
examine the NUMB-PTB binding candidates, a minimum cut-off Z-score of 3.0 was 
applied (Suppl.S2), resulting in a list of 112 potential NUMB PTB binding partners 
(Suppl.S3). The candidate list was analyzed using String software (Szklarczyk et al., 2015) 
to map a functional protein association network. Next, the network was imported into 
Navigator software (Brown et al., 2009) to create a NUMB interacting network. As shown 
in Fig.2.2B, it is intriguing that the majority of candidates are protein kinases, including 30 
tyrosine kinases and 34 serine/threonine kinases. Within the 64 kinases, PRKCQ, PRKCG, 
PPKCPE, RKCB, PRKCA and CAMK2B  have been verified as NUMB direct interacting 
partners in previous reports (Martin-Blanco et al., 2014; Smith et al., 2007; Tokumitsu et 
al., 2005). 
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Figure.2.2 NUMB PTB domain interactome 
(A) A protein array (ProtoArray®, Invitrogen) representing 8274 human proteins was probed with 
biotinylated dNUMB-PTB domain. (B) Proteins in the interactome of NUMB-PTB are grouped 
according to GO annotations. Color codes used are as follows: purple, tyrosine kinases; green, 
serine/threonine kinases; grey, all other NUMB-PTB binding partners. 
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2.4.2 Characterizing NUMB-PTB domain binding sites in the interactome  
The NUMB PTB domain is known to bind NxxF/NxxY motifs (Li et al., 1998). To better 
evaluate our ProtoArray results, we selected 50 proteins which are disease especially 
cancer relevant from the highest Z-score 18.7 to as low as -0.3 and scanned their full 
sequences for NxxF and NxxY motifs. Peptides containing 11 amino acids for 109 motifs 
within the 50 protein we selected were synthesized on a nitrocellulose membrane, as well 
as 3 positive control peptides (9:6, JIP4_HUMAN; 9:7, NAK and 9:8, NAK-AA). The PTB 
domain of NUMB was expressed as a GST fusion protein in E.coli and purified. In a far 
western assay, the membrane was hybridized with GST-NUMB-PTB domain and anti-
GST-HRP antibody sequentially, then illuminated by ECL solution and imaged using a 
BioRad imaging system (Fig.2.3A and Suppl.S4). 11 of 109 peptides exhibited detectable 
binding signals in this assay. Next, we synthesized free forms of the 11 peptides, as well 
as two positive control peptides IAIDNTAFMDE and GPIVNEGYVNT and two negative 
control peptides GKKGNLVYIID and LKPSNILYVDE. These peptides were attached 
with a fluorescein label and their binding affinities (dissociation constant, Kd) to NUMB-
PTB were determined individually by using the fluorescence polarization (FP) assay. As 
shown in Fig.2.3B, the 11 positive peptides and positive control peptides have relatively 
high binding affinities to NUMB-PTB, whereas the negative control peptides exhibit no 
binding. All binding curves with Kd less than 50 µM are shown in Fig.2.4. It is interesting 
that peptides from three receptor tyrosine kinases, ALK, ErbB2 and ROS1, exhibited 
comparatively strong binding affinity to NUMB PTB domain, suggesting that NUMB may 
generally bind to receptor tyrosine kinases via the PTB domain. It should be noted that all 
proteins containing NUMB-PTB binding motifs, as verified in the far western assay, had 
Z-scores above 3.0 (Fig.2.6E and Suppl.S4), indicating that a reasonable cut-off was 
chosen in the data analysis of ProtoArray. 
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Figure.2.3 Verifying NUMB-PTB domain binding sites in the interactome 
(A) 108 NxxF and NxxY motifs, as predicted through the interactome, were synthesized in a 
peptide array and probed with NUMB-PTB domain (GST fusion). The horizontal numbers above 
the membrane represents the column number and the vertical numbers on the right of the membrane 
represents the row number; (C) The binding affinity of selected peptides identified in the peptide 
array, including motifs from tyrosine kinases ALK, ErbB2, FGR, LCK and ROS1. 
Based on the results of far western and FP assays, we performed sequence logo analyses 
to study the amino acid preference of NUMB-PTB domain binding motifs. 13 peptides 
with binding affinity stronger than 50 µM were set as positive binding peptides of the 
NUMB-PTB domain in this analysis, while the remaining two peptides served as negative 
binding peptides. An initial one-sample analysis of all 112 peptides showed amino acid 
preferences only for N at -3 position and Y or F at zero position (Fig.2.5A). Next, we did 
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a positive and negative Two Sample Sequence Logo analysis, and determined a 
[G][F][V]Nx[A/G]Y/F[E][D] amino acid consensus sequence (Fig.2.5B). Fig.2.5B 
exhibits amino acid preferences in individually tested positive peptides. In Fig.2.5C, the 
amino acid residues are colored in a gradient from small (yellow) to large (green). There is 
an observed preference for small amino acids in the -6 and -1 positions. In Fig.2.5D, the 
amino acid residues are colored with red (acidic), blue (basic) and orange (aromatic) 
respectively, and it is apparent that acidic residues are preferred in the +1 and +2 positions 
while hydrophobic residues are preferred in the -5 position. 
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Figure.2.4 Binding curves for a selection of NUMB-PTB interactors  
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Figure.2.5 Amino acid preferences of verified NUMB-PTB binding motifs 
(A-B) Sequence LOGOs were generated from motifs exhibiting high binding affinities to NUMB-
PTB domain as determined by an in vitro FP assay. The residue positions are labeled from -7 to +2 
with respect to F or Y, which is designated as position 0; (C) small amino acid residues at -6 and -
1 positions are preferred for NUMB-PTB binding; (D) acid amino acidic residues are preferred at 
+1 and +2 positions while hydrophobic residues are preferred at -5 position; (E) overview of amino 
acid preferences in verified NUMB-PTB binding motifs. 
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2.4.3 Defining NUMB-PTB domain binding specificity 
To systematically define the NUMB-PTB domain binding specificity, we employed an 
Oriented Peptide Array Library (OPAL) strategy. In parallel, we synthesized an OPAL 
array with N fixed at P-3 and P-0 positions directly on a nitrocellulose membrane. The 
flanking residues Gly (G) was added to each to mimic natural condition of the peptides. 
Recombinant GST-NUMB-PTB protein was incubated with this OPAL array and then 
detected using anti-GST-HRP. As shown in Fig.2.6A-B, the most obvious binding 
preferences based on the spot intensity value were observed at the P -1 position, where A 
and G were preferred. Weaker binding was observed at P-5 [I, Y, F], P-4 [D, I, V], P-2 [E, 
F, Y], P+1 [D, E] and P+2 [D] with even weaker signals at P-5 [V], P-4 [Y], P-2 [L], and 
P+2 [E]. The K/R spots were discarded, as these residues are known to display non-specific 
binding properties in peptide arrays. The array was quantified, by generating a scoring 
matrix that reflects the preference for an amino acid at a given position (Suppl.S5) and a 
heat map was constructed according to the scoring matrix (Fig.2.6C).  
Next, we employed the SMALI approach to score the NUMB-PTB domain binding sites 
on the NUMB interactome identified above. A peptide with a higher SMALI score is 
considered to have a greater propensity for binding to NUMB-PTB domain. We first used 
SMALI to predict the binding between the 112 peptides and NUMB-PTB domain 
(Fig.2.6D and Suppl.S4). The SMALI scores for the positive (NUMB-PTB binding) 
peptides correlated well with their binding affinities (Kd values) and a significant 
difference was confirmed between the SMALI scores of the positive peptides and negative 
peptides (Fig.2.6E). 75% of positive peptides had SMALI scores greater than 1.25 while 
75% of negative peptides have SMALI scores less than 0.75. Among the 11 positive 
peptides, the FPCGNVNYGYQ peptide has a relatively low SMALI score, which is due 
to the incorrect recognition of the NxxF motif in the SMALI program. This peptide has 
NVNYGY sequence containing partially overlapping NVNY and NVGY motifs. Indeed, 
the peptide shifted by two amino acids (CGNVNYGYQQQ) had a high SMALI score of 
1.25, and we confirmed that NUMB-PTB bound to NYGY but not NVNY in this ALK 
peptide (Chapter 3). Overall, SMALI results represent an accurate prediction of NUMB-
PTB binding sequences on the top hits of our ProtoArray data. 
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Figure.2.6 Identifying NUMB-PTB binding specificity  
(A-B) OPAL membranes GxxNxxYxxG and GxxNxxYxxG were probed with NUMB-
PTB (GST fusion). Dark spots indicate positive binding; (C) Heat map visualization of 
amino acid preferences; (D) SMALI scores of verified binding and nonbinding motifs to 
the NUMB-PTB domain. 
2.4.4 Structural explanation of NUMB-PTB binding specificity 
Structure analysis was also performed to evaluate the binding preferences of the NUMB 
PTB domain. The structure of NUMB-PTB domain in complex with the NAK peptide 
(GFSNMSFEDFP) is shown in Fig.2.7A. (PDB code 1DDM, (Zwahlen et al., 2000)). The 
surface of NUMB PTB is colored according to its hydrophobicity while the peptide is 
shown in sticks. The PTB domain provides a hydrophobic pocket for binding peptides 
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between Gly at -6 position and Phe at position 0 (Fig.2.7A). The percentage of buried 
surface of each of the NAK peptide residues in NUMB PTB domain was calculated. A 
value of 100% means the ligand residue is fully buried in the interaction interface. Each 
residue at minus positions are captured well, with the exception of Met at -2 and Asp at +2 
positions (Fig.2.7B). A close view of Ser at -1 position reveals that it is captured by a 
hydrophobic groove with no extra space to accommodate a larger amino acid. In addition, 
as pointed by Zwahlen et al (Zwahlen et al., 2000), a residue without chemical polarity 
would be more favorable by boosting the hydrophobic interaction, which supports the 
preference for A or G at this position (Fig.2.7C). Next, two PTB domain-peptide complex 
structures were used as parallel templates for modelling. The program MODELLER (Webb 
and Sali, 2014) was used to build a model structure.  
The in-solution peptide binding assay indicated that Gly at -6 position is strongly preferred 
(Fig.2.5B). The NAK peptide in the dNUMB-PTB domain complex structure contains 
residues up to Gly at -6 position of the N-terminus but does not contain further residues. 
To study the potential role of Gly at -6 position of ligand peptides, we modelled an N-
terminally extended NAK-AA peptide in complex with the dNUMB-PTB domain. The 
structure of the ARH (autosomal recessive hypercholesterolemia) PTB domain in complex 
with a 13-mer peptide (containing the residues from -8 to +4, PDB code 3SO6) was used 
as a secondary modelling template, in conjunction with the dNUMB-PTB domain complex 
structure. The sequence identity between the two PTB domains is 30% (37/123), and both 
ARH-PTB domain and Numb-PTB belong to the Dab-like PTB domain group (Fig.2.7D). 
The dNUMB PTB domain was then modelled in complex with an extended NAK peptide. 
Two additional magenta-colored residues are at the N-terminus of the peptide. The 
modelled peptide also contains two alanine replacements (Met to Ala at -2 position, Ser to 
Ala at -1 position), named NAK-AA, which has shown significantly increased binding 
affinity compared to the wild-type NAK peptide (Zwahlen et al., 2000). These two alanine 
residues increase the hydrophobic interaction (Fig.2.7E).  
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Figure.2.7 Structural analysis of NUMB-PTB binding specificity 
(A) The NUMB-PTB domain provides a hydrophobic pocket for peptide binding between Gly at -
6 position and Phe at position 0; (B) the percentage of buried surface for each residue in the NAK 
peptide in the complex; (C) a close-up-view of Ser at -1 position in the hydrophobic groove. This 
limited binding space likely explains why Ala or Gly is preferred at this position; (D) a comparison 
between NUMB-PTB binding and ARH PTB binding; (E) the preference of Ala in -1 and -2 
positions contribute to the hydrophobic binding; (F) Gly at -6 position introduces a kink to help 
orient Thr at +7 and Lys at -8 positions in the groove without a steric hindrance. 
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In a close-up view of N-terminal residues in the modelled peptide, all residues sit well in 
the groove up to Lys at -8 position. The most likely role of the Gly at -6 position is to place 
Thr at -7 and Lys at -8 positions in the groove without steric hindrance, by introducing a 
kink at this position (Fig.2.7F). 
2.4.5 Verification of NUMB RTK interactors in vivo 
To confirm novel NUMB interactions in vivo, we performed pull down and/or co-
immunoprecipitation assays. Three representative receptor tyrosine kinases, namely ALK, 
ErbB2, FGR whose deregulations are closely related to the abnormal behaviors of cancer 
cells were examined. We transiently expressed NUMB in HEK293 cells, which have 
inherently stable ALK expression. Reciprocal immunoprecipitations (IP) were performed 
between NUMB and ALK, and both proteins can be co-immunoprecipitated with each 
other (Fig.2.8A). The NUMB-ErbB2 interaction was verified by co-immunoprecipitation 
in SKBR3 cells which are known for ErbB2 overexpression and moderate NUMB 
expression (Fig.2.8B). The NUMB-FGR interaction was verified by pulldown assay with 
HeLa cell lysate (Fig.2.8C). We found FGR preferentially bound to the NUMB-PTBL 
isoform, which is consistent with the fact that PTBL isoforms are generally located in the 
cell membrane peripheral region where membrane-localized FGR also exists. Overall, this 
in vivo verification further raises the possibility that NUMB may act as a universal binding 
partner of RTKs.  
 
Figure.2.8 NUMB binds to ALK, ErbB2, and FGR receptors in vivo 
(A) NUMB and ALK co-immunoprecipitate each other in HEK293 cells, which inherently express 
wildtype ALK. (B) ErbB2 co-immunoprecipitates NUMB in SKBR3 cells; (C) the long isoform of 
NUMB-PTB domain (PTBL/PTBi) pull down more FGR compared to the short isoform 
(PTBS/PTBo) in HeLa cells. 
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2.4.6 Predicting a genome-wide NUMB interactome by SMALI 
The human genome consists of 20,000-25,000 genes, but expresses a much larger number 
of proteins once variants and isoforms are taken into account. In our study, the ProtoArray 
only represents a limited protein spectrum with 8274 proteins. Considering the excellent 
accuracy of our SMALI prediction for NUMB-PTB binding motifs, we scanned the entire 
human protein database (Uniprot) screening for more potential NUMB binding partners. 
The top 1000 peptide hits from 1083 proteins, which are classified according to GO 
annotations are shown in Fig.2.9. 
The largest group is cell membrane proteins with 155 hits, which is consistent with the fact 
that many well characterized NUMB binding partners are membrane associated, such as 
NOTCH. Other top ranking groups include transcription (98 hits), kinases (69 hits), ion 
channels (49 hits), mitochondrial (37 hits), ubl conjugate pathway (28 hits) and protein 
tyrosine phosphatases (28 hits). A full list of NUMB-PTB binding candidates is attached 
in Suppl.S6. Aside from the tyrosine kinases that are highly enriched in this list, the PTP 
group is of special interest. We have shown above that NUMB-PTB binds to a number of 
RTKs both in vivo and in vitro, and in next chapter, a mechanistic insight into NUMB-
ALK interplay in cancer will be presented. Together, these data reveal the possibility that 
NUMB may act as a universal binding partner and regulator of RTKs, while in 
tumorigenesis, NUMB may also alter the progression of RTK positive cancer types. Thus, 
if NUMB is involved in broad interactions with PTPs resulting in biological function, we 
can speculate that a regulatory mechanism in the p-Tyr-mediated signaling network may 
also exist, in which NUMB acts as a common node to connect RTKs and PTPs in signal 
regulation. A test has been performed to examine the NUMB-PTP binding. We have 
confirmed NUMB-PTB bind to two motifs from PTP-9 and PTP-13, both with high affinity 
(Fig.2.10A-B). 
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Figure.2.9 Prediction of NUMB-PTB binding motifs genome-wide 
Classification of the top 1000 predicted NUMB-PTB binding motifs. These motifs were generated 
from 1083 proteins, and grouped according to GO annotations. 
 
Figure.2.10 NUMB binds to motifs in PTP-9 and PTP-13 
The binding curves for two motifs: TDYINASFMD from PTP-9 (A) and GGYINASFIK from PTP-
13 (B). The binding affinities are 21.6 ± 1.8 µM and 6.8 ± 0.3 µM, respectively. 
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2.5 Discussion 
2.5.1 An integrative array strategy for systematic investigation of domain-
peptide interaction mediated PPI network. 
Protein-protein interactions play a central role in almost all cellular activities. A number of 
high-throughput approaches have been well established for mapping PPI networks on a 
large scale. However, each approach has its own limitations. Although protein and peptide 
arrays may be used in systematic PPI identification in vitro (Jones et al., 2006; Tong et al., 
2002), inconsistent data are often observed using protein or peptide arrays alone, perhaps 
due to the fact that some peptides may have improperly oriented spatial arrangements (for 
instance, the peptide is not exposed in the protein surface). In our study of the NUMB-PTB 
interactome, we introduced an integrative array strategy that overcomes these limitations. 
The high-throughput interactome screen began with a ProtoArray, which generated high-
quality quantitative data representing physical interactions between NUMB-PTB and its 
binding partners. All potential ProtoArray hits for NUMB-PTB binding sites were 
individually verified in a peptide array and their binding affinities were quantitatively 
determined by FP. Further analysis suggested a good correlation in binding affinity 
quantifications between the protein and peptide arrays. In subsequent in vivo tests, a 
number of selected high scoring interactions (NUMB-RTKs) were verified and as 
presented in the next chapter, the NUMB-ALK interaction was shown to be biologically 
relevant. Although the physiological functions of the majority of interactions in this 
interactome await validation, our study provides an unbiased strategy to systematically 
explore domain-peptide mediated PPI networks.  
2.5.2 The genome-wide prediction of NUMB-PTB binding partners 
According to preliminary studies, NUMB-PTB was only known to bind NxxF and NxxY 
motifs. Here we systematically investigated NUMB-PTB domain binding specificity by 
determining the amino acid preferences from -5 to +2 positions (defining F/Y at zero 
position) via an integrative strategy combining in vitro and in vivo assays. Based on the 
determined level of specificity, we scanned the NUMB-PTB binding motif genome-wide 
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and analyzed the top 1000 candidates. It should be noted that a number of previously 
identified NUMB binding partners rank highly in this list, including NOTCH, cadherin, 
Integrin and EphB2.  
Membrane associated proteins, RTKs and PTPs are of particular interest in this study and 
comprise the largest group in the candidate list. This is consistent with the fact that NUMB 
is an endocytic protein. It is well known that NUMB localizes at the cell membrane via its 
PTB domain and recruits other endocytic proteins. As introduced earlier, RTKs are the 
most common oncogenic proteins and major therapeutic targets in cancer treatment. 
Presented in chapter 3, the NUMB-ALK interaction is shown to have biological relevance 
in which NUMB regulates ALK activity antagonistically during tumorigenesis in an 
isoform dependent manner. Considering the general function of NUMB in endocytosis, it 
can be speculated that NUMB may act similarly with other RTKs identified in our study, 
as well as with other membrane localized proteins. If supported by further evidence, 
NUMB may play a role as a crucial indirect effector of trans-membrane signaling 
transduction via altering membrane receptor abundance. Particularly in growth factor 
stimulated RTK signaling, if NUMB also assists in recruiting PTPs, an extra layer of 
regulation may be employed to the p-Tyr signaling network to make finely tuning to p-Tyr 
dynamics. 
Interestingly, proteins associated with transcription are also highly enriched in the 
prediction. Previously, few nuclear binding partners were identified for NUMB, even 
though NUMB can localize in the nucleus (Dhami et al., 2013; Martin-Blanco et al., 2014; 
Wang et al., 2015). The NUMB-p53 interaction has been thoroughly studied. Although 
NUMB binding has been shown to regulate the transcription of various genes downstream 
of p53, in this case, NUMB is only implicated in transcription regulation indirectly via p53 
stabilization. It is still uncertain whether the NUMB-p53 interaction alters the p53 
transcription activity at a molecular level. However, considering the complex interactome 
of NUMB, we cannot exclude the possibility that NUMB may be involved in transcription 
broadly by directly interacting with transcription associated proteins. 
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2.5.3 NUMB may act as a universal regulator to RTKs 
Previously, NUMB has been reported to interact with three RTKs: EphB2, TrkB and 
EGFR, of which all three interactions have been shown biologically relevance. The 
NUMB-EphB2 interaction is involved in ephrin-B1-induced spine development and 
maturation (Nishimura et al., 2006). The NUMB-TrkB interaction alters TrkB’s 
chemotactic response to BDNF (brain-derived neurotrophic factor) ligand (Zhou et al., 
2011). The NUMB-EGFR interaction is slightly more mechanically demonstrated; it has 
been shown that NUMB binding decreases EGFR at the protein level which regulates cell 
fate determination in glioblastoma stem-like cells (Jiang et al., 2012).  However, little direct 
evidence drawing solid conclusions for the functions of NUMB-RTK interactions has been 
published. Here, our study demonstrates that RTKs are highly enriched in the NUMB 
interactome and two typical oncogenic RTKs ALK and ErbB2 are directly interacting with 
NUMB in vivo. This discovery may bring NUMB to the center of tumorigenesis as a 
potential therapeutic target for RTK positive cancer types.  
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Chapter 3  
3 NUMB regulates ALK endocytosis and activity in an isoform-
dependent manner 
3.1 Abstract 
NUMB is an evolutionarily conserved protein that plays a multifaceted role in cellular 
homeostasis and is implicated in a variety of cellular events including cell adhesion and 
migration, endocytosis, polarity and cell fate determination. In cancer, NUMB is 
conventionally defined as a tumor suppressor, as loss of NUMB usually results in a disorder 
of these physiological processes. Conversely, we find that NUMB also promotes 
tumorigenesis via directing differentiated post-endocytic destinations of receptor tyrosine 
kinase ALK in an isoform dependent manner. NUMB directly interacts with ALK and 
mediates ALK endocytosis. After internalization, p66-NUMB mainly directs ALK to the 
lysosomal degradation pathway, thus attenuating the overall ALK level and the 
downstream MAPK proliferation signaling. Antagonistically, p72-NUMB promotes ALK 
recycling to the cell membrane and maintains the cell in an ALK active status. Our study 
explains some controversial findings about NUMB functions in tumorigenesis and reveals 
the tumorigenic potential of the p72-NUMB isoform, and also provides mechanistic insight 
into ALK regulation. 
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3.2  Introduction 
Anaplastic lymphoma kinase (ALK) is a member of the orphan receptor tyrosine kinase 
(RTK) subfamily, and originally was described as a fusion protein of the t (2;5) (p23;q35) 
translocation expressed in Anaplastic Large Cell Lymphomas (ALCL) (Morris et al., 1994; 
Shiota et al., 1994). Normally, the ALK receptor is only transiently expressed in the 
nervous system during early developmental stages and maintained at low level in adult 
tissue, with the exception of some neuronal cells (Morris et al., 1994). This gene is 
considered non-essential for development as only a mild behavioral phenotype was 
observed in knockout mice (Bilsland et al., 2008). However, deregulation of ALK activity, 
including mutations, amplifications and translocations, have been characterized in a subset 
of cancers. For instance, two ALK constitutively-active mutants F1174L and R1275Q are 
frequently found in neuroblastomas, which account for 15% of all childhood cancer deaths 
(George et al., 2008). ALK amplification has also been detected in neuroblastoma, 
colorectal cancer and non-small cell lung cancer (NSCLC) (Bavi et al., 2013; Salido et al., 
2011; Wang et al., 2013). It should be noted that approximately 4%~7% of NSCLC involve 
an EML4-ALK fusion kinase that is self-activated and shown to promote and maintain the 
malignant behavior of NSCLC cells (Sasaki et al., 2010; Soda et al., 2007). Similar to other 
RTK positive tumors, the deregulated ALK promotes tumorigenesis by constitutively 
stimulating various cancer-related signaling pathways including the MAPK proliferation 
pathway and the PI3K survival pathway.  Since ALK levels are low in healthy adult tissues, 
selective ALK inhibition tends to result in less adverse effects without compromising 
efficacy (Crescenzo and Inghirami, 2015). The FDA granted accelerated approvals in 2011 
and 2014 for two generations of ALK inhibitors (crizotinib and ceritinib) in treating ALK 
positive metastatic NSCLC. In addition, another inhibitor (alectinib) was recently approved 
for NSCLC patients who could not tolerate crizotinib treatment. 
Despite the oncogenic potential and therapeutic value of ALK, the mechanism to ALK 
regulation remains elusive.  Here we report that NUMB, a well-known adaptor protein, 
directly interacts with ALK, and two NUMB isoforms (p72 and p66) regulate ALK activity 
antagonistically by directing ALK to different post-endocytic pathways. NUMB is a 
membrane-associated protein that is highly conserved from fly to human and consistently 
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plays an essential role in the maintenance of cellular homeostasis in the nervous system 
(Dho et al., 1999; Pece et al., 2011). The NUMB gene was the first isolated cell fate 
determinant from Drosophila, whereby asymmetric distribution of NUMB during mitosis 
produced diverse neural cell fates (Uemura et al., 1989). In tumorigenesis, NUMB 
functions as an adaptor, and its asymmetric distribution has been implicated in a variety of 
cancer-related events and signaling pathways as well (Gulino et al., 2010; Pece et al., 
2011). Conventionally, NUMB is defined as a tumor suppressor due to its negative 
regulation of the Notch signaling pathway and cell proliferation by promoting Notch 
endocytic degradation (Couturier et al., 2012; McGill et al., 2009; McGill and McGlade, 
2003), or by preventing MDM2-mediated ubiquitination of p53 (Colaluca et al., 2008). 
Nevertheless, NUMB is also observed to promote tumorigenesis in an alternative splicing 
(AS) dependent manner. 
The NUMB gene undergoes alternative splicing to produce multiple isoforms. The four 
isoforms well characterized in both Drosophila and human share a similar structure and 
contain an N-terminal phosphotyrosine binding (PTB) domain, a proline rich region (PRR), 
two Asp-Pro-Phe (DPFs) motifs and one Asn-Pro-Phe (NPF) motif at the C-terminal. The 
isoforms are differentiated by the inclusion or exclusion of exon 3 in the PTB domain or 
exon 9 in the PRR (Bork and Margolis, 1995; Dho et al., 1999; Salcini et al., 1997; Verdi 
et al., 1996). The four isoforms exhibited distinct functions in Drosophila neuronal 
development (Verdi et al., 1999). Two PPRS isoforms primarily stimulate differentiation 
while two PRRL isoforms promote proliferation. Consistently, PRRL isoforms have been 
characterized in multiple cancer types, including breast cancer, colon cancer and lung 
cancer (Misquitta-Ali et al., 2011). It has also been reported that RBM5/6 and RBM10 
splicing factors, which are responsible for the NUMB exon 9 inclusion or exclusion, 
regulate cancer cell proliferation conversely (Bechara et al., 2013). The mechanism of these 
controversial effects is not well elucidated, but it is speculated that the exon 9 inclusion 
isoforms p72 and p71 may act antagonistically to exon 9 skipping isoforms p66 and p65 in 
cell proliferation. Indeed, in some lung cancer cells it has been shown that inclusion of 
exon 9 is correlated with increased cell proliferation (Bechara et al., 2013; Westhoff et al., 
2009). 
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In this study, we thoroughly studied the interaction between ALK and NUMB, which was 
identified from a preliminary high throughput screening of NUMB interactors, as presented 
in Chapter 2. Our results reveal that the NUMB-PTB domain binds to N1477MAF1480 
and N1585YGY1586 motifs in ALK in vivo, and the interaction directly regulates ALK 
internalization. In post-endocytic trafficking, the p66-NUMB isoform mainly promotes 
ALK degradation via the lysosomal pathway thus decreasing the activity of ALK and 
downstream MAPK proliferation signaling. Conversely, the p72-NUMB isoform recycles 
ALK back to the cell membrane to maintain ALK activity in cells. Our findings provide 
mechanistic insight into ALK regulation and the tumorigenic potential of the p72-NUMB 
isoform, and further reveal markers of potential clinical value.  
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3.3  Material and methods 
3.3.1 Cell culture 
IMR-5 cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS), 100 µg/ml penicillin/streptomycin and L-glutamine. 
HEK293 cells were grown in Roswell Park Memorial Institute (RPMI) 1640 medium 
supplemented with 10% FBS, 100 µg/ml penicillin/streptomycin and L-glutamine. Cells 
were incubated at 37 °C in a humidified atmosphere containing 5% carbon dioxide.  
3.3.2 Transient transfection 
The plasmid DNA was first diluted in serum-free Minimum Essential Medium (MEM) to 
a final concentration 0.01 µg/µl. For each 10-cm dish with 10ml culture medium, 40 µl of 
X-tremeGENE HP DNA transfection reagent (Roche) was mixed with 1ml plasmid DNA 
in MEM. The mixture was added to the culture dish after 15 min incubation at room 
temperature. Following transfection, cells were incubated for 48~72 hours to allow the 
ectopic gene expression. 
3.3.3 siRNA interference 
siRNA was synthesized to target either p66-NUMB, p72 NUMB or NUMB. For each 35-
mm dish, siRNA was first diluted with MEM to a final concentration of 2.5 µM in a 200 
µl total volume. 5 µl DharmaFECT reagent (GE) was added to 195 µl serum-free MEM 
and gently mixed. The siRNA and reagent were then mixed and added to the culture dish 
with 1.6 ml culture medium after 15 min incubation at room temperature. Cells were 
incubated for 48~72 hours before further analysis. 
3.3.4 Immunoprecipitation and western blotting 
The cultured cells were lysed in cold mammalian cell lysis buffer (1% Triton X-100, 50 
mM Tris-pH 7.2, 150 mM NaCl, 2 mM MgCl2, 0.1 mM EDTA, 0.1 mM EGTA, 0.5 mM 
DTT, 10 mM NaF) containing complete protease inhibitors (Roche). Cell debris was 
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removed by centrifugation, and 500 µg of supernatant protein was incubated for four hours 
in the presence of 1 µg antibody and 30 µl of 50% slurry protein G-Sepharose beads 
(Roche) at 4°C. The beads were subsequently washed three times with lysis buffer and 
boiled with SDS-loading dye. The immunoprecipitates were resolved by SDS-PAGE. All 
proteins were then transferred to PVDF membrane by semi-dry transferring method (Bio-
Rad), detected by immunoblotting with appropriate antibodies, and visualized by Enhanced 
Chemiluminescence (ECL). 
3.3.5 Recombinant protein expression and GST pull-down 
The BL21 strain of Escherichia coli was transformed with pGEX6P3-NUMB 
(PTBL/PTBS). Positive colonies were shaked in Lysogeny Broth (LB) medium at 37°C to 
reach OD600 0.6~0.8, then the cultures were induced with 0.5 mM IPTG for 16 hours at 
18°C. The bacterial cells were harvested and pellets were suspended in PBS buffer 
containing complete protease inhibitors (Roche). Triton X-100 was added to a final 
concentration of 2%, lysozyme was added to a final concentration 1mg/ml and benzonase 
was added to a final concentration 20 units/ml. The suspension was sonicated six times (10 
seconds each) on ice and then lysed for 30 min at room temperature. The lysate was 
centrifuged at 15,000 × g for 30 min at 4°C for collecting the supernatant. Purification of 
GST-tagged proteins was performed with glutathione resin (GE healthcare). The resin was 
washed with PBS buffer three times, and then the lysate was loaded to the resin followed 
by 3 times washing with PBS buffer. To determine the purity of GST-proteins, a small 
amount of resin was boiled with SDS-loading dye and then analyzed by SDS-
PAGE/Coomassie staining. Pull-down was performed by incubating mammalian whole 
cell lysate with GST-NUMB PTBL, GST-NUMB PTBS or GST beads for 4 hours at 4°C, 
followed by 3 washes with mammalian cell lysis buffer. Proteins that bound to GST or 
GST-PTB were resolved on SDS-PAGE and identified by Western Blotting. 
3.3.6 Gene truncation and site-directed mutagenesis 
Truncated forms of NUMB were constructed by standard PCR and re-ligation procedures. 
Five gene mutants, p66-NUMB-F162V, p72-NUMB-F162V, ALK-N1477A, ALK-
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N1583A, ALK-1477A/1583A were constructed by site-directed mutagenesis. A pair of 
complementary mutagenic primers were designed for individual mutants. The entire 
plasmids were amplified using high fidelity DNA polymerase. Then Dpn1 enzyme was 
used to digest the methylated template plasmid. Undigested plasmids were recycled and 
used for transformation. Positive colonies were identified by gene sequencing. 
3.3.7 Immunostaining and microscopic quantification 
Cell were cultured in 35-mm glass-bottomed dishes (P35G-1.0C, Matek) under standard 
conditions. When cells grew to the 20%~40% confluence, they were fixed with 4% 
paraformaldehyde and permeabilized with 0.2% triton X-100 for 10~30 mins. For staining, 
the cells were rinsed with PBS buffer three times and incubated with 3% BSA in PBS to 
block non-specific signal. The primary antibodies were diluted with 3% BSA in PBS at 
1:50~ 1:200 ratios and added to the dishes for overnight incubation. Then the cells were 
rinsed with PBS buffer three times and incubated with secondary fluorescent antibodies 
(Invitrogen, 1:1000 dilution) for 1 hour. Finally, the cells were rinsed with PBS buffer three 
times and covered with mounting medium containing DAPI (4’,6-diamidino-2-
phenylindole) fluorescent dye. For microscopic observation, a Zeiss Meta 510 LSM was 
used. To standardize images captured, all fluorescent images from different samples were 
obtained under the same setting of microscope. Z-stack scanning was applied to all samples 
with the same step distance. 
All images were processed and analyzed by ImageJ software (imagej.nih.gov/ij/). Image 
exhibiting co-localization were merged from the same z-stack slices in two different 
channels. For co-localization quantification, the Pearson product-moment correlation 
(Pearson’s) was quantified by JACoP (Just Another Colocalization Plugin) plugin of 
ImageJ software. From the unprocessed images, individual cells were picked by ROI 
(Regions of Interest) manager plugin and their Pearson’s coefficient values were 
determined by JACop plugin under standard settings. 
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3.3.8 Peptide synthesis  
Both free and membrane-bound peptides were synthesized using an automatic Intavis AG 
workstation from amino acid monomers protected with Fmoc (9-fluorenylmethyl-
oxycarbonyl). Rink-resin (Rink-NH2) was used to couple the first amino acid in free 
peptide synthesis, whereas the amine-derivate cellulose membrane (cellulose-NH2) was 
made to couple the first amino acid in on-membrane peptide synthesis. In each synthesis 
cycle, the carboxyl group of Fmoc-protected amino acid (Fmoc-R-COOH) was first linked 
to the amine group of the previous amino acid (or Rink-NH2) through an amide bond. All 
unoccupied amine groups were then blocked (acetylated) by acetic anhydride to prevent 
incorrect amide bonds forming in subsequent cycles. Next, the Fmoc group was removed 
by piperidine (de-protecting) to release the free amine group primed for linking the 
carboxyl group of next amino acid residue. Fluorescein-NHS was linked to the amine group 
of the last amino acid in free peptide synthesis. After synthesis, the on-membrane peptides 
were treated with a mixture containing 47.5% TFA (trifluoroacetic acid), 1.5% TIPS (tri-
isopropylsilane) and 51% water, to remove all other protecting groups on amino acid side 
chains. The free peptides were treated with a mixture containing 95% TFA, 3% TIPS and 
2% water to de-protect side chains while cleaving the peptide from Rink-resin. 
3.3.9 Determination of dissociation constant 
The dissociation constant between protein and peptide was determined by fluorescence 
polarization (FP) assay. The proteins and fluorescein labelled peptides were prepared 
following the procedures introduced above. To reduce variation, two independent tests 
were prepared simultaneously. 384-well flat bottom plates (Corning-3575) were used for 
sample reading and PerkinElmer Envision 2103 plate reader was used for evaluating FP. 
The peptides (approximately 2 µM each) were dissolved in 100 µl DMSO and 3 µl of this 
was diluted 100-fold in water. The concentrations of the proteins were determined and 
adjusted to 50 µM. 2-fold serial dilutions were setup to create 16 protein concentrations 
ranging from 0 to 50 µM. 30µl of each protein sample was mixed with 5 µl peptide in the 
384-well plate and the fluorescence polarization was determined by the plate reader. We 
79 
 
use an approximate equation for non-linear fitting, by assuming the concentration of 
peptide was much lower than KD value: 
∆FP = FPobs - FP0 = FPmax x [domain] / (KD + [domain]) 
The full equation without the approximation can be found in this study (Kaushansky et al., 
2010). 
3.3.10 Cell surface biotinylation assay and recycling assay 
The surface protein biotinylation based assays were performed to measure the 
internalization and recycling of ALK proteins. The HEK293/ALK cells were treated as 
described in Fig.3.3 and Fig.3.4. Briefly, ALK on cell membrane can be biotinylated at 
4°C. Returning the cells to 37°C, the biotin-ALK will eventually internalize and undergo 
endosomal sorting, which directs biotin-ALK to either the recycling pathway or 
degradation pathway.  If the cells are transferred to 18°C incubation, internalization will 
still take place but the recycling or degradation will be slow or stopped. These different 
incubation conditions, combined with MESNA (sodium 2-mercaptoethanesulfonate) or 
GSH surface biotin stripping as well as cell fractionation, will generate a sample set for 
evaluating the destination and localization of biotinylated ALK at different time points. A 
detailed description of this method can be found in this study (Smith et al., 2004)  
3.3.11 Soft agar assay 
Media with the agar concentrations of 1% and 0.7% were first prepared and autoclaved. 
For the base layer, 1% agar was melted and cooled to 40°C in a water bath. Meanwhile, 
2×RPMI with 20% FBS and 200 µg/ml penicillin/streptomycin was warmed in a 40°C 
water bath. Next, equal volumes to the two solutions were mixed to result in 0.5% agar, 
1×RPMI and 10% FBS mixture, and 1.5 ml of the mixture was quickly added to each well 
of a 6-well plate. For the top layer, 0.7% agar was used for making the mixture. Cells were 
trypsinized and the cell density was adjusted to 200,000 cells/ml in warm PBS buffer. 
30,000 cells were suspended gently in 9 ml mixture containing 0.35% agar, 1×RPMI and 
10% FBS. 1.5 ml of the mixture was quickly added to each well of 6-well plate on top of 
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the base layer. Then the plates were incubated at 37 °C in a humidified atmosphere 
containing 5% carbon dioxide, fed with 1×RPMI medium containing 10% FBS, 100 µg/ml 
penicillin/streptomycin and L-glutamine. In 10 to 30 days, when the colonies grew to 
proper sizes, the plates were stained with 0.005% crystal violet for 1 hour. Then the 
colonies were counted under stereomicroscope. 
3.3.12 Cell proliferation assay 
Overall cell viability was evaluated using WST-8 ((2-(2-methoxy-4-nitrophenyl)-3-(4-
nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt). After incubation 
with the cells, WST-8 produced a water-soluble formazan dye in the presence of cellular 
dehydrogenase. Cells were cultured in 100 µl medium volume within 96-well plates. 10 µl 
of WST-8 solution was directly added to 100 µl medium and cells were returned to the 
incubation chamber and incubated for another 30 min to 1 hour. Then the 96-well plates 
were read for absorbance at 460nm which was proportional to the total number of viable 
cells.  
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3.4 Results 
3.4.1 Identification of ALK as a novel NUMB-binding protein 
A critical region in the NUMB protein is the N-terminal PTB domain, which binds to a 
variety of proteins that are directly involved in NUMB functions (Gulino et al., 2010). 
Preliminarily, we isolated several PTB binding receptor tyrosine kinases from a high-
throughput screening of PTB binding partners, including ALK (Chapter 2). The 
endogenous NUMB-ALK interaction was first verified by co-immunoprecipitation (Co-
IP) in the IMR-5 cell line (Fig.3.1A), which is a neuroblastoma cell line known for its wild 
type ALK expression (George et al., 2008; Tumilowicz et al., 1970). In addition, by 
immunostaining we found that NUMB partially co-localized with ALK in IMR-5 cells. 
The co-localization signal was presented in a dot-like pattern and was mainly located in 
cell membrane peripheral region (Fig.3.1B), suggesting NUMB-ALK interaction may 
occur in endocytic vesicles. 
Because few cell lines were well characterized for the expression of both ALK and NUMB 
(isoforms) and the IMR-5 cell line was difficult to be transfected efficiently, in all 
following studies, we used a HEK293/ALK cell line that stably expressed wild type 
ALK(Moog-Lutz et al., 2005). Using this HEK293/ALK cell line, we validated the 
NUMB-ALK interaction by Co-IP (Fig.3.1C), then we used GST-fused PTB domains with 
or without exon 3 (GST-PTBL, long form and GST-PTBS, short form) to pull down ALK 
from the same cell line. Both GST fusion proteins, but not GST itself were capable of 
binding ALK (Fig.3.1D). To investigate whether the PTB domain is sufficient for ALK 
binding, we created a NUMB mutant bearing the F162V mutation within the PTB domain, 
which was reported to render the PTB domain incapable of motif-binding (Zwahlen et al., 
2000). Upon expression of either NUMB wildtype or the F162V mutant, a marked 
reduction of binding to ALK was detected for F162V mutant (Fig.3.1E), indicating that the 
PTB domain played a critical role in NUMB-ALK binding. In addition, when a series of 
truncated NUMB proteins with a FLAG tag were generated (Fig.3.1F) and expressed in 
the HEK293/ALK cell, only the PTB-containing fragments were found to interact with 
ALK (Fig.3.1G). 
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Figure.3.1 Identification of the interaction between NUMB and ALK 
(A) Endogenous NUMB and ALK interaction in IMR-5 neuroblastoma cells; (B) NUMB and ALK 
co-localization in IMR-5 cells immuno-stained with NUMB (green) and ALK (red) antibodies. The 
co-localization signals were mainly present in the cell membrane periphery, and in dot-like 
formations, suggesting NUMB may interact with ALK in endocytic vesicles as well (arrows); (C) 
Endogenous NUMB interaction with ectopically-expressed ALK in HEK293/ALK stable cell line. 
The identical data was presented in Fig.2.8C; (D-G) The NUMB PTB domains were crucial for 
NUMB-ALK interactions. NUMB has two forms of PTB domains, PTBi (PTBL) and PTBo (PTBS) 
due to alternative splicing. Both GST-fused PTBi/PTBo proteins, but not GST protein, were able 
to pull down ALK from the HEK293/ALK cell lysate (D), and the NUMB-ALK interaction was 
greatly attenuated with the PTB binding-deficient mutant F162V (E), indicating that the PTB 
domain was responsible for ALK binding. A variety of Flag-tagged truncated forms of NUMB (F) 
were expressed in HERK293/ALK cells, only the PTB containing fragments were found to 
pulldown ALK (G). 
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Figure.3.2 NUMB binds two motifs in ALK 
 (A) NUMB interaction with two NxxF/Y motifs in ALK. Four predicted NxxF/Y motifs, 
G1473GHVNMAFSQ1482, P1499TSLWNPTYGS1509, M1099TDYNPNYCFA1109, and 
F1577PCGNVNYGYQ1587, were synthesized on a cellulose membrane. Only 
G1473GHVNMAFSQ1482 and F1577PCGNVNYGYQ1587 interacted with GST-PTBi in a far western 
assay; (B-C) The N and F or Y residues in G1473GHVNMAFSQ1482 and F1577PCGNVNYGYQ1587 
play a critical role in NUMB-ALK interaction. Serial alanine-scanning substitution peptides were 
synthesized on a cellulose membrane for G1473GHVNMAFSQ1482 (B) and F1577PCGNVNYGYQ1587 
(C) motifs, and then blotted with GST-PTBi in a far western assay; (D) G1473GHVNMAFSQ1482 
and F1577PCGNVNYGYQ1587 motifs exhibited high binding affinities to PTBi in vitro. The 
corresponding dissociation constant values were 0.7±0.02 µM and 0.5±0.02 µM respectively, n=3; 
(E-F) ALK mutations in the two motifs, N1477A and N1583A, together abolished NUMB-ALK 
interaction in vivo. In the GST-PTBi pulldown assay (E), the single mutant N1477A greatly 
attenuated NUMB-ALK interaction while N1583A had little effect, however, the double mutant 
completely abolished the interaction. In a complementary test of NUMB co-immunoprecipitation 
(F), an identical result was observed. These data demonstrated that both motifs were responsible 
for NUMB-ALK interaction with G1473GHVNMAFSQ1482 playing a primary role. 
The NUMB PTB domain is known to bind to NxxF/NxxY motifs (Li et al., 1998). Four 
such motifs were identified in the ALK intracellular region through a full sequence 
scanning, which were then tested for NUMB-PTB binding in an in vitro peptide-domain 
binding assay. The corresponding peptides, G1473GHVNMAFSQ1482, 
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P1499TSLWNPTYGS1509, M1099TDYNPNYCFA1109, and F1577PCGNVNYGYQ1587, were 
synthesized on a cellulose membrane and then blotted with GST- PTBL in a far-western 
assay. Only G1473GHVNMAFSQ1482 and F1577PCGNVNYGYQ1587 were found to bind to 
the PTB domain (Fig.3.2A). The two motifs were then subjected to alanine-scanning 
substitution and the resulting peptide arrays were blotted with GST- PTBL as well 
(Fig.3.2B-C). The result further confirmed the importance of the N1477MAF and N1583YGY 
motifs in PTB binding and the critical role of the N and F or Y residues within in the motifs 
(Wang et al., 2009). Next, the binding affinities between the two motifs and PTBL domain 
were determined by fluorescence polarization assay. The dissociation constants between 
fluorescein-labeled G1473GHVNMAFSQ1482 / F1577PCGNVNYGYQ1587 peptides and 
PTBL were 0.7 µM and 0.5 µM respectively (Fig.3.2D). In addition, to verify this binding 
in vivo, we created ALK mutants in which either or both of Asn1477 and Asn1583 were 
mutated to Ala (N1477A/N1583A). These mutants were expressed in HEK293 cells 
transiently and the respective cell lysates were pulled down by GST-NUMB- PTBL. As 
shown in Fig.3.2E, the ALK single mutant N1477A significantly weakened NUMB-ALK 
binding, while the N1477/N1583 double mutant completely abolished the interaction. In a 
complementary test of NUMB Co-IP from the same cells, an identical result was observed 
(Fig.3.2F). 
Collectively, these data demonstrate that the PTB domain in NUMB and the N1477MAF 
and N1577YGY motifs in ALK mediate the protein-protein binding via direct physical 
interaction. 
3.4.2 NUMB regulates ALK endocytosis 
Because NUMB has been shown to be involved in the endocytosis of a number of 
membrane proteins (Gulino et al., 2010), we hypothesized that NUMB may play a similar 
role in regulating ALK endocytosis. To test this hypothesis, we examined ALK endocytosis 
by cell surface biotinylation and internalization assay. Specifically, in HEK293/ALK cells, 
membrane-localized HA-ALK was labelled with NHS-SS-biotin and then the cells were 
cultured for up to 60 min under normal conditions to allow internalization to occur, during 
which cytoplasmic biotinylated HA-ALK was pulled down by streptavidin beads at 
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different time points. The samples were then probed with HA antibody to determine the 
relative levels of internalized ALK in the cytoplasm. We observed that ALK internalized 
from the beginning and appeared to plateau at approximately 30 min (Fig.3.3A). To further 
investigate the possible function of NUMB in this process, we depleted total NUMB levels 
by RNA interference in HEK293/ALK cells followed by surface biotinylation and 
internalization assays. The NUMB knockdown cells exhibited significantly less 
internalized biotinylated ALK in the cytoplasm at the same time points compared to that 
in scramble siRNA treated cells (Fig.3.3B). Quantitatively, approximately 18% of surface 
labeled ALK was internalized after 60 min in NUMB knockdown cells while this number 
was around 34% in control cells (Fig.3.3C).  
 
 
Figure.3.3 NUMB promotes ALK internalization 
 (A) ALK was internalized from the membrane to cytosol, as exhibited in the biotinylation and 
internalization assay. In HEK293/ALK cells, membrane localized HA-ALK was labelled with 
NHS-SS-biotin, then cytoplasmic HA-ALK levels were analyzed at different time points by 
streptavidin pulldown combined with HA immunoblotting; (B-C) NUMB knockdown by RNA 
interference significantly attenuated ALK internalization. Quantitatively, approximately 34% of 
surface-labelled ALK was internalized after 60 minutes in cells transfected by scrambled RNA, 
while the number was 18% in NUMB knockdown cells, p<0.01, n=3. 
3.4.3 NUMB regulates ALK post-endocytic trafficking  
The function of NUMB in endocytosis was previously elucidated by studying NUMB-
regulated NOTCH receptor internalization (McGill et al., 2009). The NUMB p66 isoform 
was found to promote NOTCH endocytosis and lysosomal degradation which in turn 
inhibited NOTCH-stimulated cell proliferation signaling. However, this result is 
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insufficient to explain the findings that alternative NUMB splicing could increase the 
activity of NOTCH and its downstream signaling (Bechara et al., 2013; Westhoff et al., 
2009), or that alternative splicing of NUMB is correlated with promoted cell proliferation 
in multiple cancer types (Misquitta-Ali et al., 2011). Mammalian NUMB has four isoforms 
generated by alternative splicing. The p72 isoform contains both exon 3 and exon 9, the 
p71 isoform contains only exon 9, the p66 isoform contains only exon 3 and the p65 
isoform doesn’t contain either. Since all isoforms (PTBL/ PTBS, or PTBi/PTBo) bind to 
ALK (Fig.3.1B/E), we speculate that p72/p71 may play an opposing role in post-endocytic 
trafficking of receptor compared to p66/p65. Instead of promoting receptor degradation, 
P72/p71 may recycle the receptor back to cell membrane to promote the receptor activity, 
which is also a default post-endocytic destination of internalized membrane receptors (Goh 
and Sorkin, 2013). Based on a previous study in the subcellular localizations of NUMB 
isoforms, p72 and p66 tend to localize to cell membrane periphery, while p71 and p65 
typically localize in the cytoplasm (Dho et al., 1999). Thus, we picked isoforms p72 and 
p66 which generally interact with membrane localized receptors in the following 
endocytosis study. 
The p72 and p66 isoforms were transiently expressed with a FLAG tag in HEK-293/ALK 
cells, and the cell surface biotinylation assay was carried out 48 hours after transfection. 
Next, the total biotinylated protein was pulled down with streptavidin beads 1 hour after 
biotinylation, and the samples were probed with FLAG antibody. The p66 isoform was 
found to significantly decrease the total biotinylated ALK level in cytoplasm while the p72 
isoform exhibited little effect compared to the control, indicating that p66 promoted post-
endocytic ALK degradation. In addition, the PTB binding deficient p66-F162V mutant and 
a deletion form of p66 lacking C-terminal endocytosis motif failed to affect biotinylated 
ALK levels, revealing their essential functions in this process (Fig.3.4A).  
The decrease in biotinylated cell surface ALK caused by p66 isoform could be due to 
proteasome or lysosome mediated degradations. In order to identify the degradation 
pathway, we treated cells expressing p72 or p66 isoforms with the lysosome inhibitor 
concanamycin A (ConA) or the proteasome inhibitor MG132 prior to the endocytosis 
assay. Compared to the vehicle DMSO, MG132 treatment led to a general increase in 
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biotinylated ALK in all treated cells regardless whether they expressed the p72 or p66 
isoforms of NUMB. In contrast, ConA treatment led to a specific increase in biotinylated 
ALK in cells expressing the p66 isoform (Fig.3.4B). These data indicate that the p66, but 
not the p72 isoform of NUMB promote the degradation of endocytic ALK via the 
lysosomal pathway. 
To further investigate the potential function of NUMB in ALK recycling, we performed 
the biotinylation and recycling assays in HEK293/ALK cells transiently expressing p72 
and p66 isoforms. The cells were first surface-biotinylated and incubated at 18ºC for 2 
hours to allow internalization but not recycling of biotinylated ALK. Next, the cells were 
treated with glutathione (GSH) to remove biotin from cell surface. Following surface biotin 
removal, the cells were either lysed for examining the total amount of 
internalized/biotinylated ALK (Tot-ALK at 0 min) or returned to 37ºC to resume normal 
endocytic trafficking (endocytosis/recycling/degradation). After 30 min incubation at 37 
ºC, half of the cells were directly lysed (Tot-ALK at 30 min) while the other half were 
lysed after GSH treatment that removed any biotin from protein recycled back to the cell 
surface (IC-ALK at 30 min). The biotinylated ALK was pulled down using Streptavidin 
beads and blotted with HA antibody. 
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Figure.3.4 NUMB isoforms play distinct roles in ALK post-endocytic trafficking 
 (A) p66-NUMB, but not p72-NUMB, promoted post-endocytic ALK degradation. After surface 
biotinylation, the total biotinylated ALK level was determined in cells transfected with flag-tagged 
p66-NUMB and p72-NUMB isoforms, their F162V PTB binding-deficient mutants and C-terminal 
deletion forms lacking the endocytotic motif. Only p66-NUMB was found to decrease biotinylated 
ALK levels indicating degradation following endocytosis; (B) p66-NUMB promoted the 
degradation of endocytic ALK via the lysosomal pathway. The lysosome inhibitor concanamycin 
A attenuated p66-NUMB promoted biotinylated-ALK degradation, while DMSO and proteasome 
inhibitor MG132 had no obvious effect; (C-D) p72-NUMB, but not p66-NUMB, promoted post-
endocytic ALK recycling. Surface biotinylation, internalization and recycling assays were carried 
out in cells transfected with either p66-NUMB, p72-NUMB or flag tag only. The p72-NUMB 
mainly maintained the level of biotinylated ALK (Tot-ALK 30 vs. Tot-ALK 0) and quantitatively 
recycled approximate 46% biotinylated ALK to the membrane (Tot-ALK 30 minus IC-ALK 30) in 
our test. Consistently, p66-NUMB expression resulted in more biotinylated ALK degradation. 
P<0.05, n=3. 
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As shown in Fig.3.4C, the Tot-ALK level was significantly decreased in cells expressing 
the p66 isoform after 30 min of endocytosis recovery at 37ºC which was consistent with 
the results presented in Fig.3.4A. However, only a minor change was observed in cells 
expressing the p72 isoform. A relative quantification of western blotting better illustrates 
the difference between the isoforms (Fig.3.4D). At the 30 min time point without the 
second GSH treatment, the biotinylated ALK level was ~96% of the initial level with p72 
isoform expression while only ~58% with p66 isoform expression.  Upon the second GSH 
treatment, the biotinylated ALK levels were ~50% and ~27% in cells expressing p72 or 
p66 respectively. This implies that p72 expression resulted ~46% (96%-50%) ALK 
recycling and p66 expression resulted ~31% (58%-27%) ALK recycling during our 
treatment. 
To understand the mechanism underpinning the different functions of the two NUMB 
isoforms in ALK degradation and recycling, we examined their co-localizations with Rab4, 
Rab7, and Rab11 which were expressed as GFP-fused proteins in HEK293/ALK cells 
together with Flag-p66-NUMB or Flag-p72-NUMB. There was a significant increase in 
co-localization between ALK and the late endosome marker GFP-Rab7 (Chavrier et al., 
1990) in HEK293/ALK cells co-expressing the p66, but not the p72 isoform of NUMB or 
the vector control (Fig. 3.5A). This suggests that p66-NUMB may facilitate the degradation 
of ALK by routing it to the late endosome and lysosome. In contrast, expression of p72-
NUMB, but not p66-NUMB, promoted the co-localization of ALK with the early 
endosome marker Rab4 (Van Der Sluijs et al., 1991) (Fig. 3.5B). Because the recycling 
process is dependent on both Rab4 and Rab11 and/or Rab14 (Pfeffer, 2013), we also 
examined the co-localization of ALK with Rab11 in cells expressing either NUMB 
isoform. Intriguingly, neither NUMB isoform was able to significantly alter the co-
localization of ALK and Rab11 (Fig. 3.5 C). These observations were further verified by a 
quantitative analysis of Pearson’s co-efficiency from multiple cells/images respectively 
(Fig.3.5D), which exhibited significant differences in ALK-Rab4/7 co-localizations with 
the expression of p66 or p72 isoforms.  
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Figure.3.5 NUMB isoforms differentiate the co-localization between ALK and Rabs 
HEK293/ALK cells were co-transfected with different combinations of flag labelled NUMB 
isoforms and GFP-fused Rab4/7/11 endocytic markers as presented in (A-C). Co-immunostaining 
was then carried out using anti-HA (ALK, red), anti-GFP (Rab, green) and anti-Flag (Numb, blue). 
Individual cells exhibiting all three fluorescent markers were picked out for further analysis. In the 
cytoplasm but not the cell membrane, p66-NUMB expression promoted the co-localization of ALK 
and the late endosome marker Rab7 (A), while the p72-NUMB expression promoted co-
localization between ALK and early endosome marker Rab4 (B). Another early endosome marker, 
Rab11, generally co-localized to ALK in all conditions (C). These observations were further 
confirmed by the quantification of Pearson's co-efficiency (D). Rab4: p<0.01, n=8; Rab7: p<0.01, 
n=5; Rab11: p<0.01, n=5. 
These data demonstrate that NUMB plays an important role in the sorting of endocytic 
ALK. p72-NUMB facilitates the fast-recycling of ALK via Rab4-containing early 
endosome, while p66-NUMB promotes the lysosome-dependent degradation of ALK via 
the Rab7-containing late endosome.  NUMB regulates ALK activity via mediating ALK 
endocytosis 
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3.4.4 NUMB regulates ALK activity via mediating ALK endocytosis 
ALK signals through the MAPK pathway to regulate cell proliferation (Hallberg and 
Palmer, 2013). To interrogate the role of two NUMB isoforms in ALK activity, we 
examined Erk phosphorylation in HEK293/ALK cells expressing either wildtype or ALK-
binding deficient p66/p72. We used an antibody for the extracellular region of ALK, 
mAb46, to specifically stimulate the activation of ALK and MAP kinase pathway (Erk 
phosphorylation) under serum-free conditions (Moog-Lutz et al., 2005) . As shown in 
Fig.3.6A, Erk phosphorylation was promoted by mAb46 treatment in HEK293/ALK cells. 
mAb46 is the antibody specifically targeting ALK and can mimic ALK ligand to activate 
ALK. Co-expression of p66-NUMB significantly attenuated the Erk phosphorylation while 
its ALK-binding deficient form p66-F162V or endocytosis deficient form p66-∆C had little 
effects (Fig.3.6A-B).  
To further validate that the isoform-specific function of NUMB on ALK activation is 
dependent on their roles in ALK post-endocytic trafficking, we used the dominant-negative 
forms of Rab4/7/11 (GFP-Rab4/7/11DN) to specifically perturb endocytosis routes in 
HEK293/ALK co-expressed with Flag-p66-NUMB or Flag-p72-NUMB or Flag only.  
Because GFP-Rab7 DN has been shown to block endocytosis in the late endosome (Bucci 
et al., 2000), it is thought to prevent the internalized protein from lysosomal degradation. 
Indeed, we observed that the p66-NUMB mediated Erk phosphorylation level decrease 
(Fig.3.6C) was eliminated with GFP-Rab7DN expression (Fig.3.6D). This result suggested 
that the inhibitory effect of p66-NUMB on ALK activation is dependent on its ability to 
sort ALK to the late endosome.  
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Figure.3.6 p66-NUMB inhibits ALK-mediated MAPK signaling 
 (A-B) Erk phosphorylation was attenuated by p66-NUMB expression in ALK activated 
HER293/ALK cells. ALK was selectively activated by mAb46 antibody treatment in serum starved 
cells. Only p66-NUMB, but not its ALK binding-deficient F162V mutant or C-terminal deletion 
form, decreased Erk phosphorylation levels. For the pErk/Erk ratio quantification in western 
blotting, p<0.01, n=3. (C-G) Interrupting endocytosis at different stages exhibited differential 
effects for p66-NUMB or p72-NUMB in ALK-pErk signal transduction. Overexpression of Rab7 
dominant negative mutant blocked the endocytosis at late endosome, which eliminated p66-NUMB 
mediated ALK activity (Erk phosphorylation) decrease (D). Overexpression of the Rab4 dominant 
negative mutant blocked the recycling, which prevented p72-NUMB from maintaining ALK 
activity by recycling (E). Overexpression of empty vector (C) or Rab11 dominant negative mutant 
(F) had little effect. The changes in pErk/Erk ratio were significant, n=3, p<0.01 (G). 
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In the parallel tests with GFP-Rab4DN, we also observed that the block of fast recycling 
by GFP-Rab4DN (Yudowski et al., 2009) led to ~40% reduction in Erk phosphorylation in 
p72-NUMB expressing cells but had little effect in p66-NUMB expressing cells, 
demonstrating that p72-NUMB mediated ALK fast recycling promotes Erk 
phosphorylation (Fig.3.6E-F). In contrast, the block of slow recycling by GFP-Rab11DN 
had no significant effect on Erk activation in cells co-expressing either p66-Numb or p72-
Numb (Fig.3.6G-H).  
Because ALK usually exists as a constitutively active form in tumors, we also evaluated 
the NUMB mediated ALK activity with ALK-F1174L mutant. ALK-WT and ALK-
F1174L were transiently expressed in HEK293 cells. As shown in Fig.3.7A, both ALK 
forms stimulated the activation of MAPK pathway under normal cell culturing conditions 
with 10% serum, while the ALK-F1174L had significant higher Erk phosphorylation level 
as expected. This Erk phosphorylation was only attenuated by co-expression p66-NUMB 
but not p72-NUMB. Consistently, in the cell proliferation assay and soft-agar assay with 
ALK-F1174L transfected HEK293 cells, only co-expression of p66-NUMB exhibited a 
moderate inhibitory effect (Fig.3.7B-C). In conclusion, p66-NUMB and p72-NUMB act 
antagonistically in regulating ALK and MAPK activities via routing ALK to different 
endocytic pathways. 
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Figure.3.7 p66-NUMB inhibits ALK-dependent cancer cell growth 
 (A) p66-NUMB inhibited the activation of both ALK and ALK oncogenic mutant F1174L. The 
empty vectors, ALK wild type, ALK constitutively active mutant F1174L and NUMB isoforms 
were transiently expressed in HEK293 cells. After cell starvation, ALK was specifically stimulated 
by antibody. Both ALK WT and ALK-F1174L were able to increase the phosphorylation of Erk, 
which was only attenuated by co-expression of p66-NUMB. (B-C) p66-NUMB inhibited the 
anchorage-independent cell growth of HEK293/ALK cells, n=3, p<0.01. Empty vector, p66-
NUMB and p72-NUMB were transiently expressed in HEK293/ALK cells. 24 hours after 
transfection, the cells were used in a soft agar assay. (D) p66-NUMB inhibited the proliferation of 
HEK293/ALK cells. WST-8 assay was carried out 48 hours after transfection, n=3, p<0.01. 
  
95 
 
3.5 Discussion 
The NUMB protein was the first described cell fate determinant which is conserved from 
fly to human. Further studies have since revealed the complex nature of NUMB functions 
that are involved in a wide range of fields. In tumorigenesis, NUMB is defined as a tumor 
suppressor for its role in binding and regulation of the NOTCH receptor and p53 (Colaluca 
et al., 2008; Couturier et al., 2012; McGill et al., 2009; McGill and McGlade, 2003). 
Interestingly, the NUMB-NOTCH and NUMB-p53 interactions take place in the cell 
membrane periphery and nucleus, and suppress tumorigenesis via distinct mechanisms, 
exhibiting the multifaceted functional pattern of NUMB. NUMB function mainly relies on 
interactions between its modular PTB domain and binding partners (NxxF/NxxY motifs). 
As presented in Chapter 2, the PTB domain mediates interactions between NUMB and a 
large number of proteins. On the other hand, the non-PTB region of NUMB seems to play 
a more significant role for the NUMB functional diversity. The PTBL and PTBS isoforms 
exhibit little difference other than distinct sub-cellular localizations, however, the PRRL 
and PRRS isoforms are well known for their different functions in proliferation and 
differentiation during development (Bani-Yaghoub et al., 2007; Dho et al., 1999; Dooley 
et al., 2003; Verdi et al., 1999a; Yoshida et al., 2003). Consistently, our findings 
demonstrate that both PTBL and PTBS isoforms bind to two ALK motifs that are required 
for the NUMB-ALK interaction. However, the PRRL isoform p72 mediates ALK recycling 
and PRRS isoform p66 mainly promotes ALK degradation, resulting in an increase in cell 
proliferation MAPK signaling with p72 isoform expression compared to that with p66 
isoform expression. Based on microscopy data, it is clearly presented that ALK co-
localizes to different post-endocytic destination makers with p66-NUMB or p72-NUMB 
expression. Our study first methodically elucidates the functional diversity between PRRL 
and PRRS isoforms in the regulation of ALK endocytosis and endosomal sorting (Fig.3.8). 
Previously, it was reported that NUMB is involved in both recycling and endosomal 
compartmentalization of NOTCH (McGill et al., 2009). Therefore, it is possible that the 
NUMB isoforms may act in a similar manner for all NUMB-binding receptors (including 
RTKs). Our finding is consisting with reported NUMB isoform-dependent oncogenic 
behaviors (Bechara et al., 2013; Misquitta-Ali et al., 2011; Westhoff et al., 2009), which 
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further raises the possibility the p72-NUMB may universally assist in sustaining receptor 
activity thus contributing to tumorigenesis. Considering receptors are constituting a major 
portion of the NUMB-PTB binding partners, as presented in Chapter2, our study also has 
potential value for the improvement of diagnosis and therapy design of receptor positive 
cancers. 
 
Figure.3.8 Overview of NUMB-regulated ALK endocytosis 
The mechanisms by which NUMB isoforms regulate ALK endosomal sorting have not 
been well defined. Based on preliminary findings, we hypothesize that p72-NUMB and 
p66-NUMB may recruit different endosomal sorting factors following ALK 
internalization. It must be noted that p72-NUMB and p66-NUMB do not play absolutely 
opposing roles in the ALK endosomal sorting but more likely prefer the recycling or late 
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endosomal compartment respectively.  A mass spectrometry based approach has been 
employed to quantitatively compare the interactome between p72-NUMB and p66-NUMB. 
Indeed, it was found that both isoforms generally bind to several known NUMB-interacting 
endocytic proteins, but p72-NUMB bound significantly more EPS15 and AP-2 (Krieger et 
al., 2013). These data confirm the possibility that NUMB isoforms may act differently 
during endocytosis and also reveals some additional effectors that may be involved in these 
functional differentiations. Overall, further mechanistic studies will be required to 
determine the contribution of NUMB-binding proteins in both internalization and post-
endocytic trafficking events. 
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Chapter 4  
4 ALK ectodomain shedding 
4.1 Abstract 
The human ALK gene encodes a 180-kDa protein consisting of 1620 amino acids, which 
corresponds to a 220-kDa band on SDS-PAGE. In addition, the 140-kDa ALK band is 
frequently observed upon immunoblotting, suggests that ALK may undergo ectodomain 
shedding, a process employed by many different receptors to generate intracellular 
truncated fragments. Due to diversified subcellular localizations and binding partners, 
these truncated fragments exhibit a functional pattern distinct from that of the full-length 
receptor on the cell surface. To further investigate the potential function of the truncated 
ALK form, we identified the ALK cleavage regions by analyzing the ectodomain sequence 
using mass spectrometry. In addition, we found that the 140-kDa fragment is highly 
phosphorylated even in the absence of ligand-stimulated activation, suggesting ectodomain 
shedding may contribute to ALK oncogenicity by generating this cytoplasmic fragment. 
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4.2 Introduction 
Ectodomain shedding is a proteolytic cleavage of membrane proteins that results in the 
release of the ectodomain. This mechanism modulates a wide variety of cellular and 
physiological processes, including growth factor signaling, cell adhesion and inflammation 
(Hayashida et al., 2010; Weber and Saftig, 2012). It is estimated that cells selectively shed 
only 2% of membrane proteins, indicating the existence of a regulatory system for this 
process (Hayashida et al., 2010). Interestingly, ectodomain shedding is common in RTKs 
and has been reported in members of almost all RTK subfamilies (Chen and Hung, 2015; 
Miller et al., 2013).  
Ectodomain shedding is typically carried out by the matrix metalloproteinase (MMP) 
family or the a disintegrin and metalloproteinase (ADAM) family. MMPs are secreted 
proteases capable of degrading variety of proteins in the extracellular matrix (ECM) and 
can also cleave certain membrane proteins. However, ectodomain shedding by MMPs is 
not very tightly regulated, and mainly depends on MMP abundance in the ECM (Murphy, 
2008). ADAM proteases are transmembrane proteases and termed as “sheddases” that 
specifically cleave ectodomains at the cell surface (Sternlicht and Werb, 2001). Unlike that 
of MMPs, ADAM-mediated ectodomain shedding is found to be regulated by different 
types of stimulation, including undefined serum factors, peptide growth factors, calcium 
concentration and some forms of stress (Seals and Courtneidge, 2003). Although MMPs 
and ADAMs have distinct characteristics, both families are physiologically functional in 
tumorigenesis (Duffy et al., 2009; Lu et al., 2011), partially due to their involvement in the 
processing of receptors and receptor ligands. For instance, ectodomain shedding of either 
ErbB or its ligand precursors plays a crucial role in the regulation of ErbB oncogenicity. 
ADAMs mediate the release of the EGF ligand from its precursor HB-EGF membrane 
protein, which is required for the activation of ErbB RTKs (Blobel, 2005; Revillion et al., 
2008). ErbB itself also undergoes ectodomain shedding, generating a soluble ErbB 
fragment in the ECM. This free ErbB fragment has been defined as a potential biomarker 
for fast diagnosis of breast and ovarian cancers (Lafky et al., 2008; Visco et al., 2000). 
Besides ectodomain shedding, some receptors undergo further proteolytic cleavage. As 
introduced in Chapter 1, the maturation of the NOTCH receptor requires intracellular 
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cleavage by γ-secretase following ectodomain shedding. An identical process is also 
observed in ErbB2 and some other RTKs (Chen and Hung, 2015). In the cytoplasm, free 
truncated ErbBs may function similarly to endosomal ErbB by stimulating signal 
transduction. In addition, the ErbB2 intracellular region contains a typical nuclear 
localization sequence (NLS) that mediates ErbB2 nuclear translocation, where it functions 
as a transcription co-activator (Giri et al., 2005). 
ALK also undergoes ectodomain shedding. The human ALK gene encodes a 180-kDa 
protein that consist of 1620 amino acids. Upon posttranslational modification, in particular 
N-linked glycosylation, the mature ALK protein migrates as a 220-kDa band on SDS-
PAGE (Mazot et al., 2011). ALK also exists as a 140-kDa form, due to proteinase cleavage 
at the extracellular region, but the cleavage site is still undetermined (Moog-Lutz et al., 
2005). Here we present preliminary data for the investigation of ALK cleavage. We 
identified the ALK cleavage region and found the 140-kDa is highly phosphorylated even 
in the absence of ligand-stimulated activation. 
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4.3 Material and methods 
4.3.1 Cell Culture and treatment 
HEK-293/ALK is a HEK cell line stably expressing ALK. This cell line was cultured in 
DMEM media supplemented with 10% FBS, 2 mg/ml glutamine, 100 units of penicillin-
streptomycin and 2 µg/ml puromycin. HEK 293 cells were cultured in the same medium 
except without puromycin. IMR-32 cells were cultured in RPMI 1640 media supplemented 
with 10% FBS, 2 mg/ml glutamine, 100 units of penicillin-streptomycin. 2 µM BB-94 was 
added into the HEK293-ALK cell culture media. After overnight treatment, the cell lysate 
was tested for ALK by western blot. For PMA, APMA and GM6001 treatments, the 
HEK293-ALK cells were first washed with 1×PBS buffer. Next, the chemicals were 
diluted to the designated concentrations in DMEM to treat the cells. Under these 
conditions, both medium and cell lysates were collected then western blots were performed 
against ALK. Anti-N-terminal ALK antibody was used to detect ALK in the DMEM 
media. Anti-HA (1:1000) or Anti-C-terminal ALK (1:500) antibody was used to detect 
ALK in the cell lysate. The HEK293-ALK cells were treated with 1 mM, 0.5 mM and 0.25 
mM APMA for 30 minutes to determine the optimal concentration for ALK cleavage. Next, 
the HEK293-ALK cells were incubated for 30 minutes either with DMEM alone, 0.5 mM 
APMA, 0.5 mM APMA in combination with different GM6001 concentrations (10 µM & 
50 µM), or PMA at different concentrations (10 µM & 100 µM). Both media and cell 
lysates were collected for western blot analysis. 
4.3.2 PCR mediated ALK truncations 
The full length human ALK with a C-terminal HA tag was expressed in a pCBC vector 
(This plasmid was a generous gift from Dr. Marc Vigny). Truncated ALKs: ALK 509-552 
Del, ALK 552-612 Del, ALK 21-400 Del, ALK 21-700 Del and ALK 21-1031 Del were 
generated by PCR-mediated plasmid DNA deletion (Hansson et al., 2008). Primers were 
designed based on the same principles as site-directed mutagenesis:  16 to 20 nucleic acids 
upstream of the deleted region followed by 16 to 20 nucleic acids downstream. The primers 
for PCR amplification of the listed ALK truncations are as follows:   
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ALK 509-552 Del F: CACGAATGAGCCAGGACATGGCATCCTTTAGGGTCCT 
ALK509-552 Del R: AGGACCCTAAAGGATGCCATGTCCTGGCTCATTCGTG 
ALK 552-612 Del F: TTGTCCCCACCATGCGACTCGGAGCTCACATGGAGA 
ALK 552-612 Del R: TCTCCATGTGAGCTCCGAGTCGCATGGTGGGGACAA 
ALK 21-400 Del F: TGTATTCCAGGGCCACTCGGCCCACAGCTGCCGTGGAA 
ALK 21-400 Del R: TTCCACGGCAGCTGTGGGCCGAGTGGCCCTGGAATACA 
ALK 21-700 Del F: TCTGGTAGGCGTTGTTGCAGCCCACAGCTGCCGTGGAA 
ALK 21-700 Del R: TTCCACGGCAGCTGTGGGCTGCAACAACGCCTACCAGA 
ALK 21-1030 Del F: GGATCAGCGAGAGTGGCAGGCCCACAGCTGCCGTGGAA 
ALK 21-1030 Del R: TTCCACGGCAGCTGTGGGCCTGCCACTCTCGCTGATCC 
The reaction was carried out in a mixture containing: 22.5 µL of H2O, 2 µL of Pfu-Turbo 
DNA Polymerase (Agilent, Cat#600250), 7.5 µL of Pfu-Turbo PCR buffer, 10 µL of 2 mM 
dNTP, 2 µL of 125 ng/µL primers, 1.5 µL of DNA template (pCBC-ALK plasmid), and 
2.5 µL of DMSO (50 µL total reaction volume), with 30 µL mineral oil added on top. The 
PCR reactions were performed with the following conditions: denaturation at 94°C for 2 
minutes; followed by 18 cycles of 94°C denaturation for 50 seconds, 58°C annealing for 1 
minute and 68°C elongation for 30 minutes; ending with 30 minutes of additional 
elongation. Next, 1 µL of Dpn1 was added to the PCR reaction products which were 
incubated at 37°C overnight. Then, 8 µL of the Dpn1-digested PCR products were used to 
transform DH5α E. coli competent cells. The plasmid DNA from these bacterial cultures 
were purified and sent for sequencing to verify successful ALK truncation.  
4.3.3 Immunoprecipitation and western blotting 
The cultured cells were lysed in cold mammalian cell lysis buffer (1% Triton X-100, 50 
mM Tris-pH7.2, 150 mM NaCl, 2 mM MgCl2, 0.1 mM EDTA, 0.1 mM EGTA, 0.5 mM 
DTT, 10 mM NaF) containing complete protease inhibitors (Roche). Cell debris was 
removed by centrifugation, and 500 µg of supernatant was incubated for four hours in the 
presence of 1µg antibody and 30 µl of 50% slurry Protein G-Sepharose beads (Roche) at 
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4°C. The beads were subsequently washed three times with lysis buffer and boiled with 
SDS-loading dye. For western blotting, the immuno-precipitates were resolved by SDS-
PAGE. All proteins were then transferred to a PVDF membrane by semi-dry transferring 
method (Bio-Rad), detected by immunoblotting with appropriate antibodies, and visualized 
by Enhanced Chemiluminescence (ECL). For mass spectrometry analysis, the precipitated 
protein was dissolved in 8 M urea for in-solution digestion. 
4.3.4 Protein digestion and mass spectrometry analysis 
The precipitated protein was first dissolved in 8 M urea prepared in MS-grade water. After 
reduction by dithiothreitol (DTT) and alkylation by iodoacetamide (IAA), the protein 
sample was digested by trypsin, chymotrypsin and Glu-C according to the manufacturer’s 
protocol. Digested products were analyzed by Q Exactive Hybrid Quadrupole-Orbitrap 
mass spectrometry equipped with an EASY-nLC liquid chromatography peptide separation 
system. All detected peptides were profiled and then aligned with their ALK protein 
sequence.   
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4.4 Results 
4.4.1 Identification of ALK-140-kDa C-terminal fragment 
The expression of ALK was determined in two cell lines: the HEK293/ALK stable cells 
that overexpress wildtype ALK with a C-terminal HA tag, and IMR-32 neuroblastoma cells 
that are known for endogenous ALK expression. As shown in Fig.4.1A, two bands were 
detected in both cell lines, and the 140-kDa band contains the ALK C-terminal region. 
Considering the molecular weight of this ALK fragment, we estimated that the cleavage 
site may be located within amino acid 509 to 612 (aa509 ~ aa612) region. Therefore, a 
number of truncated ALK forms were designed (Fig.4.1B) and transiently expressed with 
a C terminal HA tag in HEK293 cells. As shown in Fig.4.1C, both ALK aa509~aa552 and 
ALK aa552~aa612 deletion forms display the 140-kDa band by western blot analysis, 
suggesting that the cleavage site is located outside of aa509-aa612. 
 
Figure.4.1 Identification of ALK-140-kDa fragment 
(A) ALK 220-kDa and 140-kDa bands were present in both HEK293/ALK-HA stable cells and 
IMR-32 neuroblastoma cells. Considering the high ALK expression level in HEK293/ALK cells, 
the cell lysate was directly blotted with anti-HA antibody. For IMR-32 cells, endogenous ALK was 
first immunoprecipitated with ALK antibody and then blotted with ALK C-terminal antibody; (B-
C) the cleavage site was predicted to be within aa509 to aa612 region. Several ALK truncated forms 
were designed (B) and transiently expressed in HEK293 cells, however both aa509~a552 and 
aa552-aa612 ALK deletion forms generated the 140-kDa fragment in vivo. 
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Figure.4.2 MS analysis of ALK ectodomain  
An overview of ALK ectodomain peptides identified in MS. All detected peptides, which were 
generated from digestion by three different proteases, are aligned with the ALK sequence.  
4.4.2 Screening for ALK cleavage site by MS 
We used mass spectrometry to further identify the cleavage site by screening for peptides 
throughout the ALK ectodomain. In a serum-free environment, cultured HEK293/ALK 
cells were stimulated with 0.5 mM MMP/ADAM activator APMA for 30 minutes to 
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release the ALK ectodomain to the medium, which was then immuno-precipitated with an 
ALK N-terminal antibody. The product was digested in-solution by three different 
enzymes: chymotrypsin, trypsin and Glu-C, then all resulting peptides were profiled by 
mass spectrometry. The detected peptides were aligned with ALK protein sequence as 
shown in Fig.4.2 and Suppl.S7-9; the blue bars represent peptides with high signal 
intensities. From this data, it indicates that the cleavage site is located after, but close to 
amino acid 656.  
4.4.3 MMP and ADAM mediate ALK ectodomain shedding 
Receptor ectodomain shedding is typically carried out by metalloproteinase MMPs and 
ADAMs. To confirm that ALK cleavage is indeed mediated by this mechanism, we 
compared the effects of MMP/ADAM inhibitor (BB-94) and activator (APMA) in 
generating the 140-kDa ALK fragment in HEK293/ALK stable cells. We found the relative 
levels of 140-kDa ALK were significantly reduced with BB-94 treatment (Fig.4.3A-B) and 
increased with APMA treatment (Fig.4.3C). We also tested another broad MMP/ADAM 
inhibitor GM6001. At two different concentrations, 10 µM and 50 µM, GM6001 
completely inhibited the effect of APMA and abolished ALK ectodomain shedding since 
neither the ALK ectodomain nor 140-kDa fragment were detected in the culture medium 
or cell lysate (Fig.4.3D, lane 1-4). In addition, we confirmed the ectodomain shedding of 
ALK was promoted by the activation of Protein Kinase C (PKC) with the treatment of PKC 
activator phorbol-12-myristate-13-acetate (PMA) (Fig.4.3D, lane 1, 5-6). This is consistent 
with previous reports that PKC is a major activator of ectodomain shedding (Hayashida et 
al., 2010).  
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Figure.4.3 MMPs mediate ALK ectodomain shedding 
(A) MMP/ADAM inhibitor BB-94 inhibited the generation of the 140-kDa ALK fragment; (B) The 
western blotting quantification of relative 140-kDa ALK fragment level with BB-94 treatment. n=3, 
p<0.05; (C) MMP/ADAM activator APMA promoted the generation of the 140-kDa ALK 
fragment; (D) MMP/ADAM broad inhibitor GM6001 completely blocked ALK ectodomain 
shedding (lane1-4). PKC activator PMA stimulated ALK ectodomain shedding (lane1, 5-6) 
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4.4.4 140-kDa ALK fragment is highly phosphorylated 
The intracellular RTK fragments usually exhibit higher kinase activity or phosphorylation 
level compared to their intact forms in the cell membrane. We compared the tyrosine 
phosphorylation levels of 140-kDa and full length ALK isolated from the same cell lysate. 
As predicted, the 140-kDa ALK exhibited a much higher phosphorylation level compared 
to the full length ALK during APMA activation (Fig.4.4 lane 1). 
 
Figure.4.4 140-kDa ALK fragment is highly phosphorylated 
A comparison of phosphorylation level in different ALK forms. APMA treatment was applied to 
induce ALK cleavage. Compared to the full length ALK, the 140-kDa ALK exhibited a much 
higher level of phosphorylation in western blot. 
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4.5 Discussion 
Here we presented preliminary data for the study of ALK ectodomain shedding. We 
confirmed that ALK ectodomain shedding was mediated by MMPs and identified the MMP 
cleavage region in ALK extracellular domain. More importantly, we found that the 140-
kDa ALK exhibited much higher phosphorylation levels compared to the full length ALK 
in non-stimulated conditions. These findings raise the possibility that this ALK fragment 
may have higher kinase activity compared to its full length form. Similarly, in some 
neuroblastoma cells, 140-kDa ALK was found overexpressed and had high tyrosine 
phosphorylation level (George et al., 2008). Recently, different ALK N-terminal truncated 
forms were found oncogenic either in neuroblastoma or melanoma (Cazes et al., 2013; 
Okubo et al., 2012; Wiesner et al., 2015). Although these ALK fragments were generated 
by either alternative splicing or alternative transcription initiation instead of protease 
cleavage, we could expect that the 140-kDa ALK may share similar oncogenic 
characteristic, and ectodomain shedding may contribute to the oncogenicity of ALK in 
some specific cancer types, such as the cancer type with high ALK and MMPs expressions.  
To further evaluate the hypothesis, we plan to first identify ALK cleavage site and test the 
oncogenic potential of 140-kDa ALK thoroughly in vitro. In addition, we could absolutely 
quantify the kinase activities of 140-kDa and full length ALKs. If as expected, 140-kDa 
ALK has stronger kinase activity, we will further investigate the molecular mechanism of 
140-kDa ALK over-activation after ectodomain shedding.   
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Chapter 5  
5 Summary and perspectives 
5.1 Summary of study 
NUMB is the first reported cell fate determinant, originally characterized in Drosophila 
(Uemura et al., 1989), in which asymmetric distribution of NUMB protein determines the 
fate of daughter cells during sensory organ precursor division (Rhyu et al., 1994). At the 
molecular level, NUMB directly binds to and counteracts NOTCH receptor during cell fate 
determination in this cell lineage (Guo et al., 1996). This is also the pioneer research of 
asymmetric cell division. Since the NUMB gene is evolutionarily conserved, research on 
NUMB quickly expanded to encompass advanced animal models. Consistently, NUMB is 
found to be involved in the development of brain, pancreas and retina in mice (Dho et al., 
1999), suggesting that NUMB may generally regulate asymmetric division and cell fate 
determination during animal development.  
The structure of NUMB is conserved from fly to human. As an adapter protein, NUMB 
has an PTB domain and DPF/NPF motifs, which are responsible for protein-protein 
interactions and contributing to most known NUMB functions (Bork and Margolis, 1995; 
Li et al., 1997; Li et al., 1998; Zwahlen et al., 2000). However, the PTB domain and PRR 
play different roles in NUMB function and have distinct protein binding partners. The PTB 
domain binds to a number of membrane localized or associated proteins that are crucial for 
transmembrane signal transduction (Dho et al., 1999; Dho et al., 2006; Gulino et al., 2010), 
while most known DPF/NPF binding partners are endocytic effector proteins (Salcini et 
al., 1997; Santolini et al., 2000). This binding pattern implicates a potential role for NUMB 
in endocytosis regulation. Indeed, NUMB has been shown to regulate the endocytosis and 
activity of the NOTCH receptor (Barth and Köhler, 2014; McGill et al., 2009; McGill and 
McGlade, 2003; Yamamoto et al., 2010). 
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Unlike that in Drosophila, the mammalian NUMB gene undergoes alternative splicing to 
express at least 9 isoforms, of which the four longest have been well studied. The four 
isoforms are differentiated by the exclusion or inclusion of exon 3 in the PTB domain and 
exon 9 in the PRR. Even though all four isoforms are involved in development, their 
functions differ in several animal models, particularly between the PRRL and PRRS 
isoforms as reported in a number of studies (Bani-Yaghoub et al., 2007; Dho et al., 1999a; 
Dooley et al., 2003; Verdi et al., 1999; Yoshida et al., 2003). In general, PRRL isoforms 
promote cell proliferation and PRRS isoforms stimulate cell differentiation, while their 
expression patterns vary in different cells at the tissue/organ level. It should be noted that 
ectopic expression of human PRRL or PRRS isoforms results in similar 
proliferation/differentiation phenotypes in Drosophila as well (Toriya et al., 2006). 
However, the mechanism of this isoform-dependent functional diversity has not been well 
elucidated. It is only speculated that PRRL and PRRS isoforms may recruit distinct effectors 
that are required for proliferation or differentiation respectively.  
Despite the established importance of NUMB in development, current research mainly 
focuses on studying its function in tumorigenesis. Conventionally, NUMB is defined as a 
tumor suppressor, due to its negative regulation of the NOTCH receptor, the first reported 
NUMB binding partner and one of the most frequently deregulated receptors in solid 
tumors (Espinoza and Miele, 2013; Leong and Gao, 2008). The pivotal role of NOTCH is 
to control cell fate determination and proliferation at the cellular level. At the tissue level, 
NOTCH is also involved in angiogenesis and epithelial-mesenchymal transition (Leong 
and Karsan, 2006). NUMB promotes NOTCH endocytosis and subsequent lysosomal 
degradation, thus suppressing tumorigenesis. In addition, NUMB also attenuates cell 
immortality by preventing MDM2 mediated ubiquitination of p53 (Colaluca et al., 2008). 
On the other hand, NUMB exhibits some oncogenic properties in an isoform dependent 
manner. PRRL isoforms, but not PRRS isoforms, have been shown to correlate with 
promoted cell proliferation, and the RBM5/6 and RBM10 splicing factors, which are 
responsible for NUMB exon 9 inclusion or exclusion, regulate the cancer cell proliferation 
conversely (Bechara et al., 2013; Westhoff et al., 2009).  
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To further elucidate the complex nature of NUMB function, particularly in tumorigenesis, 
we systematically investigated the NUMB interactome and defined the binding specificity 
of NUMB-PTB domain by employing an integrative strategy combining both protein and 
peptide arrays. The interactome of NUMB-PTB domain was profiled in a protein array that 
contained 8274 human proteins. Simultaneously, an oriented peptide array library was 
synthesized and probed with NUMB-PTB domain. The peptide array data were processed 
using the SMALI program to generate a prediction of NUMB-PTB binding sites in 
candidate interactors identified in the protein array. Next, the candidate interactors and 
PTB binding sites were validated via conventional immunoprecipitation, pulldown or 
protein-peptide binding assays.  
 It is interesting that a number of RTKs were isolated from the protein array and their 
binding to NUMB-PTB was confirmed in vitro and in vivo. Previously, NUMB has been 
reported to interact with at least three RTKs: EphB2, TrkB and EGFR. These interactions 
are functional, even though mechanistic demonstration is still lacking (Jiang et al., 2012; 
Nishimura et al., 2006; Zhou et al., 2011). Some evidence suggests that NUMB likely 
promotes EGFR endocytosis and lysosomal degradation (Jiang et al., 2012), similar to its 
regulation of the NOTCH receptor. Our studies exhibit that RTKs are highly enriched in 
the NUMB interactome and three common oncogenic RTKs, ALK, ErbB2 and Fgr directly 
interact with NUMB. Because NUMB generally interacts with membrane 
localized/associated proteins via the PTB domain and recruits endocytic effectors via 
DPF/NPF motifs, it can be speculated that NUMB may play the same role in connecting 
RTKs and endocytic effectors, thus promoting RTK endocytosis. 
Considering the high accuracy of our SMALI prediction of NUMB-PTB binding sites, we 
scanned the entire human protein database for isolating more potential NUMB-PTB 
binding partners. It is intriguing that RTKs and PTPs are highly enriched in the top hit list. 
These data further increase the possibility that NUMB may act as a universal binding 
partner and regulator of RTKs.  
This hypothesized model is supported by our studies on the interplay between NUMB and 
ALK. As presented in Chapter 2, we isolated a number of RTKs as NUMB-PTB binding 
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partners and validated the interactions in vivo for ALK, ErbB2 and Fgr. ALK was chosen 
for subsequent functional studies for two main reasons: (1) ALK is a hot therapeutic target 
and frequently deregulated in many cancer types. Unlike other oncogenic RTKs, ALK 
drives the malignant characteristics of cancer cells in many different ways, including gene 
amplification, overexpression, constitutively active mutations, alternative transcription 
initiation, and most notably, translocation fusion mutations (Hallberg and Palmer, 2013); 
At least 22 ALK fusion proteins have been characterized clinically. The mechanism is 
unclear and it is speculated that the ALK gene is located in an active translocation region 
in the genome; (2) ALK potentially has less cross-talk with other RTKs. ALK belongs to 
a small RTK subfamily, consisting of only two members: ALK and LTK, as defined by 
their unique extracellular domains containing a glycine-rich region (Palmer et al., 2009). 
ALK is an ideal therapeutic target because it has no physiological significance in adults 
and only expressed in selected cancer types (Morris et al., 1994). This makes it possible to 
study ALK in a relatively clean background with less negative impact from functional 
redundancy or cross-talk among RTKs. We take advantage of a HEK293-based stable cell 
line with ALK expression for most our studies, which is easily subjected to experimental 
manipulation. More importantly, we took advantage an ALK stimulating antibody (mimics 
of ligand) that is highly specific for ALK activation, which greatly facilitates the evaluation 
of ALK-driven oncogenic behaviors in HEK293/ALK cells. 
As predicted, NUMB binds two ALK motifs: G1473GHVNMAFSQ1482 and 
F1577PCGNVNYGYQ1587 in vitro and in vivo. In terms of ALK binding, little difference is 
found between PTBL and PTBS domains. Both PRRL and PRRS isoforms regulate ALK 
endocytosis, and direct internalized ALK to distinct destinations during endosomal sorting, 
as verified by surface biotinylation assays and quantitative fluorescent microscopy. The 
p72 isoform (PRRL) mainly recycles ALK back to the membrane while the p66 isoform 
(PRRS) encourages ALK to compartmentalize in the late endosome. Fluorescent 
microscopy clearly exhibits that ALK co-localizes with different post-endocytic 
destination markers with p66-NUMB or p72-NUMB expression. The preference for 
endosomal sorting has different effects on cell proliferation and anchorage-dependent cell 
growth that are driven by ALK activation. In particular, the p72 isoform assists in 
sustaining the active status of the ALK and MAPK proliferation signal pathway. 
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Conversely, the p66 isoform promotes ALK degradation, thus attenuating ALK activity 
and MAPK signaling.  
Our findings provide the first evidence for the differential functions of NUMB isoforms in 
endosomal sorting and the regulation of RTK activity. NUMB generally promotes the 
endocytosis of ALK and further determines the destination of internalized ALK in an 
isoform-dependent manner. The p72 isoform recycles ALK back to the membrane to 
sustain ALK activity, thus being potentially oncogenic. In contrast, the p66 isoform mainly 
directs ALK to the late endosome for lysosomal degradation. Considering the functional 
pattern of NUMB proteins, it is possible that the NUMB isoforms may act in a similar 
manner for all NUMB-binding receptors, including RTKs. This is consistent with previous 
reports that the NUMB PRRL isoform correlates with malignant behaviors in a number of 
cancer types (Bechara et al., 2013; Misquitta-Ali et al., 2011; Westhoff et al., 2009). 
5.2  NUMB isoforms, endosomal sorting and cancer diagnosis 
NUMB is defined as an endocytic adaptor. As introduced above, the PTB domain binds to 
receptors on the membrane while the DPF/NPF recruits endocytic effector proteins. This 
functional pattern raises a possibility that NUMB may act as a universal bi-directional 
regulator of receptors by regulating endocytosis and subsequent endosomal sorting of 
receptors. It has been reported that NUMB is involved in both recycling and endosomal 
compartmentalization of NOTCH (McGill et al., 2009), and NUMB alternative splicing 
could increase the activity of NOTCH and its downstream signaling (Bechara et al., 2013; 
Westhoff et al., 2009). This is in agreement with our model, and it is likely that NUMB 
regulates NOTCH in the same way.   
An immediate question to address is how PRRL and PPRS determine the direction of 
endosomal sorting. It can be speculated that PRRL and PPRS may recruit different sets of 
endocytic effectors that in turn decide the destination of internalized proteins. But this is 
challenged by a mass spectrometry based study that compares the interactome between p72 
and p66 isoforms. It is reported that both isoforms bind to the same few endocytic proteins, 
but with different binding affinities (Krieger et al., 2013).  However, only a limited number 
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of binding partners were identified in this study and we cannot exclude the possibility that 
PRRL and PPRS recruit different endocytic proteins. In our study, even with the 
overexpression of the two isoforms, the differences in cell proliferation and anchorage-
dependent growth are only moderate. This suggests that p72 and p66 isoforms may not 
play absolutely opposing roles in ALK endosomal sorting; instead, they likely just prefer 
the recycling or late endosomal compartmentalization of ALK, respectively. To further 
characterize the function of NUMB isoforms in endosomal sorting, a structural analysis 
and systematic interactome profile are necessary. In addition, the strategy employed in our 
studies may be repeated for the study of NUMB and other RTKs, but it will be important 
to establish a proper cell line/system to carry out these experiments. 
Based on our studies and previous reports, the p72 isoform may contribute to the 
oncogenicity of NUMB by sustaining the activity of membrane localized receptors. On the 
other hand, NUMB is able to suppress tumor growth in parallel pathways, either by 
promoting receptor endocytosis and subsequent degradation, or by stabilizing p53 to 
attenuate cell immortality. Therefore, simultaneously identifying of the status of p53, 
receptors, and NUMB alternative splicing forms may better predict the prognosis of 
specific tumor types and guide the design of adjuvant therapy. We have scheduled a 
computational analysis for evaluating p53 levels, NOTCH/ALK/ErbB2 expression levels 
and NUMB alternative splicing forms from published cancer cell microarray data. For 
select cell lines with distinct fingerprints, we will thoroughly characterize their oncogenic 
behaviors and responses to target therapeutics. 
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Supplemental Data 
S1 ProtoArray grid design 
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S2 ProtoArray quantification of NUMB-PTB domain (Z-Score>3.0) 
Rank Uniprot Name Grid Row Column Signal Z-Score 
1 PVRL3_HUMAN 3 18 5 36315.3 30.74933 
2 PVRL3_HUMAN 3 18 6 33886.8 28.66454 
3 GLYG2_HUMAN 1 17 20 30656.6 25.89145 
4 SLAI2_HUMAN 48 15 10 27682.6 23.33829 
5 SLAI2_HUMAN 48 15 9 23388.9 19.6522 
6 CJ091_HUMAN 17 18 3 22245.8 18.67084 
7 CJ091_HUMAN 17 18 4 21979 18.44183 
8 PIM1_HUMAN 1 19 20 20991.3 17.59388 
9 LCK_HUMAN 39 19 19 19938.7 16.69021 
10 LCK_HUMAN 39 19 20 19769.6 16.54503 
11 M3K2_HUMAN 42 19 18 17040.1 14.2018 
12 M3K2_HUMAN 42 19 17 16796.4 13.9926 
13 FGFR2_HUMAN 48 19 18 16583.1 13.80947 
14 FGFR4_HUMAN 47 19 20 15525.1 12.90122 
15 TOPK_HUMAN 27 19 16 15383 12.77921 
16 CDK5_HUMAN 44 19 12 15223.1 12.64197 
17 FGFR2_HUMAN 48 19 17 15196.7 12.61931 
18 TOPK_HUMAN 27 19 15 14900 12.3646 
19 FGFR4_HUMAN 47 19 19 14785.2 12.26599 
20 FYN_HUMAN 3 19 19 14654 12.15338 
21 PIM1_HUMAN 1 19 19 14214.7 11.77621 
22 FYN_HUMAN 3 19 20 14207.8 11.7703 
23 ALK_HUMAN 41 19 18 13745.1 11.37306 
24 GLYG2_HUMAN 1 17 19 13543.5 11.19998 
25 Q96E28_HUMAN 48 12 20 13396.9 11.07417 
26 ALK_HUMAN 41 19 17 13103.2 10.82204 
27 FLT3_HUMAN 3 19 13 12455 10.26558 
28 KPCB_HUMAN 3 19 9 12054.5 9.92171 
29 Q96E28_HUMAN 48 12 19 11980.4 9.85811 
30 FLT3_HUMAN 3 19 14 11912 9.79937 
31 FGR_HUMAN 30 19 20 11650.1 9.57456 
32 FGR_HUMAN 30 19 19 10870.2 8.90499 
33 CDK5_HUMAN 44 19 11 10537.2 8.61912 
34 KPCB_HUMAN 3 19 10 10188.4 8.31969 
35 EMC9_HUMAN 23 16 3 9668.02 7.87296 
36 CDK2_HUMAN 42 19 13 9578.64 7.79623 
37 FGFR3_HUMAN 9 19 11 9517.92 7.7441 
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38 CSK21_HUMAN 5 19 13 9484.94 7.71578 
39 CUED1_HUMAN 47 5 19 9330.07 7.58283 
40 LIMC1_HUMAN 1 7 20 9319.14 7.57345 
41 IGF1R_HUMAN 41 19 15 8877.21 7.19406 
42 HCK_HUMAN 35 19 10 8868.84 7.18687 
43 LYN_HUMAN 11 19 9 8780.18 7.11076 
44 RIPK2_HUMAN 3 19 18 8775.8 7.107 
45 FLT3_HUMAN 35 19 13 8752.18 7.08672 
46 KPCD_HUMAN 19 15 5 8748.06 7.08318 
47 AKT1_HUMAN 44 19 10 8720.24 7.0593 
48 CUED1_HUMAN 47 5 20 8713.85 7.05381 
49 FGFR3_HUMAN 9 19 12 8641.57 6.99177 
50 CDK2_HUMAN 42 19 14 8631.38 6.98301 
51 BTK_HUMAN 4 19 9 8459.87 6.83578 
52 PADI4_HUMAN 1 1 19 8441.76 6.82023 
53 RIPK2_HUMAN 3 19 17 8384.91 6.77142 
54 YES_HUMAN 25 19 14 8299.2 6.69784 
55 AKT1_HUMAN 44 19 9 8285.45 6.68603 
56 CSK21_HUMAN 5 19 14 8188.7 6.60298 
57 ROS1_HUMAN 20 19 10 8188.17 6.60253 
58 TBK1_HUMAN 37 19 13 8170.14 6.58705 
59 FLT3_HUMAN 35 19 14 8168.28 6.58544 
60 BTK_HUMAN 4 19 10 8154.94 6.57399 
61 NTKL_HUMAN 48 13 4 8128.75 6.55151 
62 SRPK1_HUMAN 1 19 14 8119.07 6.54321 
63 ROS1_HUMAN 20 19 9 8091.6 6.51962 
64 CSF1R_HUMAN 37 19 17 8076.69 6.50682 
65 PPID_HUMAN 42 18 9 8062.23 6.49441 
66 YES_HUMAN 25 19 13 8038.5 6.47403 
67 PPID_HUMAN 42 18 10 7961 6.4075 
68 KPCG_HUMAN 1 19 11 7897.96 6.35338 
69 MP2K1_HUMAN 2 19 11 7893.63 6.34967 
70 NTKL_HUMAN 48 13 3 7868.84 6.32838 
71 IGF1R_HUMAN 41 19 16 7806.25 6.27465 
72 KPCG_HUMAN 1 19 12 7755.49 6.23107 
73 HCK_HUMAN 35 19 9 7714.97 6.19629 
74 JAK2_HUMAN 4 19 11 7690.65 6.17541 
75 SRPK1_HUMAN 1 19 13 7610.42 6.10653 
76 PDPK1_HUMAN 10 19 12 7579.43 6.07993 
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77 PDPK1_HUMAN 10 19 11 7506.73 6.01752 
78 IKKA_HUMAN 47 19 13 7466.15 5.98267 
79 TBK1_HUMAN 37 19 14 7426.09 5.94828 
80 EMC8_HUMAN 1 3 13 7316.67 5.85435 
81 FBX38_HUMAN 35 16 15 7316.45 5.85416 
82 IKKA_HUMAN 47 19 14 7291.03 5.83234 
83 EMC8_HUMAN 1 3 14 7246.75 5.79432 
84 LYN_HUMAN 11 19 10 7206.27 5.75957 
85 QKI_HUMAN 45 5 4 7175.25 5.73294 
86 LYN_HUMAN 45 19 11 7147.52 5.70914 
87 BLK_HUMAN 31 19 20 7107.49 5.67477 
88 TOPK_HUMAN 42 9 19 7046.54 5.62245 
89 MP2K1_HUMAN 2 19 12 7019.51 5.59924 
90 TOPK_HUMAN 42 9 20 6999.5 5.58206 
91 JAK2_HUMAN 4 19 12 6980.62 5.56585 
92 PADI4_HUMAN 1 1 20 6959.65 5.54785 
93 BLK_HUMAN 31 19 19 6818.67 5.42682 
94 ST17A_HUMAN 46 19 17 6698.89 5.32399 
95 LYN_HUMAN 45 19 12 6626.09 5.26149 
96 HCK_HUMAN 44 16 6 6508.78 5.16078 
97 EPHB4_HUMAN 27 19 19 6491.82 5.14623 
98 CT55_HUMAN 45 7 3 6358.62 5.03188 
99 SGK1_HUMAN 21 11 2 6313.66 4.99328 
100 ST17A_HUMAN 46 19 18 6187.43 4.88491 
101 Q8IY52_HUMAN 18 17 8 6117.21 4.82463 
102 RBP10_HUMAN 45 19 20 6097.39 4.80761 
103 CT55_HUMAN 45 7 4 6079.7 4.79243 
104 KS6A1_HUMAN 24 19 9 6048.34 4.7655 
105 KPCT_HUMAN 19 19 14 6027.71 4.74779 
106 KS6A1_HUMAN 24 19 10 6003.57 4.72707 
107 CSF1R_HUMAN 37 19 18 5900.46 4.63855 
108 SDCG3_HUMAN 26 15 5 5883.08 4.62362 
109 Q8IY52_HUMAN 18 17 7 5785.89 4.54019 
110 HCK_HUMAN 44 16 5 5782.46 4.53724 
111 PTK6_HUMAN 32 19 10 5728.43 4.49086 
112 SGK1_HUMAN 21 11 1 5721.5 4.48492 
113 RPC6_HUMAN 44 14 13 5660.13 4.43223 
114 TGFR2_HUMAN 35 14 13 5651.01 4.42439 
115 KPCA_HUMAN 1 19 18 5620.63 4.39831 
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116 AR6P4_HUMAN 25 6 18 5593.06 4.37465 
117 KPCD_HUMAN 5 19 11 5580.17 4.36358 
118 KPCT_HUMAN 19 19 13 5508.64 4.30217 
119 KPCD_HUMAN 5 19 12 5490.67 4.28675 
120 NUSAP_HUMAN 18 5 18 5488.44 4.28483 
121 LMX1B_HUMAN 42 11 7 5484.62 4.28156 
122 PAK4_HUMAN 32 19 14 5453.11 4.25451 
123 ILKAP_HUMAN 36 11 7 5434.85 4.23882 
124 SDCG3_HUMAN 26 15 6 5385.02 4.19605 
125 KPCA_HUMAN 1 19 17 5373.54 4.18619 
126 LMX1B_HUMAN 42 11 8 5315.51 4.13637 
127 TM1L2_HUMAN 8 16 1 5285.32 4.11045 
128 PAK4_HUMAN 32 19 13 5240.19 4.07171 
129 UFO_HUMAN 47 19 18 5229.03 4.06213 
130 TM169_HUMAN 23 16 2 5192.73 4.03097 
131 TGFR2_HUMAN 35 14 14 5167.85 4.00961 
132 ILKAP_HUMAN 36 11 8 5128.1 3.97548 
133 SRC_HUMAN 7 19 19 5120.55 3.969 
134 GBA2_HUMAN 44 11 8 5113.66 3.96309 
135 PDE4A_HUMAN 36 4 7 5050.26 3.90866 
136 MYL6B_HUMAN 2 15 8 5047.82 3.90657 
137 PCCA_HUMAN 39 4 15 5028.7 3.89015 
138 PTK6_HUMAN 32 19 9 5007.69 3.87212 
139 LIMC1_HUMAN 1 7 19 4981.93 3.85 
140 MP2K1_HUMAN 35 19 15 4978.09 3.84671 
141 UBXN6_HUMAN 37 5 3 4951.69 3.82404 
142 PAK3_HUMAN 19 19 18 4939.15 3.81327 
143 EPHA8_HUMAN 48 19 11 4936.82 3.81128 
144 BMX_HUMAN 17 19 15 4932.6 3.80765 
145 QKI_HUMAN 45 5 3 4919.16 3.79611 
146 RM19_HUMAN 46 17 17 4902.87 3.78213 
147 MYL6B_HUMAN 2 15 7 4898.98 3.77878 
148 M4K2_HUMAN 33 19 19 4895.71 3.77598 
149 CK074_HUMAN 7 19 5 4878.44 3.76115 
150 ERBB2_HUMAN 17 19 11 4795.76 3.69018 
151 ARFG1_HUMAN 36 6 3 4786.86 3.68253 
152 ANS4B_HUMAN 19 14 2 4786.81 3.68249 
153 SRC_HUMAN 7 19 20 4783.57 3.67971 
154 PAK3_HUMAN 19 19 17 4762.73 3.66182 
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155 Q8TB46_HUMAN 18 2 12 4761.44 3.66071 
156 UFO_HUMAN 47 19 17 4743.09 3.64496 
157 SMTL2_HUMAN 45 15 3 4727.37 3.63146 
158 RM19_HUMAN 46 17 18 4703.64 3.61109 
159 TM1L2_HUMAN 8 16 2 4688.19 3.59783 
160 L7RTI5_HUMAN 4 19 13 4639.4 3.55594 
161 M4K2_HUMAN 33 19 20 4633.61 3.55097 
162 UBXN6_HUMAN 37 5 4 4632.58 3.55009 
163 BMX_HUMAN 17 19 16 4591.67 3.51497 
164 TEC_HUMAN 25 19 20 4560.56 3.48826 
165 YES_HUMAN 48 15 17 4558.41 3.48641 
166 BEGIN_HUMAN 37 8 5 4548.89 3.47824 
167 ARFG1_HUMAN 36 6 4 4544.26 3.47427 
168 EPHB4_HUMAN 27 19 20 4531.18 3.46304 
169 Q8TB46_HUMAN 18 2 11 4522.1 3.45524 
170 ERBB2_HUMAN 17 19 12 4515.15 3.44927 
171 M3K3_HUMAN 35 19 11 4482.24 3.42102 
172 NTRK1_HUMAN 39 19 11 4458.61 3.40074 
173 IRS1_HUMAN 19 7 19 4451.18 3.39435 
174 SMTL2_HUMAN 45 15 4 4448.79 3.39231 
175 M3K11_HUMAN 33 19 16 4446.09 3.38998 
176 PCCA_HUMAN 39 4 16 4405.68 3.35529 
177 NUAK1_HUMAN 6 19 18 4389.85 3.3417 
178 SNAG_HUMAN 11 11 12 4382.94 3.33577 
179 M3K11_HUMAN 33 19 15 4373.26 3.32746 
180 RBP10_HUMAN 45 19 19 4364.82 3.32022 
181 MET_HUMAN 13 19 20 4363.51 3.31909 
182 TEC_HUMAN 25 19 19 4350.54 3.30796 
183 DAPK2_HUMAN 33 19 14 4318.56 3.2805 
184 IRAK4_HUMAN 16 19 17 4295.26 3.2605 
185 Q8WUK8_HUMAN 5 4 9 4284.99 3.25168 
186 FRK_HUMAN 46 19 20 4274.22 3.24244 
187 PCKGC_HUMAN 46 17 11 4273.91 3.24217 
188 TMOD2_HUMAN 12 14 9 4259.88 3.23013 
189 CK074_HUMAN 7 19 6 4250.07 3.22171 
190 YES_HUMAN 48 15 18 4245.22 3.21754 
191 JAK3_HUMAN 43 19 17 4241.14 3.21404 
192 FRK_HUMAN 46 19 19 4240.98 3.2139 
193 MP2K1_HUMAN 35 19 16 4238.36 3.21165 
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194 MAPK3_HUMAN 30 19 15 4235.18 3.20892 
195 MET_HUMAN 13 19 19 4220.96 3.19672 
196 HOIL1_HUMAN 19 18 2 4218.22 3.19437 
197 IRS1_HUMAN 19 7 20 4192.95 3.17267 
198 NTRK1_HUMAN 39 19 12 4188.01 3.16843 
199 AURKB_HUMAN 31 19 11 4162.79 3.14678 
200 IRAK4_HUMAN 16 19 18 4149.08 3.13501 
201 MYL1_HUMAN 1 10 17 4135.88 3.12368 
202 TMOD2_HUMAN 12 14 10 4132.82 3.12104 
203 CACO1_HUMAN 22 19 2 4128.69 3.1175 
204 CPLX2_HUMAN 2 5 11 4121.33 3.11119 
205 MYL1_HUMAN 1 10 18 4113.2 3.1042 
206 JAK3_HUMAN 43 19 18 4081.93 3.07736 
207 B3KVH4_HUMAN 10 11 11 4068.79 3.06608 
208 EPHA8_HUMAN 48 19 12 4067.12 3.06464 
209 NUAK1_HUMAN 6 19 17 4055.6 3.05475 
210 TOM1_HUMAN 18 15 12 4046.53 3.04697 
211 AURKB_HUMAN 31 19 12 4039.26 3.04073 
212 ABL2_HUMAN 28 19 14 4029.12 3.03203 
213 TOM1_HUMAN 18 15 11 4013.05 3.01822 
214 BEGIN_HUMAN 37 8 6 4005.81 3.01201 
215 RPC6_HUMAN 44 14 14 3999.14 3.00628 
216 KCC2B_HUMAN 42 19 16 3994.02 3.00189 
 
 
 
 
 
 
 
 
 
 
135 
 
S3 NUMB interactome 
# Uniprot Name Gene names 
1 ABL2_HUMAN ABL2 ABLL ARG 
2 AKT1_HUMAN AKT1 PKB RAC 
3 ALK_HUMAN ALK 
4 ANS4B_HUMAN ANKS4B HARP 
5 AR6P4_HUMAN ARL6IP4 
6 ARFG1_HUMAN ARFGAP1 ARF1GAP 
7 AURKB_HUMAN AURKB AIK2 AIM1 AIRK2 ARK2 STK1 STK12 STK5 
8 B3KVH4_HUMAN  
9 BEGIN_HUMAN BEGAIN KIAA1446 
10 BLK_HUMAN BLK 
11 BMX_HUMAN BMX 
12 BTK_HUMAN BTK AGMX1 ATK BPK 
13 CACO1_HUMAN CALCOCO1 KIAA1536 PP13275 UNQ2436/PRO4996 
14 CDK2_HUMAN CDK2 CDKN2 
15 CDK5_HUMAN CDK5 CDKN5 
16 CJ091_HUMAN C10orf91 
17 CK074_HUMAN C11orf74 
18 CPLX2_HUMAN CPLX2 
19 CSF1R_HUMAN CSF1R FMS 
20 CSK21_HUMAN CSNK2A1 CK2A1 
21 CT55_HUMAN CT55 CXorf48 
22 CUED1_HUMAN CUEDC1 
23 DAPK2_HUMAN DAPK2 
24 EMC8_HUMAN EMC8 C16orf2 C16orf4 COX4AL COX4NB FAM158B NOC4 
25 EMC9_HUMAN EMC9 C14orf122 FAM158A CGI-112 
26 EPHA8_HUMAN EPHA8 EEK HEK3 KIAA1459 
27 EPHB4_HUMAN EPHB4 HTK MYK1 TYRO11 
28 ERBB2_HUMAN ERBB2 HER2 MLN19 NEU NGL 
29 FBX38_HUMAN FBXO38 SP329 
30 FGFR2_HUMAN FGFR2 BEK KGFR KSAM 
31 FGFR3_HUMAN FGFR3 JTK4 
32 FGFR4_HUMAN FGFR4 JTK2 TKF 
33 FGR_HUMAN FGR SRC2 
34 FLT3_HUMAN FLT3 CD135 FLK2 STK1 
35 FRK_HUMAN FRK PTK5 RAK 
36 FYN_HUMAN FYN 
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37 GBA2_HUMAN GBA2 KIAA1605 AD035 
38 GLYG2_HUMAN GYG2 
39 HCK_HUMAN HCK 
40 HOIL1_HUMAN RBCK1 C20orf18 RNF54 UBCE7IP3 XAP3 XAP4 
41 IGF1R_HUMAN IGF1R 
42 IKKA_HUMAN CHUK IKKA TCF16 
43 ILKAP_HUMAN ILKAP 
44 IRAK4_HUMAN IRAK4 
45 IRS1_HUMAN IRS1 
46 JAK2_HUMAN JAK2 
47 JAK3_HUMAN JAK3 
48 KCC2B_HUMAN CAMK2B CAM2 CAMK2 CAMKB 
49 KPCA_HUMAN PRKCA PKCA PRKACA 
50 KPCB_HUMAN PRKCB PKCB PRKCB1 
51 KPCD_HUMAN PRKCD 
52 KPCG_HUMAN PRKCG PKCG 
53 KPCT_HUMAN PRKCQ PRKCT 
54 KS6A1_HUMAN RPS6KA1 MAPKAPK1A RSK1 
55 L7RTI5_HUMAN PRKCE 
56 LCK_HUMAN LCK 
57 LIMC1_HUMAN LIMCH1 KIAA1102 
58 LMX1B_HUMAN LMX1B 
59 LYN_HUMAN LYN JTK8 
60 M3K11_HUMAN MAP3K11 MLK3 PTK1 SPRK 
61 M3K2_HUMAN MAP3K2 MAPKKK2 MEKK2 
62 M3K3_HUMAN MAP3K3 MAPKKK3 MEKK3 
63 M4K2_HUMAN MAP4K2 GCK RAB8IP 
64 MAPK3_HUMAN MAPKAPK3 
65 MET_HUMAN MET 
66 MP2K1_HUMAN MAP2K1 MEK1 PRKMK1 
67 MYL1_HUMAN MYL1 
68 MYL6B_HUMAN MYL6B MLC1SA 
69 NTKL_HUMAN SCYL1 CVAK90 GKLP NTKL TAPK TEIF TRAP HT019 
70 NTRK1_HUMAN NTRK1 MTC TRK TRKA 
71 NUAK1_HUMAN NUAK1 ARK5 KIAA0537 OMPHK1 
72 NUSAP_HUMAN NUSAP1 ANKT BM-037 PRO0310 
73 PADI4_HUMAN PADI4 PAD4 PADI5 PDI5 
74 PAK3_HUMAN PAK3 OPHN3 
75 PAK4_HUMAN PAK4 KIAA1142 
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76 PCCA_HUMAN PCCA 
77 PCKGC_HUMAN PCK1 PEPCK1 
78 PDE4A_HUMAN PDE4A DPDE2 
79 PDPK1_HUMAN PDPK1 PDK1 
80 PIM1_HUMAN PIM1 
81 PPID_HUMAN PPID CYP40 CYPD 
82 PTK6_HUMAN PTK6 BRK 
83 PVRL3_HUMAN PVRL3 PRR3 
84 Q8IY52_HUMAN DYNC1I1 
85 Q8TB46_HUMAN ANKRD50 
86 Q8WUK8_HUMAN STAC 
87 Q96E28_HUMAN SULF1 
88 QKI_HUMAN QKI HKQ 
89 RBP10_HUMAN RANBP10 KIAA1464 
90 RIPK2_HUMAN RIPK2 CARDIAK RICK RIP2 UNQ277/PRO314/PRO34092 
91 RM19_HUMAN MRPL19 KIAA0104 MRPL15 
92 ROS1_HUMAN ROS1 MCF3 ROS 
93 RPC6_HUMAN POLR3F 
94 SDCG3_HUMAN SDCCAG3 
95 SGK1_HUMAN SGK1 SGK 
96 SLAI2_HUMAN SLAIN2 KIAA1458 
97 SMTL2_HUMAN SMTNL2 
98 SNAG_HUMAN NAPG SNAPG 
99 SRC_HUMAN SRC SRC1 
100 SRPK1_HUMAN SRPK1 
101 ST17A_HUMAN STK17A DRAK1 
102 TBK1_HUMAN TBK1 NAK 
103 TEC_HUMAN TEC PSCTK4 
104 TGFR2_HUMAN TGFBR2 
105 TM169_HUMAN TMEM169 
106 TM1L2_HUMAN TOM1L2 
107 TMOD2_HUMAN TMOD2 NTMOD 
108 TOM1_HUMAN TOM1 
109 TOPK_HUMAN PBK TOPK 
110 UBXN6_HUMAN UBXN6 UBXD1 UBXDC2 
111 UFO_HUMAN AXL UFO 
112 YES_HUMAN YES1 YES 
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S4 NUMB-PTB peptide array quantification 
Position Intensity Sequences SMALI Score Protein Name Z-Score 
1:1 0.347763 VLEENLYFQGS 0.4818 VGFR3_HUMAN 1.46173 
1:2 0.300605 GVQINEEFCQR 0.6127 VGFR3_HUMAN 1.46173 
1:3 0.662353 KLASNYVYEVM 0.7411 TEC_HUMAN 3.30796 
1:4 0.671989 VHDANTLYIFA 0.346 TEC_HUMAN 3.30796 
1:5 0.36597 DKYGNEGYIPS 1.455 TEC_HUMAN 3.30796 
1:6 0.387521 IFKEHNFSFYP 0.481 TEC_HUMAN 3.30796 
1:7 0.97945 FPRENLEFGKV 0.5042 FLT3_HUMAN 10.26558 
1:8 0.953695 GSSDNEYFYVD 0.8388 FLT3_HUMAN 10.26558 
1:9 0.525919 TMFPNMDYDII 0.8348 CUED1_HUMAN 7.58283 
1:10 0.722152 LFLQNEEFMKE 0.5733 CUED1_HUMAN 7.58283 
1:11 0.771759 ELQRNRDFLLA 0.362 CUED1_HUMAN 7.58283 
1:12 1.281694 VDPDNVTFCVL 0.7521 GA45G_HUMAN -0.00226 
1:13 0.823835 RDVHNLDYYKK 0.623 FGFR3_HUMAN 7.7441 
2:1 1.382014 PMHSNHYYQTV 0.3074 C1QT1_HUMAN -0.31358 
2:2 0.878876 GERENAIFSEE 0.543 C1QT1_HUMAN -0.31358 
2:3 0.86461 ALAINKSFDQR 0.9228 3MG_HUMAN 1.03914 
2:4 0.841948 IHTENKLYLVF 0.4167 CDK2_HUMAN 7.79623 
2:5 1.309699 PTTENLYFQGA 0.5379 CDK5_HUMAN 8.61912 
2:6 2.698102 EKYKNSKYHGV 0.8614 CDK2_HUMAN 7.79623 
2:7 1.87173 NPICNDHYRSV 0.5912 TOPK_HUMAN 12.3646 
2:8 0.842733 TLATNDIYCQG 0.2427 GLYG2_HUMAN 11.19998 
2:9 0.980089 QGLLNSFFRNW 0.5015 GLYG2_HUMAN 11.19998 
2:10 1.114231 MKPWNYKYNPQ 0.6042 GLYG2_HUMAN 11.19998 
2:11 1.452584 NLSSNTMYTYS 0.3743 GLYG2_HUMAN 11.19998 
2:12 1.025716 DNAKNSLYLQM 0.3037 Q6N089_HUMAN 0.57969 
2:13 0.973497 EEQYNSTYRVV 0.7218 Q6N089_HUMAN 0.57969 
3:1 0.450261 TTEENPIFVVS 0.376 TBK1_HUMAN 6.58705 
3:2 0 KVFNNISFLRP 0.7385 TBK1_HUMAN 6.58705 
3:3 0.505069 LSLTNQCFDIE 0.6826 TBK1_HUMAN 6.58705 
3:4 0.121551 NFFLNSIYKSR 0.6554 ROS1_HUMAN 6.51962 
3:5 2.58423 VGLANACYAIH 0.5308 ROS1_HUMAN 6.51962 
3:6 96.3106 SGVINESFEGE 1.2859 ROS1_HUMAN 6.51962 
3:7 8.322358 DIYKNDYYRKR 0.9268 ROS1_HUMAN 6.51962 
3:8 1.380868 SSEENVKYSSS 0.3072 CHK1_HUMAN 2.51454 
3:9 2.284798 RREGNIQYLFL 0.3055 CHK1_HUMAN 2.51454 
3:10 9.817924 HIQSNLDFSPV 0.3631 CHK1_HUMAN 2.51454 
3:11 5.792815 FAIFNLVYWAT 0.9211 Q53F42_HUMAN 0.51696 
3:12 2.102681 GKKGNLVYIID 0.4311 KC1D_HUMAN 0.80639 
3:13 2.722263 LKPENLLFKDN 0.7907 MAPK5_HUMAN 2.84084 
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4:1 0.189837 ADGTNTGFPRY 0.8664 RET_HUMAN 2.57367 
4:2 0.633538 TWIENKLYGMS 0.8189 RET_HUMAN 2.57367 
4:3 2.101196 ITPHNKVYCCD 0.2088 M3K5_HUMAN 0.56847 
4:4 1.238038 MCTGNYTFVPY 0.6921 M3K5_HUMAN 0.56847 
4:5 1.732325 QNLHNSYYSVP 0.4253 CCNG2_HUMAN 0.32324 
4:6 5.498213 QVARNGSFTSI 0.5362 M3K2_HUMAN 13.9926 
4:7 1.611094 EDLDNTVFGAE 0.7767 M3K2_HUMAN 13.9926 
4:8 0.211608 SDYDNPIFEKF 1.3775 M3K2_HUMAN 13.9926 
4:9 2.471434 RKLDNGGYYIT 1.4048 FYN_HUMAN 12.15338 
4:10 100.3686 QGFRNAAFEA 1.6076 CJ091_HUMAN 18.67084 
4:11 75.73975 FPCGNVNYGYQ 0.3971 ALK_HUMAN 10.82204 
4:12 6.301939 MTDYNPNYCFA 0.5677 ALK_HUMAN 10.82204 
4:13 88.21687 GGHVNMAFSQS 1.1598 ALK_HUMAN 10.82204 
5:1 0 TSLWNPTYGSW 0.6734 ALK_HUMAN 10.82204 
5:2 2.846114 DYNPNYCFAGK 0.4522 ALK_HUMAN 10.82204 
5:3 51.76767 CGNVNYGYQQQ 1.247 ALK_HUMAN 10.82204 
5:4 4.155225 APGSNEQYNVG 0.4221 TNIK_HUMAN 0.78304 
5:5 1.211726 NELLNDEFFTS 0.469 PLK1_HUMAN 2.38864 
5:6 1.545762 PRGSNPAFLYK 0.9716 BTK_HMUAN 6.83578 
5:7 1.268331 VKPENLLYTSK 0.489 MAPK3_HUMAN 3.20892 
5:8 1.063448 ITPANVVFLYM 0.428 CDK5_HUMAN 8.61912 
5:9 2.984181 KVQPNSSYQNN 0.4397 CDK5_HUMAN 8.61912 
5:10 7.809663 TNAENKLYLAE 0.3826 BMX_HUMAN 3.80765 
5:11 6.424343 YLAENYCFDSI 0.7079 BMX_HUMAN 3.80765 
5:12 2.858528 LTKTNLSYYEY 0.7545 BMX_HUMAN 3.80765 
5:13 5.01853 QPNFNMQYIPR 0.2998 BMX_HUMAN 3.80765 
6:1 0 YVHVNATYVNV 0.9134 MET_HUMAN 3.19672 
6:2 1.371775 LDCSNCPYHIR 0.2644 ABEC4_HUMAN 1.75749 
6:3 3.182088 SYPLNNAFPGQ 0.912 ABEC4_HUMAN 1.75749 
6:4 1.262137 NPVWNETFVFN 0.9784 KPCG_HUMAN 6.35338 
6:5 0.621182 IMEHNVSYPKS 0.3766 KPCA_HUMAN 4.18619 
6:6 1.449479 NPQWNESFTFK 0.7417 KPCA_HUMAN 4.18619 
6:7 1.810219 FSYVNPQFVHP 1.0977 KPCA_HUMAN 4.18619 
6:8 1.524729 IMEHNVAYPKS 0.8052 KPCB_HUMAN 9.92171 
6:9 1.722045 NPEWNETFRFQ 0.7249 KPCB_HUMAN 9.92171 
6:10 1.856262 HEVKNHKFTAR 0.5356 KPCB_HUMAN 9.92171 
6:11 1.263951 FSYTNPEFVIN 0.8792 KPCB_HUMAN 9.92171 
6:12 0.818664 EDEANQPFCAV 0.2902 KPCD_HUMAN 4.36358 
6:13 1.295992 FSFVNPKFEHL 1.1675 KPCD_HUMAN 4.36358 
7:1 0.286851 HYIKNHEFIAT 0.6509 KPCD_HUMAN 4.36358 
7:2 1.290646 CNINNFIFHKV 0.7879 KPCD_HUMAN 4.36358 
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7:3 1.38879 EHVNNTDFKQL 0.4497 CSK21_HUMAN 7.71578 
7:4 1.206525 NMFRNFSFMNP 0.955 KPCT_HUMAN 4.30217 
7:5 1.366103 QTKENLFFVME 0.572 KPCT_HUMAN 4.30217 
7:6 2.788234 FKKTNQFFAIK 0.4389 KPCT_HUMAN 4.30217 
7:7 3.410254 RMLMNARYFLE 0.6304 KPCT_HUMAN 4.30217 
7:8 2.4609 IRMDNPFYPRW 0.6844 KPCT_HUMAN 4.30217 
7:9 1.848984 IREMNPNYTEF 0.393 GSK3A_HUMAN 1.98293 
7:10 1.857878 RGEPNVSYICS 0.3656 GSK3A_HUMAN 1.98293 
7:11 1.047852 KVIGNGSFGVV 0.9251 GSK3A_HUMAN 1.98293 
7:12 1.142243 PTAENPEYLGL 0.3438 ERBB2_HUMAN 3.69018 
7:13 10.2265 PAFDNLYYWDQ 1.3717 ERBB2_HUMAN 3.69018 
8:1 1.00998 GAVENPEYLTP 0.5545 ERBB2_HUMAN 3.69018 
8:2 2.373537 HKATNMEYAVK 0.3672 KS6A1_HUMAN 4.7655 
8:3 2.281122 LADVNHPFVVK 0.5991 KS6A1_HUMAN 4.7655 
8:4 4.389185 TIDWNKLYRRE 0.3572 KS6A1_HUMAN 4.7655 
8:5 5.203229 LHGKNLVFSDG 0.7122 KS6A1_HUMAN 4.7655 
8:6 13.5614 LKPSNILYVDE 0.5877 KS6A1_HUMAN 4.7655 
8:7 14.47223 VHTPNRTYYLM 0.5936 PDPK1_HUMAN 6.01752 
8:8 12.225 ELFENKPYTAT 0.7671 IKKA_HUMAN 5.98267 
8:9 4.30782 HSEKNVVYRDL 0.6092 AKT1_HUMAN 6.68603 
8:10 1.901632 RDQQNLPYGVT 0.5234 MARK2_HUMAN 1.84412 
8:11 1.354292 ANCTNELYMMM 0.518 FGFR2_HUMAN 12.61931 
8:12 1.173946 RDINNIDYYKK 0.6759 FGFR2_HUMAN 12.61931 
8:13 1.102273 SVKTNPAFLYK 1.0612 FGFR2_HUMAN 12.61931 
9:1 0.72588 TLTTNEEYLDL 0.7264 FGFR2_HUMAN 12.61931 
9:2 33.68871 SQAINPGFLDS 1.3673 FGR_HUMAN 8.90499 
9:3 6.164813 DVCENCHYPIV 0.2215 LCK_HUMAN 16.69021 
9:4 96.61679 RNLDNGGFYIS 1.4048 LCK_HUMAN 16.69021 
9:5 24.6589 GGYINASFIKI 1.3359 KC1E_HUMAN 1.34505 
9:6 100.1917 KGIENKAFDRN 1.5721 JIP4_HUMAN #N/A 
9:7 101.9599 TGFSNMSFEDF 1.2611 
Q9U485_DROME 
(NAK) 
#N/A 
9:8 103.6306 TGFSNAAFEDF 1.801 
NAK Mutant (NAK-
AA) 
#N/A 
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S5 OPAL Scoring Matrix of NUMB-PTB 
Pos/AA -5 -4 -2 -1 1 2 
K 0.0607 0.09 0.0705 0.0687 0.0752 0.0567 
R 0.0607 0.09 0.0705 0.0687 0.0752 0.0567 
H 0.0768 0.0129 0.0153 0.0185 0.0675 0.0417 
D 0.0017 0.3445 0.0484 0.0149 0.2874 0.3109 
E 0 0.1098 0.1888 0.0262 0.2983 0.1158 
N 0.0031 0.0218 0.0255 0.0757 0.0878 0.0349 
Q 0.0607 0.0306 0.0801 0.021 0.0494 0.0318 
S 0.0266 0.0292 0.0363 0.1992 0.0351 0.0292 
T 0.0561 0.09 0.0563 0.2231 0.0552 0.0344 
A 0.0287 0.0355 0.1778 0.6278 0.0924 0.0567 
G 0.0319 0.0335 0.1339 0.5881 0.0752 0.0447 
P 0.0567 0.0592 0.08 0.1179 0.0434 0.0476 
I 0.4199 0.3052 0.0494 0.0438 0.0428 0.0498 
L 0.1753 0.1139 0.1756 0.0625 0.0544 0.0715 
V 0.2497 0.3218 0.0644 0.0687 0.079 0.0634 
M 0.0939 0.0663 0.0665 0.0587 0.0957 0.081 
F 0.357 0.1188 0.1782 0.0659 0.0708 0.1472 
Y 0.5542 0.2631 0.2528 0.1023 0.1132 0.1483 
W 0.1296 0.0906 0.0705 0.0863 0.0814 0.1071 
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S6 Prediction of NUMB-PTB binding partners 
Rank Peptide Seq Uniprot Name Peptide Position SMAL 
1 IDNDGFED ITA4_HUMAN Pos (384-391) 2.0101 
2 YKNPAFDD CT075_HUMAN Pos (724-731) 1.9503 
3 YVNPAFER PDE8B_HUMAN Pos (293-300) 1.9388 
4 ILNGAFED S3TC2_HUMAN Pos (557-564) 1.9047 
5 IDNTAFMD STX3_HUMAN Pos (26-33) 1.8551 
6 YENGAFDE GP133_HUMAN Pos (220-227) 1.8289 
7 TVNYGFED OAS3_HUMAN Pos (270-277) 1.828 
8 YGNDGFDD HNRH3_HUMAN Pos (161-168) 1.8225 
9 YYNEAFSF SYT5_HUMAN Pos (305-312) 1.8162 
10 YVNAGYAL AXN1_HUMAN Pos (305-312) 1.8058 
11 ITNVAFDD MFAP3_HUMAN Pos (111-118) 1.8004 
12 YYNEAYGR TBB1_HUMAN Pos (50-57) 1.7658 
13 HDNFGFDD HAX1_HUMAN Pos (76-83) 1.7859 
14 IDNPGYEP WDR1_HUMAN Pos (440-447) 1.7784 
15 YKNPGYYD ITLN1_HUMAN Pos (134-141) 1.7364 
  ITLN2_HUMAN Pos (146-153)  
16 YDNISYED PKHG1_HUMAN Pos (661-668) 1.7565 
17 YVNGGFAV EAA3_HUMAN Pos (503-510) 1.7538 
18 LVNEAFDF RORB_HUMAN Pos (338-345) 1.7483 
19 VYNDGYDD DYR1A_HUMAN Pos (135-142) 1.7476 
20 FINQAFDM RIPK5_HUMAN Pos (373-380) 1.7385 
21 YVNWAFSE TRPM6_HUMAN Pos (1452-1459) 1.7252 
22 LVNEGFEY HIRA_HUMAN Pos (946-953) 1.7206 
23 YFNYGFNE FIP1_HUMAN Pos (175-182) 1.7175 
24 YVNSAFTE TULP4_HUMAN Pos (1084-1091) 1.7111 
25 YPNYAFRE MMP8_HUMAN Pos (236-243) 1.685 
26 YINGGFTV SMUF1_HUMAN Pos (505-512) 1.7 
27 IYNQGFEI CATC_HUMAN Pos (87-94) 1.6993 
28 YKNLAFYW RISC_HUMAN Pos (418-425) 1.6679 
29 FDNVGYEG ATP7B_HUMAN Pos (39-46) 1.697 
30 IVNFAFAI TRPV5_HUMAN Pos (557-564) 1.6899 
31 YNNPAYAD CV013_HUMAN Pos (202-209) 1.6871 
32 VDNSAFYD TM179_HUMAN Pos (161-168) 1.6824 
33 YINTAFLK AOC2_HUMAN Pos (488-495) 1.6546 
34 FDNFAFAM CAC1C_HUMAN Pos (346-353) 1.6809 
  CAC1D_HUMAN Pos (347-354)  
35 ITNLGFRD FAM3C_HUMAN Pos (173-180) 1.6597 
36 YDNTGFVA LRRC7_HUMAN Pos (774-781) 1.6788 
37 ICNAGFEL FBN2_HUMAN Pos (600-607) 1.5556 
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38 IINAAYKP SMBT2_HUMAN Pos (571-578) 1.6535 
39 IVNAKFED FCERA_HUMAN Pos (80-87) 1.5974 
40 YYNQAYFL ECHP_HUMAN Pos (487-494) 1.6675 
41 YLNEAFSF CI126_HUMAN Pos (146-153) 1.667 
42 YVNDAFGT PGK1_HUMAN Pos (160-167) 1.6618 
  PGK2_HUMAN Pos (160-167)  
43 ICNEGYEG DNER_HUMAN Pos (122-129) 1.5398 
44 YDNIGFVG TAB2_HUMAN Pos (632-639) 1.6599 
45 IDNCAFRL PHKG2_HUMAN Pos (350-357) 1.5389 
46 YGNYAFVW GRID2_HUMAN Pos (734-741) 1.6544 
47 LVNLAFSD NK3R_HUMAN Pos (124-131) 1.6465 
48 FVNAAFGK NET1_HUMAN Pos (55-62) 1.6163 
49 YINASFMD PTN9_HUMAN Pos (357-364) 1.643 
50 LDNPAFEE LNX2_HUMAN Pos (206-213) 1.6417 
51 FRNAAFEA CJ091_HUMAN Pos (138-145) 1.6076 
52 YVNSGFNP ADRB2_HUMAN Pos (316-323) 1.6358 
53 FVNAAFNV LAMC1_HUMAN Pos (54-61) 1.6356 
54 FWNAAFFD K0513_HUMAN Pos (306-313) 1.6349 
55 KINAAFGD XKR5_HUMAN Pos (419-426) 1.5576 
56 YNNHAFEE SP17_HUMAN Pos (69-76) 1.6332 
57 IVNEGYVN SNG3_HUMAN Pos (43-50) 1.6325 
58 ICNGGYEL FBN3_HUMAN Pos (1429-1436) 1.5117 
59 KVNKAYEF DNJCD_HUMAN Pos (1345-1352) 1.5263 
60 YANPAFET PDE8A_HUMAN Pos (239-246) 1.6302 
61 KVNEAFEA MYOG_HUMAN Pos (96-103) 1.5541 
62 IENKAFDR JIP4_HUMAN Pos (370-377) 1.5721 
63 QINYAYFD ERRFI_HUMAN Pos (206-213) 1.6282 
64 LVNLAYES ASAHL_HUMAN Pos (115-122) 1.628 
65 LDNRAYEM DPP6_HUMAN Pos (762-769) 1.5974 
66 IANLGFKD GRIA4_HUMAN Pos (239-246) 1.6052 
67 YYNDAYGA RBM4B_HUMAN Pos (210-217) 1.6254 
68 YFNFAFKG KIT_HUMAN Pos (503-510) 1.5989 
69 YKNFAFTM AT8B2_HUMAN Pos (896-903) 1.5864 
70 YSNMGFHD Z3H7A_HUMAN Pos (99-106) 1.6164 
71 VSNKAYED KGP1A_HUMAN Pos (330-337) 1.5864 
  KGP1B_HUMAN Pos (346-353)  
72 VVNLAYAY GRK5_HUMAN Pos (246-253) 1.6156 
73 KINEAFEA MYF6_HUMAN Pos (108-115) 1.5375 
74 IDNDAFRL OPT_HUMAN Pos (192-199) 1.5873 
75 IVNEGYLN SNG1_HUMAN Pos (43-50) 1.6079 
76 KVNEAFET MYOD1_HUMAN Pos (124-131) 1.5318 
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77 YKNFAFTL AT8B1_HUMAN Pos (956-963) 1.5769 
  AT8B4_HUMAN Pos (878-885)  
78 YINSYFED RPO3G_HUMAN Pos (199-206) 1.6072 
79 YVNASFID PTPRA_HUMAN Pos (588-595) 1.6067 
80 IANLAFSD NPY4R_HUMAN Pos (80-87) 1.6048 
81 IYNWAYGF PERP_HUMAN Pos (148-155) 1.6037 
82 VRNYGFWD HPLN1_HUMAN Pos (235-242) 1.5729 
83 IGNLAFSD NPY5R_HUMAN Pos (90-97) 1.6028 
84 YYNNAYGA RBM4_HUMAN Pos (210-217) 1.6025 
85 INNAAFEA PRPS2_HUMAN Pos (260-267) 1.6023 
86 YINASFLD PTPRF_HUMAN Pos (1684-1691) 1.6017 
87 YENLAFQK TULP2_HUMAN Pos (205-212) 1.5735 
88 YINFSYEV AMELX_HUMAN Pos (28-35) 1.5985 
89 PDNEAYEM SYUA_HUMAN Pos (120-127) 1.5971 
90 PYNYGFDY ARSF_HUMAN Pos (154-161) 1.5964 
91 IMNRAFFD KIF3B_HUMAN Pos (599-606) 1.5662 
92 IYNAAYSL SCNNG_HUMAN Pos (384-391) 1.5952 
93 IVNKAFGI JIP3_HUMAN Pos (374-381) 1.565 
94 KINAGFGD RPB1_HUMAN Pos (1234-1241) 1.5179 
95 FVNAAFGQ PSMD2_HUMAN Pos (380-387) 1.5914 
96 CDNAGFDA TCPH_HUMAN Pos (450-457) 1.4545 
97 YENGAFQE DTYMK_HUMAN Pos (151-158) 1.5909 
98 YINASFID PTPRD_HUMAN Pos (1699-1706) 1.5901 
  PTPRE_HUMAN Pos (481-488)  
  PTPRS_HUMAN Pos (1735-1742)  
99 YINASYID CD45_HUMAN Pos (705-712) 1.5901 
  PTPRE_HUMAN Pos (189-196)  
100 FTNAAFDP LYAM3_HUMAN Pos (821-828) 1.5876 
101 YRNGGYIF PK2L2_HUMAN Pos (195-202) 1.5562 
102 IDNMAFTL FANCB_HUMAN Pos (756-763) 1.5854 
103 IANLGFTD GRIA2_HUMAN Pos (237-244) 1.5852 
104 HDNCAYDY TLL1_HUMAN Pos (512-519) 1.4848 
105 FDNFGFSM CAC1S_HUMAN Pos (275-282) 1.5839 
106 LVNRAYID SC15B_HUMAN Pos (364-371) 1.5491 
107 KINEGFDL ADH1A_HUMAN Pos (354-361) 1.5017 
  ADH1B_HUMAN Pos (354-361)  
  ADH1G_HUMAN Pos (354-361)  
108 FDNVGFGY SCN1A_HUMAN Pos (1415-1422) 1.5775 
109 FDNFGFGT GRIPE_HUMAN Pos (924-931) 1.5774 
110 YRNLAFLG ZN254_HUMAN Pos (46-53) 1.5467 
  ZN539_HUMAN Pos (46-53)  
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  ZNF91_HUMAN Pos (46-53)  
111 YGNFGYGF AL2SA_HUMAN Pos (241-248) 1.5764 
112 YPNLAFCV ENTK_HUMAN Pos (546-553) 1.4802 
113 YINGTFDL UBP47_HUMAN Pos (83-90) 1.5753 
114 IINATYEF MCAR1_HUMAN Pos (285-292) 1.5715 
115 YINFSYEN AMELY_HUMAN Pos (28-35) 1.57 
116 FDNQAYPE PAR15_HUMAN Pos (642-649) 1.5686 
117 FGNFAFDK PAPD1_HUMAN Pos (448-455) 1.5406 
118 VLNHGYDD DYR1B_HUMAN Pos (87-94) 1.5653 
119 VDNAGFLY F109A_HUMAN Pos (18-25) 1.5628 
120 FVNYTFKD KBTB4_HUMAN Pos (16-23) 1.5408 
121 IINDAFNL AMPN_HUMAN Pos (660-667) 1.5606 
122 YHNGAYYE FCGBP_HUMAN Pos (2789-2796) 1.5578 
123 YGNYGYAN BET1_HUMAN Pos (15-22) 1.5559 
124 YINYIFND HERC5_HUMAN Pos (868-875) 1.5547 
125 YTNYTFDF CNOT6_HUMAN Pos (479-486) 1.5547 
126 IRNVAYDT PLOD3_HUMAN Pos (240-247) 1.5239 
127 YENWAYGE MRC1_HUMAN Pos (736-743) 1.5533 
128 IENPGFEA GI24_HUMAN Pos (240-247) 1.5528 
129 FINCAYVK YLA1_HUMAN Pos (171-178) 1.4257 
130 FRNRGFGD ZIC1_HUMAN Pos (102-109) 1.4917 
131 PVNLAFDM HUNK_HUMAN Pos (699-706) 1.5503 
132 LTNYAYDE TAF1A_HUMAN Pos (260-267) 1.5491 
133 YGNYGYNS HNRPD_HUMAN Pos (302-309) 1.5456 
134 PVNEGFVD STAB1_HUMAN Pos (2371-2378) 1.5453 
135 IYNPAFFK SIA4B_HUMAN Pos (256-263) 1.5183 
136 IVNTAFTV GTR1_HUMAN Pos (315-322) 1.5444 
137 FDNKGYFC CRDL1_HUMAN Pos (329-336) 1.4309 
138 KFNYGFEY DYHC_HUMAN Pos (1865-1872) 1.467 
139 YCNKGFKK ZN236_HUMAN Pos (971-978) 1.3447 
140 QDNFGYEL SPTN4_HUMAN Pos (454-461) 1.5413 
141 VVNYPFDD CBPD_HUMAN Pos (676-683) 1.5405 
142 VKNLGYRD ARAF_HUMAN Pos (291-298) 1.4895 
143 YLNLGYVS S3TC2_HUMAN Pos (125-132) 1.54 
144 FDNIGYAW CAC1G_HUMAN Pos (337-344) 1.5385 
  CAC1H_HUMAN Pos (361-368)  
  CAC1I_HUMAN Pos (340-347)  
145 YWNQGYGY ROAA_HUMAN Pos (274-281) 1.5365 
146 VVNEGFFE GAPR1_HUMAN Pos (138-145) 1.535 
147 IVNNAYGV UGTAP_HUMAN Pos (250-257) 1.5336 
148 ITNTGFEM PZP_HUMAN Pos (307-314) 1.5336 
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149 SVNAAFEM ECHM_HUMAN Pos (243-250) 1.5333 
150 IVNSAFPR PTPRR_HUMAN Pos (80-87) 1.5059 
151 IVNNAFKH ACO11_HUMAN Pos (287-294) 1.5119 
152 LQNRAFDD ASXL1_HUMAN Pos (857-864) 1.5025 
153 KENDAFED OPTN_HUMAN Pos (501-508) 1.4559 
154 FCNPAFEP MFRP_HUMAN Pos (21-28) 1.4107 
155 QDNFGFDL SPTB2_HUMAN Pos (447-454) 1.5304 
156 QDNFGYDL SPTB1_HUMAN Pos (446-453) 1.5304 
157 YENYSFEE MYCB2_HUMAN Pos (2341-2348) 1.5301 
158 ILNEAYRK PACA_HUMAN Pos (87-94) 1.4823 
159 EDNYGYDA NUP88_HUMAN Pos (304-311) 1.5295 
160 YWNLGFQL SUIS_HUMAN Pos (349-356) 1.5294 
161 YCNKAFTL ZBT38_HUMAN Pos (1070-1077) 1.3792 
162 YTNGAYGP BAG4_HUMAN Pos (131-138) 1.5287 
163 FYNEAFSA GLT11_HUMAN Pos (159-166) 1.5285 
164 VINAAFML AP180_HUMAN Pos (192-199) 1.5277 
  PICAL_HUMAN Pos (192-199)  
165 YNNYGYGN HNRH3_HUMAN Pos (156-163) 1.527 
166 ICNSGYEV FBN1_HUMAN Pos (749-756) 1.406 
167 IVNSGFGK MCM3A_HUMAN Pos (134-141) 1.498 
168 YYNVIYDD PIWL4_HUMAN Pos (784-791) 1.5238 
169 YCNDGFCE KCNH2_HUMAN Pos (43-50) 1.3065 
  KCNH6_HUMAN Pos (43-50)  
  KCNH7_HUMAN Pos (43-50)  
170 VWNEGFEW DYSF_HUMAN Pos (45-52) 1.5226 
171 YGNAGYRL BMF_HUMAN Pos (97-104) 1.5003 
172 YFNQAFHL ZSWM1_HUMAN Pos (385-392) 1.5199 
173 KVNEAYRF PGCB_HUMAN Pos (99-106) 1.4215 
174 LDNAAFPF TFR1_HUMAN Pos (537-544) 1.516 
175 YLNDAFLE LAP2_HUMAN Pos (144-151) 1.5145 
  LRRC7_HUMAN Pos (144-151)  
176 LDNSGFEL CF211_HUMAN Pos (252-259) 1.514 
177 YLNKAFHI K0056_HUMAN Pos (684-691) 1.4837 
178 FDNQAFLP MUCDL_HUMAN Pos (713-720) 1.5114 
179 VVNAAYFV SPB5_HUMAN Pos (161-168) 1.5113 
180 RDNPAYDT APS_HUMAN Pos (47-54) 1.4348 
181 LDNDGFPD ITA9_HUMAN Pos (374-381) 1.5106 
182 LVNLAFAE NK1R_HUMAN Pos (71-78) 1.5087 
183 KENEAFEF MPIP1_HUMAN Pos (141-148) 1.4326 
184 YSNLGFYP NR1H4_HUMAN Pos (77-84) 1.5079 
185 GYNFGFEY M3K4_HUMAN Pos (1039-1046) 1.5079 
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186 FPNGAFDH GLIS1_HUMAN Pos (601-608) 1.507 
187 LSNVAYED AP4E1_HUMAN Pos (821-828) 1.5059 
188 TVNFAYDT MYOC_HUMAN Pos (448-455) 1.5057 
189 VCNAGFEL FBN3_HUMAN Pos (515-522) 1.3854 
190 ICNYGFVG SUSD1_HUMAN Pos (58-65) 1.3845 
191 RDNAAYFF SIGL6_HUMAN Pos (103-110) 1.4288 
192 IINHGYAR CHD4_HUMAN Pos (1741-1748) 1.4776 
193 RDNPGFEA PKD2_HUMAN Pos (89-96) 1.4283 
194 VDNYMFDD K2022_HUMAN Pos (291-298) 1.504 
195 FINDAYQE VP13A_HUMAN Pos (1274-1281) 1.5036 
196 YINANYVD PTPRG_HUMAN Pos (906-913) 1.5028 
  PTPRS_HUMAN Pos (1446-1453)  
  PTPRZ_HUMAN Pos (1781-1788)  
197 ICNEGYYL MCP_HUMAN Pos (126-133) 1.3815 
198 IKNYGFVH RBM4B_HUMAN Pos (34-41) 1.4715 
  RBM4_HUMAN Pos (34-41)  
199 YPNQAFKR PA24A_HUMAN Pos (685-692) 1.4532 
200 LVNYKYED DOCK9_HUMAN Pos (123-130) 1.4278 
201 IQNAAFMY KPCD1_HUMAN Pos (793-800) 1.5001 
  KPCD2_HUMAN Pos (761-768)  
  KPCD3_HUMAN Pos (786-793)  
202 KVNQAFET MYF5_HUMAN Pos (98-105) 1.4231 
203 ISNGGFES KCC2A_HUMAN Pos (361-368) 1.4986 
204 YLNNAYAR CLIC6_HUMAN Pos (672-679) 1.4705 
205 TINAGFEL USP9X_HUMAN Pos (1490-1497) 1.497 
  USP9Y_HUMAN Pos (1499-1506)  
206 IDNSGYVS PLSI_HUMAN Pos (25-32) 1.497 
207 DVNCAFEF TR100_HUMAN Pos (333-340) 1.3968 
208 LENYGFDK PMS1_HUMAN Pos (44-51) 1.4701 
209 YVNFNFTD CCR9_HUMAN Pos (28-35) 1.496 
210 FLNVAFDG WDR67_HUMAN Pos (45-52) 1.4952 
211 YENRAYTP TTC3_HUMAN Pos (367-374) 1.4651 
212 YKNDAYFL CAH11_HUMAN Pos (212-219) 1.4627 
213 YWNLGFTS SIA7B_HUMAN Pos (211-218) 1.4929 
214 VVNGAFMV WDR22_HUMAN Pos (321-328) 1.4923 
215 QLNPAFED ERCC8_HUMAN Pos (380-387) 1.4916 
216 VCNLGYEA FBN3_HUMAN Pos (708-715) 1.3684 
217 YVNYSFRV NRCAM_HUMAN Pos (714-721) 1.4666 
218 KDNTGYDL D2HDH_HUMAN Pos (244-251) 1.4085 
219 YVNANYID PTPRD_HUMAN Pos (1410-1417) 1.4832 
220 FTNIAYDL HS2ST_HUMAN Pos (89-96) 1.4831 
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221 RVNSAYQD PGCA_HUMAN Pos (95-102) 1.4069 
222 YLNGGFII ATS12_HUMAN Pos (752-759) 1.4827 
223 YLNIAFTM CAC1E_HUMAN Pos (1511-1518) 1.4815 
224 VFNWAFEE SIG10_HUMAN Pos (165-172) 1.4809 
225 YKNVAYVN AT10D_HUMAN Pos (1119-1126) 1.4503 
226 KDNEGFGF SHAN2_HUMAN Pos (43-50) 1.4045 
227 VDNGGFVC FATH_HUMAN Pos (4071-4078) 1.3952 
228 QINPAFAD OGT1_HUMAN Pos (423-430) 1.477 
229 YKNDAYLL CAH10_HUMAN Pos (210-217) 1.4463 
230 AINKAYEE RBL2_HUMAN Pos (333-340) 1.4463 
231 QVNKAFLD PERL_HUMAN Pos (44-51) 1.4461 
232 FDNQGYFN WDR22_HUMAN Pos (271-278) 1.4754 
233 DVNLAYEI T2EA_HUMAN Pos (196-203) 1.475 
234 LLNLAYEK TM16C_HUMAN Pos (609-616) 1.4476 
235 FVNVGYFL TSN1_HUMAN Pos (53-60) 1.4736 
236 GMNAGFED KMO_HUMAN Pos (316-323) 1.4733 
237 FCNPGFES EMR1_HUMAN Pos (198-205) 1.3526 
238 FHNKGYEE SYT14_HUMAN Pos (218-225) 1.4426 
239 YPNCAYRT RNAS1_HUMAN Pos (120-127) 1.3508 
240 IFNFAFWG FPRL2_HUMAN Pos (177-184) 1.4708 
241 ILNAAYHV RIPK5_HUMAN Pos (520-527) 1.4703 
242 VWNMAFDF REV1_HUMAN Pos (1224-1231) 1.4692 
243 YLNTAYGH TM6S1_HUMAN Pos (102-109) 1.4691 
244 YTNWAYVP ENK1_HUMAN Pos (100-107) 1.4691 
  ENK4_HUMAN Pos (101-108)  
  ENK6_HUMAN Pos (101-108)  
245 VVNAAYSA ALG12_HUMAN Pos (353-360) 1.4689 
246 YWNRGFVA ABCA6_HUMAN Pos (170-177) 1.4391 
247 IPNGAFVY NGL1_HUMAN Pos (139-146) 1.4681 
248 IYNKGFLH ELTD1_HUMAN Pos (523-530) 1.4377 
249 LTNAGYDY RIOK2_HUMAN Pos (75-82) 1.4669 
250 YINANYID PTPRF_HUMAN Pos (1395-1402) 1.4666 
  PTPRK_HUMAN Pos (940-947)  
  PTPRT_HUMAN Pos (964-971)  
  PTPRU_HUMAN Pos (927-934)  
251 VVNFPYDD SORCN_HUMAN Pos (183-190) 1.4659 
252 IPNYGYRI CSMD1_HUMAN Pos (1223-1230) 1.445 
253 YKNRGFLP FGF19_HUMAN Pos (154-161) 1.4048 
254 IVNLSFSD NPY1R_HUMAN Pos (79-86) 1.4625 
255 IRNRAFYM PDLI7_HUMAN Pos (374-381) 1.4024 
256 LVNYAYTS KLH23_HUMAN Pos (91-98) 1.4621 
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257 FVNTGFTK DHB13_HUMAN Pos (220-227) 1.4351 
258 TDNVAFDM GOLI_HUMAN Pos (321-328) 1.4612 
259 RVNAAFYR LOXL3_HUMAN Pos (224-231) 1.358 
260 HDNIAFQD LRMP_HUMAN Pos (143-150) 1.4588 
261 LTNLAFVD OR5MB_HUMAN Pos (63-70) 1.4586 
262 EVNLAYEN DYHC_HUMAN Pos (522-529) 1.4584 
263 YDNCSFYF TPTE_HUMAN Pos (489-496) 1.3583 
264 IRNAAFLA VASH2_HUMAN Pos (84-91) 1.4266 
265 QPNRAFED GPR98_HUMAN Pos (5397-5404) 1.4274 
266 LENAAYLD PC11Y_HUMAN Pos (450-457) 1.456 
267 YVNFKFYF ACA_HUMAN Pos (64-71) 1.3833 
268 ADNAGYDS TCPB_HUMAN Pos (450-457) 1.4557 
269 YGNEGYIP TEC_HUMAN Pos (223-230) 1.455 
270 LVNAAFSE LGI3_HUMAN Pos (71-78) 1.4536 
271 LLNYGYDT ASB14_HUMAN Pos (155-162) 1.4519 
272 YQNGAFGS SOX14_HUMAN Pos (172-179) 1.4509 
273 YINEQYEK SEPT3_HUMAN Pos (132-139) 1.4242 
274 FVNTGFIK DHRS8_HUMAN Pos (220-227) 1.4227 
275 IFNKGFGF VDAC2_HUMAN Pos (43-50) 1.4197 
276 LVNAAFYQ ST18_HUMAN Pos (651-658) 1.4477 
277 IANYAYGN CRAC1_HUMAN Pos (195-202) 1.4461 
278 YLNTGYQR A2MG_HUMAN Pos (1007-1014) 1.4186 
279 ILNPAFLY TRRAP_HUMAN Pos (1776-1783) 1.4443 
280 VCNVAFEK PPR3D_HUMAN Pos (195-202) 1.2969 
281 LDNLGYNL PLVAP_HUMAN Pos (250-257) 1.4428 
282 LINEAFRI ECHP_HUMAN Pos (626-633) 1.4221 
283 LCNEGYEL FBN2_HUMAN Pos (1999-2006) 1.322 
284 FQNMAFQD SYNE2_HUMAN Pos (3606-3613) 1.4422 
285 SINLGFSD SPT16_HUMAN Pos (378-385) 1.4415 
286 LVNLAFCG O4F29_HUMAN Pos (163-170) 1.3452 
  OR4F3_HUMAN Pos (163-170)  
287 RDNNGYSD PCLO_HUMAN Pos (4593-4600) 1.3648 
288 IRNVTFED FGFR2_HUMAN Pos (329-336) 1.4066 
289 LDNFAYLA GLTL1_HUMAN Pos (245-252) 1.4369 
290 GVNDAFKD FUBP1_HUMAN Pos (26-33) 1.416 
291 YWNVGFLK PIGV_HUMAN Pos (311-318) 1.4084 
292 IENQAFYK FRMD5_HUMAN Pos (288-295) 1.4075 
293 YVNHSFEG NPCL1_HUMAN Pos (1333-1340) 1.4335 
294 ITNLGYKV AASS_HUMAN Pos (50-57) 1.4122 
295 YKNPVYED MYPC1_HUMAN Pos (1033-1040) 1.4021 
296 LGNEAFKD TDRD7_HUMAN Pos (167-174) 1.4115 
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297 FENAAFGR LAMC3_HUMAN Pos (39-46) 1.4043 
298 LCNKAFRD ACM1_HUMAN Pos (420-427) 1.2597 
299 LINAAYKP SMBT1_HUMAN Pos (545-552) 1.4089 
300 KDNPAFAF SF04_HUMAN Pos (215-222) 1.3526 
301 TVNSAYGD CD166_HUMAN Pos (30-37) 1.4281 
302 YPNRGFPK METH_HUMAN Pos (988-995) 1.3721 
303 GINTAFCD NOTC1_HUMAN Pos (926-933) 1.3321 
304 LDNGAYNA ARP6_HUMAN Pos (6-13) 1.426 
305 IDNYVYEH AZIN1_HUMAN Pos (25-32) 1.4259 
306 IINENYDY NUP98_HUMAN Pos (1659-1666) 1.4253 
307 YANDAFPE RHOJ_HUMAN Pos (41-48) 1.4251 
  RHOQ_HUMAN Pos (29-36)  
308 VINGGFGL HUTU_HUMAN Pos (600-607) 1.4236 
309 FRNLGFGW CP11A_HUMAN Pos (450-457) 1.393 
310 YWNQGYGN HNRPD_HUMAN Pos (297-304) 1.4231 
311 IGNAGFNE DDEF2_HUMAN Pos (492-499) 1.4229 
312 YINGNYID PTPRM_HUMAN Pos (953-960) 1.4227 
313 ISNGAYRE NUAK2_HUMAN Pos (262-269) 1.4018 
314 KDNGAYRC FCRL5_HUMAN Pos (159-166) 1.2421 
315 LENFGFEL ATBF1_HUMAN Pos (1949-1956) 1.4212 
  ZFHX2_HUMAN Pos (299-306)  
316 MCNLAFAD FSHR_HUMAN Pos (401-408) 1.3006 
  TSHR_HUMAN Pos (453-460)  
317 ILNGAFRS PHF2_HUMAN Pos (401-408) 1.3999 
318 YSNIAFNL ESPL1_HUMAN Pos (730-737) 1.4199 
319 LINFAYNG KLH18_HUMAN Pos (27-34) 1.419 
320 VDNVGFNR ZBED4_HUMAN Pos (676-683) 1.3912 
321 VGNKAFRD PKHG4_HUMAN Pos (1046-1053) 1.3676 
322 KINEAFIE MATR3_HUMAN Pos (433-440) 1.3411 
323 YTNYCYHD ZSWM6_HUMAN Pos (68-75) 1.2754 
324 IKNGAFVN ANFY1_HUMAN Pos (309-316) 1.3855 
325 FVNYYFER PHF14_HUMAN Pos (619-626) 1.3889 
326 IENCGFQY DNMT2_HUMAN Pos (137-144) 1.3155 
327 WINIGYEG MARK4_HUMAN Pos (309-316) 1.4153 
328 VVNTAYGR NLGN2_HUMAN Pos (43-50) 1.3875 
329 LDNLGYRT ADDA_HUMAN Pos (384-391) 1.3931 
  ADDB_HUMAN Pos (371-378)  
  ADDG_HUMAN Pos (378-385)  
330 WDNEAYVH IL1B_HUMAN Pos (108-115) 1.4114 
331 GINRGFGD MYEF2_HUMAN Pos (423-430) 1.3818 
332 VRNMGFGD GRHL3_HUMAN Pos (592-599) 1.3804 
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333 LINLAYLL ERCC5_HUMAN Pos (851-858) 1.4098 
334 VVNMGYSY UBAP1_HUMAN Pos (399-406) 1.4095 
335 YCNMGFSG ELTD1_HUMAN Pos (43-50) 1.2886 
336 GVNGGYET ANR38_HUMAN Pos (667-674) 1.4084 
337 YRNLTFDP TRI65_HUMAN Pos (330-337) 1.3779 
338 LANLAFWD GPR37_HUMAN Pos (300-307) 1.4065 
339 VPNKAFEL AN30A_HUMAN Pos (477-484) 1.377 
340 PFNEAFEE LCB2_HUMAN Pos (58-65) 1.4062 
341 KDNFGFIE CSDE1_HUMAN Pos (527-534) 1.3301 
342 YINRNFDR DEPD5_HUMAN Pos (321-328) 1.3497 
343 RMNEAFGD TIF1B_HUMAN Pos (794-801) 1.3297 
344 LDNGGFYI HCK_HUMAN Pos (202-209) 1.4048 
  LCK_HUMAN Pos (185-192)  
345 LDNGGYYI FYN_HUMAN Pos (207-214) 1.4048 
  LYN_HUMAN Pos (187-194)  
  YES_HUMAN Pos (216-223)  
346 YPNETFEM ABCAC_HUMAN Pos (2176-2183) 1.4046 
347 VSNFGYDL PEDF_HUMAN Pos (58-65) 1.4041 
348 YDNPIFEK M3K2_HUMAN Pos (250-257) 1.3775 
349 GVNGGYES ANR25_HUMAN Pos (503-510) 1.4032 
350 EINKAFEL ADHX_HUMAN Pos (353-360) 1.3733 
351 YVNFDFDG IF36_HUMAN Pos (300-307) 1.4012 
352 YDNFSYRS CX045_HUMAN Pos (90-97) 1.3805 
353 YINRTFFF POMT2_HUMAN Pos (96-103) 1.371 
354 VWNEAFRF PA24D_HUMAN Pos (71-78) 1.3793 
355 RDNAGYCA BCOR_HUMAN Pos (1493-1500) 1.2278 
356 FRNAGYAV SYJ2B_HUMAN Pos (85-92) 1.3687 
357 YGNKYYED NDUAC_HUMAN Pos (44-51) 1.3697 
358 YSNDGFCK KCNH1_HUMAN Pos (44-51) 1.2766 
  KCNH5_HUMAN Pos (42-49)  
359 HENAAFKD TOIP1_HUMAN Pos (498-505) 1.3783 
  TOIP2_HUMAN Pos (384-391)  
360 LINAGYRA SARDH_HUMAN Pos (760-767) 1.3783 
361 PNNGGYDD DYRK2_HUMAN Pos (125-132) 1.3988 
  DYRK3_HUMAN Pos (185-192)  
362 LSNLAFVD OR1C1_HUMAN Pos (63-70) 1.3978 
  OR8U1_HUMAN Pos (63-70)  
363 SINTAYER MMP14_HUMAN Pos (367-374) 1.3709 
364 YMNDGYAP DLG1_HUMAN Pos (409-416) 1.397 
365 ICNEGYSG TENA_HUMAN Pos (610-617) 1.2766 
366 KVNYNFED OAS2_HUMAN Pos (609-616) 1.3202 
152 
 
367 FENFKYED PRAX_HUMAN Pos (72-79) 1.3229 
368 GVNMGFGD COQ6_HUMAN Pos (378-385) 1.3944 
369 VKNYAYKP IPO11_HUMAN Pos (328-335) 1.3431 
370 WINAAFRA COG7_HUMAN Pos (16-23) 1.3723 
371 GINGGYET ANR15_HUMAN Pos (998-1005) 1.3918 
372 ICNGAFTT ZN236_HUMAN Pos (717-724) 1.2712 
373 LDNGGFAA SDK1_HUMAN Pos (2056-2063) 1.3909 
374 VINPAYAT KRIT1_HUMAN Pos (190-197) 1.3895 
375 KVNLAFKQ VP26A_HUMAN Pos (51-58) 1.2929 
376 GENYGYRD CSMD3_HUMAN Pos (2793-2800) 1.3687 
377 YANSAFNP ADRB1_HUMAN Pos (367-374) 1.3892 
  ADRB3_HUMAN Pos (336-343)  
378 ITNGAYNS TBR1_HUMAN Pos (152-159) 1.3886 
379 LDNVAYAR RAD51_HUMAN Pos (186-193) 1.3611 
380 YCNRDFDD ZN207_HUMAN Pos (15-22) 1.2379 
381 LVNLGFAT ASCL1_HUMAN Pos (133-140) 1.3876 
382 YYNESFSF SYT1_HUMAN Pos (339-346) 1.3876 
383 TINLAFGF AQP3_HUMAN Pos (58-65) 1.3871 
384 TGNKGFED MEPE_HUMAN Pos (121-128) 1.3574 
385 ILNLGFLT S22A3_HUMAN Pos (160-167) 1.3863 
386 PTNYGYND ATS8_HUMAN Pos (699-706) 1.3863 
387 IENGAFQG PGS2_HUMAN Pos (191-198) 1.3855 
388 IENAVFED E2AK3_HUMAN Pos (1071-1078) 1.3854 
389 KMNEGFEW DUS12_HUMAN Pos (153-160) 1.3093 
390 IPNEAFLN TLR8_HUMAN Pos (654-661) 1.385 
391 VTNQAFDI SCN9A_HUMAN Pos (1512-1519) 1.3848 
392 MVNLAFVK UBP19_HUMAN Pos (332-339) 1.3548 
393 LYNAAFAG LMBRL_HUMAN Pos (438-445) 1.3811 
394 LANLGFMD GRIA1_HUMAN Pos (230-237) 1.3811 
395 YINKYYDQ PLXB1_HUMAN Pos (2094-2101) 1.3514 
396 WDNAGFKG ADA17_HUMAN Pos (267-274) 1.3599 
397 KDNRAYNC PCD12_HUMAN Pos (745-752) 1.1913 
398 LANLAFLD OR4M2_HUMAN Pos (63-70) 1.3795 
399 TINEAFLF CCNB3_HUMAN Pos (1002-1009) 1.3795 
400 PVNNAFSD POSTN_HUMAN Pos (408-415) 1.3778 
401 LGNLAFLD OR4KE_HUMAN Pos (64-71) 1.3775 
  OR4N2_HUMAN Pos (63-70)  
  OR4N4_HUMAN Pos (63-70)  
402 ADNNGYVD ITA4_HUMAN Pos (446-453) 1.3767 
403 FLNGGYSY ADCY8_HUMAN Pos (142-149) 1.3763 
404 IPNGAFAH HES1_HUMAN Pos (233-240) 1.3749 
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405 FENLGFRP FAKD2_HUMAN Pos (426-433) 1.3533 
406 VLNDAYEN SYNE2_HUMAN Pos (3250-3257) 1.373 
407 AINTAFEA DCR1A_HUMAN Pos (858-865) 1.373 
408 NYNVAFEE SPEG_HUMAN Pos (1811-1818) 1.3725 
409 IANLAYVT MOV10_HUMAN Pos (63-70) 1.3722 
410 SINEAYGY NR1I3_HUMAN Pos (325-332) 1.3719 
411 FDNLYYWD ERBB2_HUMAN Pos (1217-1224) 1.3717 
412 RVNIAFNY UAP56_HUMAN Pos (355-362) 1.2958 
413 SVNQGFEA SMAD2_HUMAN Pos (397-404) 1.3716 
  SMAD3_HUMAN Pos (355-362)  
414 YSNCGYSV PTPRT_HUMAN Pos (38-45) 1.27 
415 RINLAFMS K0652_HUMAN Pos (190-197) 1.2942 
416 YLNSGYIT NPT4_HUMAN Pos (291-298) 1.3697 
417 FKNKAFAL IPYR2_HUMAN Pos (258-265) 1.3092 
418 PDNLGYTY TYRP1_HUMAN Pos (457-464) 1.3684 
419 IFNDAFWL ATM_HUMAN Pos (1927-1934) 1.3678 
420 AINPGFLD FGR_HUMAN Pos (60-67) 1.3673 
421 PYNLAYKY RENR_HUMAN Pos (292-299) 1.3467 
422 IKNMAFQK AQR_HUMAN Pos (1104-1111) 1.3103 
423 LVNLGFQA ASCL2_HUMAN Pos (65-72) 1.3669 
424 DINMAFLD DSG4_HUMAN Pos (773-780) 1.3665 
425 LGNLAFID OR5V1_HUMAN Pos (63-70) 1.3659 
426 YGNVAFPH FIP1_HUMAN Pos (426-433) 1.365 
427 ILNVAYGV DUS19_HUMAN Pos (95-102) 1.3646 
428 FLNFGFAN PTN22_HUMAN Pos (783-790) 1.3645 
429 YENHGYQP TMPS2_HUMAN Pos (15-22) 1.3644 
430 FWNLGYWL ACM3_HUMAN Pos (525-532) 1.3642 
431 DVNWGYEK SCG1_HUMAN Pos (579-586) 1.3371 
432 LINKGFVE SYDC_HUMAN Pos (210-217) 1.3339 
433 FTNLGYRA THOC6_HUMAN Pos (329-336) 1.3426 
434 ISNYGFPS MMP8_HUMAN Pos (365-372) 1.3626 
435 YINASFIK PTN13_HUMAN Pos (2262-2269) 1.3359 
436 AINEAYKE ANXA6_HUMAN Pos (471-478) 1.3415 
437 LSNLAFID OR8I2_HUMAN Pos (63-70) 1.3616 
438 RANLAYGD PITM2_HUMAN Pos (534-541) 1.2857 
439 YYNTCFSD SASH1_HUMAN Pos (69-76) 1.2196 
440 YNNKGYHS ABCA2_HUMAN Pos (1732-1739) 1.3313 
441 VDNKGFPT EZRI_HUMAN Pos (49-56) 1.3306 
442 YINASFIM CD45_HUMAN Pos (1015-1022) 1.3602 
443 YINASYIM PTPRG_HUMAN Pos (1205-1212) 1.3602 
  PTPRZ_HUMAN Pos (2076-2083)  
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444 LYNIAFMY NCF2_HUMAN Pos (124-131) 1.3596 
445 CVNEGYAQ ASCL3_HUMAN Pos (107-114) 1.2229 
446 YDNQEFPD CP2E1_HUMAN Pos (398-405) 1.3593 
447 LLNSGYEF ATPG_HUMAN Pos (173-180) 1.3591 
448 KCNMGYEY CFAH_HUMAN Pos (236-243) 1.1619 
449 KINGAYFC TIE2_HUMAN Pos (95-102) 1.1984 
450 IDNYSYRG B3GL1_HUMAN Pos (210-217) 1.3363 
451 LLNNAFEE MCM3_HUMAN Pos (65-72) 1.3566 
452 IWNTGYLF CAH5A_HUMAN Pos (95-102) 1.3565 
453 ALNFAFKD ADT1_HUMAN Pos (85-92) 1.3347 
  ADT2_HUMAN Pos (85-92)  
  ADT3_HUMAN Pos (85-92)  
454 FLNGRFED RHES_HUMAN Pos (39-46) 1.2827 
455 ILNNAFRL NFKB1_HUMAN Pos (843-850) 1.3338 
456 KDNMAYMC ASPM_HUMAN Pos (398-405) 1.1952 
457 IGNGAYGV MK07_HUMAN Pos (60-67) 1.3537 
458 KVNAAFTT TRPC3_HUMAN Pos (606-613) 1.2777 
459 MVNYNFED OAS2_HUMAN Pos (265-272) 1.3534 
460 VLNSGFLD FA62A_HUMAN Pos (741-748) 1.3533 
461 YHNPGYLV LAT_HUMAN Pos (156-163) 1.353 
462 IVNEIYHD ATS2_HUMAN Pos (297-304) 1.3527 
  ATS3_HUMAN Pos (287-294)  
463 KENGAYDA CSN3_HUMAN Pos (170-177) 1.2763 
464 ICNTGYRL FHR1_HUMAN Pos (113-120) 1.211 
  FHR2_HUMAN Pos (113-120)  
465 TDNRAFGY DAB2_HUMAN Pos (129-136) 1.3224 
466 LANFAYDP ARMC7_HUMAN Pos (40-47) 1.3518 
467 KDNLGFPV FACE1_HUMAN Pos (440-447) 1.2757 
468 SCNAAFND FBX42_HUMAN Pos (143-150) 1.2309 
469 SINDAFEG PTF1A_HUMAN Pos (178-185) 1.351 
470 IKNHAFRL GAMT_HUMAN Pos (152-159) 1.2997 
471 YRNITFDE METH_HUMAN Pos (164-171) 1.3199 
472 YINASYVN PTN3_HUMAN Pos (695-702) 1.3503 
473 IVNLLYEL RYR1_HUMAN Pos (517-524) 1.3496 
474 AENEAFDW TTBK1_HUMAN Pos (303-310) 1.3496 
475 HMNEAFVD CAN12_HUMAN Pos (199-206) 1.3496 
476 ICNKAYQQ ZBT40_HUMAN Pos (1010-1017) 1.1994 
477 EKNYAFEI DPOLA_HUMAN Pos (436-443) 1.3187 
478 KENPGFDF NUDC2_HUMAN Pos (129-136) 1.2732 
479 ICNPGYKG TEN4_HUMAN Pos (647-654) 1.2079 
480 VDNHGYNV SUIS_HUMAN Pos (108-115) 1.3488 
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481 ICNPGYMG NOTC2_HUMAN Pos (594-601) 1.2284 
482 LSNWAYEF SMCA4_HUMAN Pos (815-822) 1.3483 
483 LLNPAYDV PO210_HUMAN Pos (244-251) 1.3478 
484 VINGTYDY ALG3_HUMAN Pos (81-88) 1.3476 
485 YENEMFDY DOCK1_HUMAN Pos (1304-1311) 1.3472 
486 FPNLAFIR PRELP_HUMAN Pos (265-272) 1.3191 
487 YINVWYDP MK08_HUMAN Pos (320-327) 1.3451 
  MK10_HUMAN Pos (358-365)  
488 PTNEAFEK BGH3_HUMAN Pos (280-287) 1.3183 
  POSTN_HUMAN Pos (274-281)  
489 IINDTYEI CHL1_HUMAN Pos (955-962) 1.3447 
490 YVNLLFWY AT10B_HUMAN Pos (1123-1130) 1.3438 
  AT10D_HUMAN Pos (1124-1131)  
491 ICNSGFKR I15RA_HUMAN Pos (58-65) 1.1762 
492 SYNTAFEL IL1F9_HUMAN Pos (158-165) 1.3436 
493 YINKKFCF SYT14_HUMAN Pos (45-52) 1.1458 
494 FINGSFEI SO1A2_HUMAN Pos (60-67) 1.3434 
495 VVNRLFED TXND3_HUMAN Pos (577-584) 1.3137 
496 EYNTGYDY RBM6_HUMAN Pos (491-498) 1.3432 
497 ISNGAYGA MAST1_HUMAN Pos (380-387) 1.3427 
  MAST2_HUMAN Pos (518-525)  
  MAST3_HUMAN Pos (373-380)  
  MAST4_HUMAN Pos (397-404)  
498 IFNDGYKL FGL1_HUMAN Pos (86-93) 1.3219 
499 FLNDAYNW PHTF1_HUMAN Pos (638-645) 1.342 
500 VWNMGFSD MBTP1_HUMAN Pos (764-771) 1.3409 
501 LANLGFTD GRIA3_HUMAN Pos (247-254) 1.3406 
502 GVNLGFGF AQP7_HUMAN Pos (69-76) 1.3398 
503 PLNLAFLD STAG2_HUMAN Pos (994-1001) 1.3393 
504 INNEAFSG TDRD3_HUMAN Pos (461-468) 1.3381 
505 VLNLAYNK TLR5_HUMAN Pos (316-323) 1.3115 
506 LSNAAFES KI18A_HUMAN Pos (592-599) 1.3376 
507 ANNIAYED SCG2_HUMAN Pos (236-243) 1.3369 
508 LINDAYKR AFG32_HUMAN Pos (704-711) 1.2886 
509 LDNPAYVS LNX1_HUMAN Pos (179-186) 1.3358 
510 DINEAFKE HTF4_HUMAN Pos (592-599) 1.3145 
  ITF2_HUMAN Pos (579-586)  
  TFE2_HUMAN Pos (564-571)  
511 EDNAAYYL GNAZ_HUMAN Pos (149-156) 1.3348 
512 YYNEYFVF OTOF_HUMAN Pos (296-303) 1.3346 
513 YDNCPFFF TPTE2_HUMAN Pos (471-478) 1.2346 
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514 ELNFAFEE NAL14_HUMAN Pos (263-270) 1.334 
515 INNLAFLT RYR3_HUMAN Pos (3321-3328) 1.3339 
516 YDNLCYLV PKDRE_HUMAN Pos (1227-1234) 1.1921 
517 FTNQGYFF IL2RB_HUMAN Pos (359-366) 1.3332 
518 YVNRRFHF EDG2_HUMAN Pos (75-82) 1.2299 
519 GPNAAYDF MAGD1_HUMAN Pos (121-128) 1.3313 
520 FKNKAYLL DICER_HUMAN Pos (1667-1674) 1.2712 
521 ILNVAFTI CAC1S_HUMAN Pos (1152-1159) 1.331 
522 FDNVSYLD TOPRS_HUMAN Pos (110-117) 1.3304 
523 IYNFPFDV 5HT3R_HUMAN Pos (161-168) 1.3299 
524 YVNACFFV SMO_HUMAN Pos (269-276) 1.188 
525 IDNGVFEV GRP78_HUMAN Pos (237-244) 1.3287 
526 YHNIAFIH AAKG2_HUMAN Pos (433-440) 1.3288 
527 HCNRAFAD SLUG_HUMAN Pos (217-224) 1.1784 
528 YCNFVFKD PLD1_HUMAN Pos (649-656) 1.1872 
529 KLNWAFEM HPCL4_HUMAN Pos (99-106) 1.2522 
530 RDNLGFSP KCNKF_HUMAN Pos (301-308) 1.2516 
531 SCNAGYEE EPHA3_HUMAN Pos (258-265) 1.2066 
532 YINASYIP PTPRB_HUMAN Pos (1757-1764) 1.3268 
533 IVNEFYEQ PDE3A_HUMAN Pos (968-975) 1.3265 
  PDE3B_HUMAN Pos (955-962)  
534 VYNFEFED CM031_HUMAN Pos (126-133) 1.3264 
535 YINEYYAK ABCA2_HUMAN Pos (1966-1973) 1.2996 
536 INNTGFAF FOXJ2_HUMAN Pos (403-410) 1.3257 
537 MYNFAYVK SCN7A_HUMAN Pos (1399-1406) 1.2987 
538 YSNSGFWN MRC1_HUMAN Pos (903-910) 1.3241 
539 PYNEGYVY ETV1_HUMAN Pos (470-477) 1.324 
540 SVNEAFGR PWP1_HUMAN Pos (465-472) 1.2969 
541 PENFAFDV LBXCO_HUMAN Pos (176-183) 1.3233 
542 DDNYAFLH ABC3F_HUMAN Pos (174-181) 1.3229 
543 RINLGFNS MXRA5_HUMAN Pos (59-66) 1.2466 
544 KDNKGYCA MUSK_HUMAN Pos (311-318) 1.1205 
545 LDNIAYIM HM2L1_HUMAN Pos (591-598) 1.3208 
546 YRNQTFEG DIDO1_HUMAN Pos (2078-2085) 1.2904 
547 QCNEGYEV FBN1_HUMAN Pos (1957-1964) 1.1993 
548 LENMAYEH DDX3X_HUMAN Pos (570-577) 1.3194 
  DDX3Y_HUMAN Pos (569-576)  
549 IINIKFAD FLNA_HUMAN Pos (2114-2121) 1.2465 
  FLNC_HUMAN Pos (2109-2116)  
550 LYNLGFGH ITIH1_HUMAN Pos (430-437) 1.319 
551 DINEAYVE ATG4B_HUMAN Pos (234-241) 1.3183 
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552 LVNMAYTL ITBA1_HUMAN Pos (59-66) 1.3181 
553 YTNQTFDK RPC2_HUMAN Pos (782-789) 1.2915 
554 IENIGYVL TRPC3_HUMAN Pos (643-650) 1.3177 
  TRPC6_HUMAN Pos (700-707)  
  TRPC7_HUMAN Pos (645-652)  
555 DYNEAYNY DNJC7_HUMAN Pos (43-50) 1.3175 
556 LMNIAFND TBCD2_HUMAN Pos (851-858) 1.3175 
557 FDNRSYDS ENAH_HUMAN Pos (524-531) 1.2878 
558 FINYTYKR STK38_HUMAN Pos (440-447) 1.27 
559 ILNVAFPP NTCP_HUMAN Pos (269-276) 1.317 
560 YINYLFYS GBRT_HUMAN Pos (348-355) 1.3171 
561 YNNPLYDD PARM1_HUMAN Pos (302-309) 1.3168 
562 KENKGYFD ATRX_HUMAN Pos (1896-1903) 1.2108 
563 YSNPGYSS RFFL_HUMAN Pos (29-36) 1.3158 
564 LDNVGFKP GAS8_HUMAN Pos (449-456) 1.2951 
565 YDNPSFLR ZDH17_HUMAN Pos (286-293) 1.289 
566 ILNLSFCD GPR75_HUMAN Pos (83-90) 1.2195 
567 ILNRGFPI CENPJ_HUMAN Pos (30-37) 1.2856 
568 IANYSFKD ITA8_HUMAN Pos (237-244) 1.2935 
569 YINASFIN PTPRA_HUMAN Pos (295-302) 1.3141 
570 SDNLGFRC SUMF2_HUMAN Pos (283-290) 1.21 
571 YINGKFKK UCR11_HUMAN Pos (47-54) 1.1939 
572 EDNAAFYI SO1C1_HUMAN Pos (218-225) 1.3131 
573 YPNERFEL UBXD7_HUMAN Pos (447-454) 1.2407 
574 IYNISFEK ZPBP1_HUMAN Pos (185-192) 1.2866 
575 YYNLPYTF KV1C_HUMAN Pos (91-98) 1.3132 
576 IINATFFE EMR3_HUMAN Pos (248-255) 1.3126 
577 TCNEGYDL CSMD2_HUMAN Pos (368-375) 1.1919 
578 LYNLGFGN ITIH3_HUMAN Pos (418-425) 1.3122 
579 LVNRGFVP SURF1_HUMAN Pos (176-183) 1.2823 
580 IDNGNYDI PRIC1_HUMAN Pos (638-645) 1.3112 
581 IENIAFGS NAMPT_HUMAN Pos (375-382) 1.3113 
582 YDNAEYAE CD109_HUMAN Pos (655-662) 1.3109 
583 LKNLAFME CP2CJ_HUMAN Pos (234-241) 1.2802 
584 YANGCFEF BIRC6_HUMAN Pos (4593-4600) 1.1691 
585 RWNDAFCD FCER2_HUMAN Pos (267-274) 1.1384 
586 YMNRTFTD KIT_HUMAN Pos (350-357) 1.2802 
587 KMNVAFEE HM20B_HUMAN Pos (208-215) 1.2333 
588 ACNAAFPD BIG1_HUMAN Pos (1331-1338) 1.1886 
  BIG2_HUMAN Pos (1278-1285)  
589 YVNYQFRV NFASC_HUMAN Pos (695-702) 1.2884 
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590 YRNGKYDL ENOB_HUMAN Pos (251-258) 1.2057 
591 VDNDGFIN EFHB_HUMAN Pos (609-616) 1.3084 
592 RVNLGYLQ KCNT1_HUMAN Pos (1155-1162) 1.2324 
593 YVNSSFYK ABCG2_HUMAN Pos (336-343) 1.2814 
594 IINKVFEE RASL2_HUMAN Pos (371-378) 1.2784 
595 GDNKAFNE DGLA_HUMAN Pos (632-639) 1.2783 
596 INNAGFPA FLRT2_HUMAN Pos (75-82) 1.3077 
597 LENDAFSD OSBL5_HUMAN Pos (295-302) 1.3073 
598 INNRAYCH PAP2_HUMAN Pos (1745-1752) 1.1817 
599 SVNHGFEA SMAD5_HUMAN Pos (395-402) 1.3068 
600 KSNLAYDI HSP74_HUMAN Pos (84-91) 1.2305 
601 HYNGTFED FKB10_HUMAN Pos (68-75) 1.3061 
602 RQNVAYEY IQGA1_HUMAN Pos (36-43) 1.2301 
603 YDNYIFWS LRP1B_HUMAN Pos (2414-2421) 1.3059 
604 YANSGYSA BET1_HUMAN Pos (20-27) 1.3059 
605 IANPAFVV DRD2_HUMAN Pos (184-191) 1.3056 
606 VINSGFIC OR4CF_HUMAN Pos (199-206) 1.2221 
607 IDNADFEI IRK2_HUMAN Pos (287-294) 1.3052 
608 KDNPAFSM GP178_HUMAN Pos (569-576) 1.2291 
609 LVNDAYKT HSC20_HUMAN Pos (123-130) 1.2829 
610 LINVGFLE B4GT7_HUMAN Pos (144-151) 1.3032 
611 KVNRAFNS ACO11_HUMAN Pos (114-121) 1.1978 
612 VENEAFPK CE110_HUMAN Pos (182-189) 1.2762 
613 IRNDAFLQ GPR98_HUMAN Pos (598-605) 1.2723 
614 EKNEAFLD GIPR_HUMAN Pos (122-129) 1.2719 
615 LLNYAYNG USP9Y_HUMAN Pos (1384-1391) 1.3023 
616 CVNSAFRC PLXA2_HUMAN Pos (680-687) 1.0611 
617 FDNGLYDE CN102_HUMAN Pos (667-674) 1.3011 
618 LINQGYRA CT059_HUMAN Pos (300-307) 1.2806 
619 YLNLMFND LRC34_HUMAN Pos (142-149) 1.3011 
620 WLNVAYLD OCTC_HUMAN Pos (85-92) 1.301 
621 YDNTSFGL THSD1_HUMAN Pos (812-819) 1.3009 
622 HVNLGYTK NPS3A_HUMAN Pos (172-179) 1.2742 
  NPS3B_HUMAN Pos (172-179)  
623 DVNYAFLH DCE2_HUMAN Pos (86-93) 1.3002 
624 INNRAFCN PAPPA_HUMAN Pos (1571-1578) 1.1749 
625 VVNTLYED DUS18_HUMAN Pos (56-63) 1.2995 
626 LENVGFEV CO6_HUMAN Pos (236-243) 1.2993 
627 IRNLTFQD GI24_HUMAN Pos (89-96) 1.2689 
628 YKNATYGY CALU_HUMAN Pos (129-136) 1.2686 
629 VFNYGYLT PIGB_HUMAN Pos (98-105) 1.2982 
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630 ITNPGFGG TROP_HUMAN Pos (1050-1057) 1.2979 
631 ILNGTYRD QKI_HUMAN Pos (199-206) 1.2769 
632 FTNQAYAI ADRB2_HUMAN Pos (194-201) 1.2971 
633 SDNFGYNL AT8A2_HUMAN Pos (316-323) 1.2967 
634 YVNYVFQI HERC3_HUMAN Pos (893-900) 1.2967 
635 MDNAGYSA PCDGC_HUMAN Pos (322-329) 1.2961 
636 VVNYKYEQ DOC10_HUMAN Pos (122-129) 1.2231 
637 YDNHTYGK MYT1L_HUMAN Pos (651-658) 1.269 
638 YVNFRFPA PABP5_HUMAN Pos (63-70) 1.223 
639 YVNQSFAP ATG12_HUMAN Pos (103-110) 1.2953 
640 RDNQGFCI S27A5_HUMAN Pos (478-485) 1.1232 
641 NVNGAFAE LYL1_HUMAN Pos (152-159) 1.2948 
  TAL1_HUMAN Pos (202-209)  
642 TVNKGYWF OX2G_HUMAN Pos (228-235) 1.2651 
643 FSNCSFED ADAM2_HUMAN Pos (351-358) 1.1946 
644 KPNNAYEF SPAG1_HUMAN Pos (802-809) 1.2187 
645 SLNAAFEI DEPD5_HUMAN Pos (1348-1355) 1.2942 
646 RLNDGFKD S12A3_HUMAN Pos (919-926) 1.1972 
647 IINSSFEN CENPF_HUMAN Pos (2509-2516) 1.2938 
648 SENLAFID KCNK4_HUMAN Pos (341-348) 1.2935 
649 RENIAFEL IFNK_HUMAN Pos (61-68) 1.2175 
650 IGNSAFAR VPS39_HUMAN Pos (859-866) 1.2666 
651 IHNCAFNG FSHR_HUMAN Pos (185-192) 1.1931 
652 LVNPAFPG ZP2_HUMAN Pos (44-51) 1.293 
653 ICNRGFSS PATZ1_HUMAN Pos (499-506) 1.1428 
654 IINAIYEP NP1L1_HUMAN Pos (120-127) 1.2926 
  NP1L2_HUMAN Pos (154-161)  
655 QENPAYEE ACOX2_HUMAN Pos (661-668) 1.2924 
656 ICNTGYSL FHR5_HUMAN Pos (113-120) 1.1709 
657 VLNLAFAQ ANC5_HUMAN Pos (624-631) 1.2912 
658 IINECYNY K1333_HUMAN Pos (513-520) 1.15 
659 RQNIAYEY IQGA2_HUMAN Pos (32-39) 1.2151 
660 LVNNAYRG CI096_HUMAN Pos (562-569) 1.2703 
661 SDNEGYFL PRIC2_HUMAN Pos (784-791) 1.2903 
662 QINRAYQF K0103_HUMAN Pos (263-270) 1.2608 
663 HKNQGYYD ODO1_HUMAN Pos (960-967) 1.2591 
664 FGNGAYTM RN139_HUMAN Pos (480-487) 1.2884 
665 KYNEAYIS CSR2B_HUMAN Pos (695-702) 1.2124 
666 LSNYAFLY GP155_HUMAN Pos (313-320) 1.2878 
667 LVNNAYAG DHRS1_HUMAN Pos (89-96) 1.2875 
668 LRNSAFES U520_HUMAN Pos (1312-1319) 1.2569 
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669 LLNYAYNS USP9X_HUMAN Pos (1375-1382) 1.2868 
670 LDNPGYSV KCNS2_HUMAN Pos (177-184) 1.2864 
671 YPNPTFEL PLXA2_HUMAN Pos (1155-1162) 1.2863 
672 GVNCTFED PLXA4_HUMAN Pos (590-597) 1.186 
673 VINESFEG ROS_HUMAN Pos (2238-2245) 1.2859 
674 RINDAFRL ACE2_HUMAN Pos (710-717) 1.1888 
675 SVNHGFET SMAD1_HUMAN Pos (395-402) 1.2845 
676 RENEGYYF CD8A_HUMAN Pos (107-114) 1.2078 
677 IDNPDYYD MFAP2_HUMAN Pos (42-49) 1.2834 
678 ILNTGFTI FREM2_HUMAN Pos (832-839) 1.2832 
679 YINHLYSD PLSI_HUMAN Pos (413-420) 1.2832 
680 VLNPAFRE GNAS1_HUMAN Pos (80-87) 1.2624 
681 SDNAGFCI SCRB2_HUMAN Pos (305-312) 1.1868 
682 LINSAFLK INT7_HUMAN Pos (60-67) 1.2557 
683 LVNRGYQP GCP6_HUMAN Pos (1794-1801) 1.2527 
684 PTNLAYDG ENK19_HUMAN Pos (290-297) 1.2822 
685 IWNGTFEE AT10B_HUMAN Pos (337-344) 1.2816 
686 FCNDGYRL CSMD3_HUMAN Pos (2620-2627) 1.1402 
687 DINVGFDT IRK5_HUMAN Pos (256-263) 1.2812 
688 LVNASFKD PA24D_HUMAN Pos (732-739) 1.2602 
689 LQNDAYND CF113_HUMAN Pos (373-380) 1.2808 
690 LENSGFDR UBP37_HUMAN Pos (695-702) 1.2536 
691 LGNPGFDE GRK4_HUMAN Pos (279-286) 1.2801 
692 QYNGTYDD LRFN5_HUMAN Pos (450-457) 1.2791 
693 VFNKGYGF VDAC3_HUMAN Pos (17-24) 1.2495 
694 ILNLTFSD CAD13_HUMAN Pos (50-57) 1.2785 
695 EVNEAFAP THIM_HUMAN Pos (318-325) 1.2784 
696 IRNQGYST WT1_HUMAN Pos (144-151) 1.2476 
697 FSNRAFAL TTL12_HUMAN Pos (495-502) 1.2484 
698 ITNKMFED SP100_HUMAN Pos (84-91) 1.2483 
699 FENYSYDL GPR1_HUMAN Pos (12-19) 1.2777 
700 KLNPGFDL PLAL1_HUMAN Pos (292-299) 1.2016 
701 YDNQVYWY NCKX5_HUMAN Pos (191-198) 1.2772 
702 YDNFLFLC PAEP_HUMAN Pos (117-124) 1.1938 
703 VCNKAYKR ZN319_HUMAN Pos (432-439) 1.0799 
704 YINGRYYS CD166_HUMAN Pos (464-471) 1.2044 
705 LQNSGFEY RNF14_HUMAN Pos (58-65) 1.2769 
706 YDNLNYTL 3BHS1_HUMAN Pos (264-271) 1.2767 
707 TNNEAYFD AP3M1_HUMAN Pos (175-182) 1.2762 
  AP3M2_HUMAN Pos (175-182)  
708 GFNFGFDL GMCL1_HUMAN Pos (413-420) 1.2759 
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  GMCLL_HUMAN Pos (413-420)  
709 DINVGFDS IRK2_HUMAN Pos (249-256) 1.276 
710 YDNVVYRY SO3A1_HUMAN Pos (617-624) 1.2553 
711 HDNTAFLE TITIN_HUMAN Pos (5653-5660) 1.2756 
712 RINLGFSN DMBT1_HUMAN Pos (1803-1810) 1.1996 
713 FDNNCYRD SC6A2_HUMAN Pos (335-342) 1.1131 
714 IINAEYEP NP1L3_HUMAN Pos (150-157) 1.275 
715 RDNKGFFN CALL6_HUMAN Pos (83-90) 1.1695 
716 YVNYNFSN BPIL2_HUMAN Pos (75-82) 1.2745 
717 ARNLAYDT PLOD1_HUMAN Pos (228-235) 1.2439 
718 LRNYGYRH HPLN4_HUMAN Pos (249-256) 1.2231 
719 PRNLGFET PI4KB_HUMAN Pos (698-705) 1.2431 
720 FENSAYVV GSH1_HUMAN Pos (435-442) 1.2733 
721 GVNRAYPY CEBPZ_HUMAN Pos (489-496) 1.2437 
722 FINKCYEL MTM1_HUMAN Pos (187-194) 1.1025 
723 YDNDSYTL ASB12_HUMAN Pos (35-42) 1.273 
724 LVNNGYVR LCAT_HUMAN Pos (152-159) 1.2464 
725 SDNGGFKR TSSC4_HUMAN Pos (117-124) 1.225 
726 QFNQGFYD DDX56_HUMAN Pos (303-310) 1.2718 
727 GYNAAYNR MGP_HUMAN Pos (87-94) 1.2451 
728 MVNYSYDE NR5A2_HUMAN Pos (73-80) 1.2709 
729 EINEAFAA THIC_HUMAN Pos (319-326) 1.2709 
730 VLNRAFKK SYNJ2_HUMAN Pos (312-319) 1.1938 
731 CNNLGYEI LIPL_HUMAN Pos (310-317) 1.1336 
732 PPNLGFVD MLL2_HUMAN Pos (2026-2033) 1.2695 
733 IINKLFFD TRAIP_HUMAN Pos (58-65) 1.2398 
734 KENVAFEQ LACTB_HUMAN Pos (243-250) 1.1928 
735 GLNQAFEE SYNE1_HUMAN Pos (6357-6364) 1.2678 
736 RVNLSFDF PXDC2_HUMAN Pos (158-165) 1.1919 
737 LYNTGYYL CD109_HUMAN Pos (616-623) 1.2675 
738 YYNEKYGG CBPN_HUMAN Pos (171-178) 1.1947 
739 VCNAGFHV FBN1_HUMAN Pos (556-563) 1.1465 
740 YVNWRFMR SMUF1_HUMAN Pos (591-598) 1.1676 
741 GVNAAFQA MTMR5_HUMAN Pos (287-294) 1.2654 
742 RTNSGFEE ANR44_HUMAN Pos (554-561) 1.1892 
743 YDNLNYIL 3BHS2_HUMAN Pos (263-270) 1.2643 
744 VANLAFAK MYO15_HUMAN Pos (1294-1301) 1.2377 
745 FWNKAFLT BAP29_HUMAN Pos (47-54) 1.2347 
746 LINSGFPE DHX9_HUMAN Pos (964-971) 1.2641 
747 LTNYGFYG PA2G5_HUMAN Pos (38-45) 1.2641 
748 ISNVKFED NVL_HUMAN Pos (259-266) 1.1914 
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749 ISNVRYED FSTL5_HUMAN Pos (400-407) 1.1914 
750 RSNAGFDG LRRC6_HUMAN Pos (201-208) 1.1879 
751 SENGAYLD CTGE5_HUMAN Pos (299-306) 1.2634 
752 TYNLAFCG OR5M8_HUMAN Pos (162-169) 1.1673 
753 VENEGFTL ANKF1_HUMAN Pos (232-239) 1.2631 
754 YNNITFEE CSN4_HUMAN Pos (316-323) 1.2626 
755 GVNCSFED PLXA1_HUMAN Pos (595-602) 1.1621 
756 WDNPAYSG PK2L1_HUMAN Pos (20-27) 1.2617 
757 YANLCFEA LCTL_HUMAN Pos (181-188) 1.1203 
758 ACNRGYYD ANR11_HUMAN Pos (209-216) 1.1114 
759 ISNMAFLV O13C3_HUMAN Pos (201-208) 1.2612 
760 YDNGRFIG SV2C_HUMAN Pos (497-504) 1.1888 
761 IDNYCFFQ KLH11_HUMAN Pos (543-550) 1.1198 
762 YDNHPFWF MBOA5_HUMAN Pos (261-268) 1.2605 
763 RVNGGFSG MA1A2_HUMAN Pos (566-573) 1.1843 
764 RVNGGYSG MA1A1_HUMAN Pos (580-587) 1.1843 
765 IQNNAYAV GBRA2_HUMAN Pos (362-369) 1.2596 
766 LCNFAFYG CTL5_HUMAN Pos (437-444) 1.1392 
767 VGNHAYEN MCLN3_HUMAN Pos (141-148) 1.2595 
768 FLNMAYQG CD1E_HUMAN Pos (127-134) 1.2593 
769 HGNFAFEG SNX17_HUMAN Pos (457-464) 1.2593 
770 FDNETFRI BMP7_HUMAN Pos (185-192) 1.2384 
771 ITNNGFNP PLCD1_HUMAN Pos (675-682) 1.2589 
772 VLNEGFLV B3GN1_HUMAN Pos (365-372) 1.2583 
773 WKNAAFLY UTX_HUMAN Pos (127-134) 1.2279 
  UTY_HUMAN Pos (124-131)  
774 IDNKMYDP ENPP1_HUMAN Pos (275-282) 1.2286 
775 FENVGFTK MSS4_HUMAN Pos (77-84) 1.2312 
776 YENGSFYF NEUA_HUMAN Pos (212-219) 1.2575 
777 QLNKAYEA TANK_HUMAN Pos (8-15) 1.2279 
778 WLNNAFQD FBXW5_HUMAN Pos (219-226) 1.2571 
779 QVNEGFQP CAH4_HUMAN Pos (175-182) 1.2564 
780 FDNNSFEQ MYO1D_HUMAN Pos (390-397) 1.2563 
781 YINANYMP PTPRJ_HUMAN Pos (1094-1101) 1.2562 
782 VYNGTYGD MUC2_HUMAN Pos (4349-4356) 1.2559 
783 LENSGFEP PGS1_HUMAN Pos (195-202) 1.2554 
784 FGNAGFSV ASPH1_HUMAN Pos (263-270) 1.2549 
785 IINYSYIN UBP24_HUMAN Pos (96-103) 1.2548 
786 TKNSAFEE K0232_HUMAN Pos (699-706) 1.2243 
787 LINNAFQL ARTS1_HUMAN Pos (627-634) 1.2547 
788 FPNLGYIQ FA38A_HUMAN Pos (437-444) 1.2545 
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789 FENPAFSG CRBB3_HUMAN Pos (119-126) 1.2544 
790 LENYAYPG ACON_HUMAN Pos (178-185) 1.2538 
791 LLNYGYVG NRX1A_HUMAN Pos (635-642) 1.2538 
792 VVNLKFLD LRRN3_HUMAN Pos (259-266) 1.1811 
793 VKNLGFGG CPLX4_HUMAN Pos (13-20) 1.2233 
794 VCNLAYSG PSD10_HUMAN Pos (10-17) 1.1329 
795 TVNRAYGL O52L1_HUMAN Pos (196-203) 1.2229 
  O52L2_HUMAN Pos (196-203)  
796 KDNQGYTP ANR44_HUMAN Pos (768-775) 1.1762 
797 VKNKAYFK RL5_HUMAN Pos (6-13) 1.1655 
798 LVNARFDY TEN1_HUMAN Pos (2034-2041) 1.1793 
799 VRNFGYPL TAB1_HUMAN Pos (362-369) 1.2209 
800 SLNDAYDF DUS7_HUMAN Pos (302-309) 1.2513 
801 FDNLDFDL ATF6A_HUMAN Pos (57-64) 1.2509 
802 TRNVAFER AN13D_HUMAN Pos (150-157) 1.1933 
803 VTNCAFSF CN104_HUMAN Pos (312-319) 1.1498 
804 LINDGFQR CASZ1_HUMAN Pos (459-466) 1.2231 
805 IINHYFCD OR8D1_HUMAN Pos (173-180) 1.1536 
806 YVNVFYKF ZN430_HUMAN Pos (182-189) 1.2287 
807 YFNYKYGW CCG5_HUMAN Pos (170-177) 1.1768 
808 ALNKAYHD MACF1_HUMAN Pos (1513-1520) 1.2193 
809 IENLSYDA SACS_HUMAN Pos (2735-2742) 1.2486 
810 FGNKAYRT PTPA_HUMAN Pos (135-142) 1.1984 
811 LLNEAFVV CHLE_HUMAN Pos (301-308) 1.2482 
812 TNNLGYMD CAND1_HUMAN Pos (767-774) 1.2482 
813 QDNVAFVL NCLN_HUMAN Pos (302-309) 1.2479 
814 IINQSFKF K1377_HUMAN Pos (594-601) 1.2268 
815 FVNAVYDT HECD2_HUMAN Pos (189-196) 1.2471 
816 FSNGAFLG SIG10_HUMAN Pos (548-555) 1.247 
817 NVNYGYQQ ALK_HUMAN Pos (1581-1588) 1.247 
818 YFNEEFDL AN13A_HUMAN Pos (335-342) 1.2469 
819 EVNFGYIE F10C1_HUMAN Pos (190-197) 1.2467 
820 MENQAFDP TRAM2_HUMAN Pos (274-281) 1.2466 
821 EYNYGFVV F125A_HUMAN Pos (253-260) 1.2464 
822 FLNMAYQQ STEA2_HUMAN Pos (333-340) 1.2464 
823 NCNEGFEP FBN2_HUMAN Pos (2237-2244) 1.1259 
824 AVNVGFCF NSD3_HUMAN Pos (859-866) 1.1502 
825 VFNWAFKK SIG11_HUMAN Pos (166-173) 1.1987 
826 YQNFVFEE LYST_HUMAN Pos (696-703) 1.2458 
827 KENEGFGF MAGI2_HUMAN Pos (926-933) 1.1698 
828 EVNEAFSL THIL_HUMAN Pos (351-358) 1.245 
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829 IVNLRYFE CAC1E_HUMAN Pos (1148-1155) 1.1726 
830 SWNFGFEV JPH2_HUMAN Pos (41-48) 1.2452 
831 TKNYGYVY CF206_HUMAN Pos (255-262) 1.2143 
832 LHNQAFEI RBCC1_HUMAN Pos (1161-1168) 1.2442 
833 YYNYFFVS ASM3A_HUMAN Pos (406-413) 1.2442 
834 LHNVGFAD OBSCN_HUMAN Pos (2046-2053) 1.244 
835 LRNAAYFL CENPU_HUMAN Pos (351-358) 1.2132 
836 IYNFTYKV ABCAC_HUMAN Pos (646-653) 1.2229 
837 KINETFVD PPIL4_HUMAN Pos (138-145) 1.1677 
838 IGNSAFLL MA2A1_HUMAN Pos (599-606) 1.2434 
839 EINEAFAS THIK_HUMAN Pos (343-350) 1.2434 
840 YFNESFSF SYT2_HUMAN Pos (336-343) 1.2433 
841 FVNGVFEV IF16_HUMAN Pos (686-693) 1.2431 
842 YRNSSYEN ZBT38_HUMAN Pos (581-588) 1.2129 
843 KKNASFED OR2J1_HUMAN Pos (4-11) 1.1369 
844 FANAGFTS EPHB2_HUMAN Pos (934-941) 1.2428 
845 FSNGGFFV CSMD1_HUMAN Pos (2241-2248) 1.2424 
846 RTNCGYES CF058_HUMAN Pos (109-116) 1.0663 
847 FKNNAYLA SYDC_HUMAN Pos (240-247) 1.2114 
848 MANEGFDP S27A3_HUMAN Pos (641-648) 1.2413 
849 LINKLYDD UN45B_HUMAN Pos (358-365) 1.2118 
850 RVNSGFGR STCH_HUMAN Pos (340-347) 1.1388 
851 DPNFGFEE ATP4B_HUMAN Pos (167-174) 1.2413 
852 YHNTTFDW S4A4_HUMAN Pos (659-666) 1.241 
853 KVNATFER GCYA2_HUMAN Pos (370-377) 1.1384 
854 ITNLKYEE MUC16_HUMAN Pos (12554-12561) 1.1683 
855 ITNLRYEE MUC16_HUMAN Pos (15363-15370) 1.1683 
856 LVNASYTD TRPV1_HUMAN Pos (190-197) 1.2402 
857 FVNPKFEH KPCD_HUMAN Pos (665-672) 1.1675 
858 QDNTAFVL RLF_HUMAN Pos (291-298) 1.2398 
859 VCNPGFLF ZAN_HUMAN Pos (1075-1082) 1.1194 
860 QDNPAYLL SNPC4_HUMAN Pos (1356-1363) 1.2389 
861 SYNAGYSY ELOV4_HUMAN Pos (101-108) 1.239 
862 YINANFIK PTN12_HUMAN Pos (88-95) 1.2124 
  PTN22_HUMAN Pos (84-91)  
863 YINANYIK PTN6_HUMAN Pos (301-308) 1.2124 
864 YINANYIR PTN5_HUMAN Pos (329-336) 1.2124 
  PTN7_HUMAN Pos (149-156)  
  PTPRR_HUMAN Pos (446-453)  
865 FCNPGFPI TM9S2_HUMAN Pos (173-180) 1.1183 
866 AVNYEFED DAPK1_HUMAN Pos (231-238) 1.2387 
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867 VFNRAFYS MBTP2_HUMAN Pos (56-63) 1.2092 
868 NPNAAYDK DCTN2_HUMAN Pos (48-55) 1.212 
869 RLNAAYSF MKS3_HUMAN Pos (363-370) 1.1625 
870 TLNQAYQD ABCA2_HUMAN Pos (593-600) 1.2382 
871 KVNTGFLM CO038_HUMAN Pos (90-97) 1.1623 
872 LRNGSYED ABCAC_HUMAN Pos (410-417) 1.2076 
873 CDNSAFII ZN248_HUMAN Pos (307-314) 1.1012 
874 ISNWAFIP GP115_HUMAN Pos (256-263) 1.2378 
875 FENQGFFQ PASK_HUMAN Pos (1071-1078) 1.2376 
876 RINNAFFL TMM27_HUMAN Pos (111-118) 1.1615 
877 YDNGYYLP E2AK3_HUMAN Pos (475-482) 1.2369 
878 RRNVGFES NUP50_HUMAN Pos (45-52) 1.1307 
879 WVNWGYAT NUAK2_HUMAN Pos (302-309) 1.2368 
880 IKNSGYIS E2AK3_HUMAN Pos (579-586) 1.2063 
881 VLNGAFLA A4GAT_HUMAN Pos (215-222) 1.2364 
882 LENQAFCF KIF2C_HUMAN Pos (304-311) 1.1402 
883 TKNIAFER AN13A_HUMAN Pos (238-245) 1.1783 
884 WVNWGYKS NUAK1_HUMAN Pos (305-312) 1.2144 
885 YVNALFSK HXA7_HUMAN Pos (6-13) 1.2081 
886 YFNIPYDW ERG25_HUMAN Pos (122-129) 1.2348 
887 LLNAGYKK RPC1_HUMAN Pos (716-723) 1.187 
888 SYNGGYGF KR191_HUMAN Pos (79-86) 1.2341 
889 PVNRAYFA PPM1F_HUMAN Pos (188-195) 1.2043 
890 IDNRDFPD PIGL_HUMAN Pos (109-116) 1.2041 
891 LDNDGYIT NCS1_HUMAN Pos (109-116) 1.2335 
892 LENKGYYF PCSK4_HUMAN Pos (556-563) 1.2041 
893 RINGTYDF LPH_HUMAN Pos (1670-1677) 1.1575 
894 LYNRGFSL ERBB3_HUMAN Pos (423-430) 1.2036 
895 SVNFGFSK MRE11_HUMAN Pos (98-105) 1.2065 
896 VSNKAYVF SCRB2_HUMAN Pos (111-118) 1.2034 
897 LKNAGFTE LMTK2_HUMAN Pos (749-756) 1.2022 
898 LCNFAFKT ZEP2_HUMAN Pos (1831-1838) 1.0909 
899 IRNLSFDS RBM28_HUMAN Pos (338-345) 1.2013 
900 YNNYIYDL KIF23_HUMAN Pos (226-233) 1.2315 
901 FINPIFEF NR1H2_HUMAN Pos (349-356) 1.2315 
  NR1H3_HUMAN Pos (335-342)  
902 AINAAFSA MS3L1_HUMAN Pos (218-225) 1.2313 
903 LHNLAFAF SPTN5_HUMAN Pos (235-242) 1.2312 
904 FDNVHFEY ABCB7_HUMAN Pos (474-481) 1.231 
905 YLNETFSE PYR1_HUMAN Pos (1558-1565) 1.2309 
906 PTNYGFCF GRB14_HUMAN Pos (301-308) 1.1348 
166 
 
907 IVNHFFCD O5AS1_HUMAN Pos (173-180) 1.1338 
908 IVNHFYCD OR8U1_HUMAN Pos (173-180) 1.1338 
909 VVNELFRD BCLX_HUMAN Pos (126-133) 1.2089 
910 YSNAYFTD SEM5A_HUMAN Pos (1060-1067) 1.2296 
911 FTNIAYFT AAA1_HUMAN Pos (282-289) 1.2294 
912 VPNLGFGM LIPP_HUMAN Pos (227-234) 1.2288 
913 IPNNAYLH IFIT2_HUMAN Pos (277-284) 1.2285 
914 DENEGYEH ZFYV9_HUMAN Pos (370-377) 1.2284 
915 GLNGGYQD MTG8R_HUMAN Pos (325-332) 1.2281 
916 VCNKAFRT ZN295_HUMAN Pos (941-948) 1.0576 
917 VCNHAFHF RBX1_HUMAN Pos (74-81) 1.1075 
918 KDNIGFHH MEPE_HUMAN Pos (42-49) 1.1519 
919 FWNNAFTL NOC4L_HUMAN Pos (206-213) 1.2276 
920 NVNLAYLG RNPC1_HUMAN Pos (82-89) 1.2274 
921 QVNSSFED ATR_HUMAN Pos (577-584) 1.2272 
922 LVNMGFPQ CJ035_HUMAN Pos (71-78) 1.2269 
923 YDNGNFFP HDAC5_HUMAN Pos (895-902) 1.2267 
924 EENEGFEH CJ086_HUMAN Pos (336-343) 1.2267 
925 KINCNFED ENTK_HUMAN Pos (344-351) 1.0508 
926 ITNERFGD SRBS1_HUMAN Pos (772-779) 1.1535 
927 ACNVGYYD ANR12_HUMAN Pos (225-232) 1.1053 
928 IANTAYLQ GRK7_HUMAN Pos (11-18) 1.2257 
929 YVNWRFLR SMUF2_HUMAN Pos (585-592) 1.1263 
930 LVNYVYRD TRRAP_HUMAN Pos (2420-2427) 1.2047 
931 FVNHCYVD ITPR2_HUMAN Pos (1426-1433) 1.084 
  ITPR3_HUMAN Pos (1416-1423)  
932 IDNPMFDT MPP5_HUMAN Pos (99-106) 1.2249 
933 FNNRAYSK SPF30_HUMAN Pos (181-188) 1.1689 
934 HVNPAFFP CPSF6_HUMAN Pos (356-363) 1.2248 
935 YFNTRYPD S13A1_HUMAN Pos (268-275) 1.1523 
936 YSNFRFDT SIDT1_HUMAN Pos (568-575) 1.1521 
937 FPNFTFRD ENPP7_HUMAN Pos (265-272) 1.2036 
938 ITNTTFDF AF9_HUMAN Pos (538-545) 1.2239 
939 GINRAYGK AUMH_HUMAN Pos (93-100) 1.1673 
940 EKNQGFDF MK06_HUMAN Pos (520-527) 1.1928 
941 FINSPFRD TRPV4_HUMAN Pos (226-233) 1.2025 
942 YTNYSFTL USH2A_HUMAN Pos (3651-3658) 1.2229 
943 HTNQAFEI LIPL_HUMAN Pos (357-364) 1.2228 
944 HENRGFEI RNF6_HUMAN Pos (157-164) 1.1933 
945 YKNYSYLH CHD8_HUMAN Pos (393-400) 1.1923 
  CHD9_HUMAN Pos (720-727)  
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946 HVNYTFEI EPHA6_HUMAN Pos (407-414) 1.2226 
947 FSNSGFKE P3C2A_HUMAN Pos (5-12) 1.2016 
948 IDNYLYVV BTBD5_HUMAN Pos (524-531) 1.2221 
949 YSNLVYDW GUP1_HUMAN Pos (293-300) 1.2222 
950 LVNYPFID ERF_HUMAN Pos (113-120) 1.2215 
951 MVNLQFED MASP1_HUMAN Pos (223-230) 1.2215 
952 INNPAFIS SGTB_HUMAN Pos (219-226) 1.2215 
953 YKNYRYRA SMO_HUMAN Pos (394-401) 1.0976 
954 GVNPAYPE ETS1_HUMAN Pos (144-151) 1.2207 
955 WPNLAYWF AMPD3_HUMAN Pos (450-457) 1.2208 
956 LGNLAFAE TTC16_HUMAN Pos (378-385) 1.2204 
957 DVNVTFED PFD4_HUMAN Pos (12-19) 1.2202 
958 LFNLGFVC TUSC4_HUMAN Pos (82-89) 1.1368 
959 PSNLGYEL PK1L1_HUMAN Pos (396-403) 1.2194 
960 YKNYFFVF AT133_HUMAN Pos (1102-1109) 1.1891 
961 QCNQGYEL FBLN3_HUMAN Pos (278-285) 1.0987 
962 FRNLTFEG GUC2C_HUMAN Pos (355-362) 1.1887 
963 VFNPAFYS T2R44_HUMAN Pos (70-77) 1.2187 
964 QPNSAYDF SMC2_HUMAN Pos (950-957) 1.2186 
965 KYNPGYVL XRN1_HUMAN Pos (910-917) 1.1424 
966 SSNRAYDF AAT1_HUMAN Pos (32-39) 1.1887 
967 PINFVFED TITIN_HUMAN Pos (15732-15739) 1.218 
968 GGNFGFGD ROA2_HUMAN Pos (204-211) 1.2178 
969 FWNSAYQA VGLL2_HUMAN Pos (145-152) 1.2178 
970 ITNHGFLI TRIM5_HUMAN Pos (454-461) 1.2175 
971 FMNQAFLQ DZIP1_HUMAN Pos (207-214) 1.2174 
972 ILNRTFQD TIP_HUMAN Pos (149-156) 1.1877 
973 LGNYAYCQ FANCM_HUMAN Pos (220-227) 1.1212 
974 YANYTFNV EPHA1_HUMAN Pos (412-419) 1.2168 
975 YGNVPFEY GPTC3_HUMAN Pos (232-239) 1.2166 
976 EFNKAFEL CALB1_HUMAN Pos (189-196) 1.1869 
977 VLNGGFRN THTR_HUMAN Pos (125-132) 1.1957 
978 ILNHVFDD ES8L1_HUMAN Pos (260-267) 1.2161 
979 FVNLTFTK LAMP3_HUMAN Pos (289-296) 1.1894 
980 HINPAYIK TTC6_HUMAN Pos (275-282) 1.1893 
981 WRNYGFGI CHSS1_HUMAN Pos (688-695) 1.1855 
982 VCNAGYSG TENX_HUMAN Pos (451-458) 1.0954 
983 PVNNAFSY MCR_HUMAN Pos (336-343) 1.2152 
984 STNCAYDR DNSL3_HUMAN Pos (228-235) 1.0885 
985 LKNEGFYS LAT3_HUMAN Pos (40-47) 1.1846 
986 NVNLGFLL YSK4_HUMAN Pos (154-161) 1.2145 
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987 SDNVGFGE WNT8B_HUMAN Pos (133-140) 1.2146 
988 FDNIKYDN GLTL4_HUMAN Pos (280-287) 1.1419 
989 EVNKAYWR RM39_HUMAN Pos (137-144) 1.1582 
990 FDNIRFDT GALT8_HUMAN Pos (307-314) 1.1414 
991 VLNPAFYS T2R50_HUMAN Pos (70-77) 1.2138 
992 YENETFLC MOB3_HUMAN Pos (181-188) 1.1303 
993 YINWKYFL DJBP_HUMAN Pos (1124-1131) 1.1409 
994 IINHFFCD OR5A1_HUMAN Pos (176-183) 1.1172 
  OR6A2_HUMAN Pos (178-185)  
  OR6J1_HUMAN Pos (172-179)  
  OR6P1_HUMAN Pos (173-180)  
995 IINHFYCD OR8J1_HUMAN Pos (173-180) 1.1172 
  OR8J3_HUMAN Pos (173-180)  
996 PDNTAFKQ CC50A_HUMAN Pos (28-35) 1.1923 
997 RKNEGYMR IF38_HUMAN Pos (893-900) 1.08 
998 VINLNYKD SSRA_HUMAN Pos (172-179) 1.1923 
999 VVNELYVD ERGI1_HUMAN Pos (52-59) 1.2127 
1000 VNNLAFLK ABCAD_HUMAN Pos (109-116) 1.186 
 
  
169 
 
S7 MS analysis of ALK ectodomain (chymotrypsin digestion) 
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S8 MS analysis of ALK ectodomain (Glu-C digestion) 
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S9 MS analysis of ALK ectodomain (Trypsin digestion) 
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